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The infectious disease tuberculosis (TB) is a global health problem. Diagnosis of 
extrapulmonary TB is often challenging due to non-specific symptoms and findings, 
and the lack of sensitive diagnostic tests. This leads to both under- and overdiagnosis 
and extensive use of empirical TB treatment, which increases the risk of placing 
individuals without TB or individuals with multi-drug resistant TB on prolonged, 
incorrect treatment. New tools for diagnosis and assessment of treatment response of 
extrapulmonary TB are needed to improve TB care. 
The overall aim of this thesis was to investigate new methods for diagnosis and 
treatment monitoring of extrapulmonary TB. Specific aims included to assess the 
performance of the MPT64 antigen detection test (MPT64 test) and the Xpert Ultra 
assay for the diagnosis of extrapulmonary TB in a low TB prevalent setting. Further, 
to reproduce an anti-MPT64 antibody for large-scale use of the MPT64 test. Finally, 
to study the potential of IP-10 measured in dried plasma or blood spots as a 
biomarker for treatment response in patients with extrapulmonary TB. 
Extrapulmonary samples received for TB diagnostics at the Microbiology and/or 
Pathology laboratories in a clinical setting in Norway were collected and subjected to 
the MPT64 test and/or Xpert Ultra. The performance of the new tests was compared 
to results of routine TB diagnostics. New anti-MPT64 antibodies were developed in 
mice and rabbits by use of different antigen-adjuvant combinations and screening in 
immunohistochemistry. The best performing individual antibodies were pooled, and 
the performance of the final pooled anti-MPT64 antibody was evaluated in patients 
samples. IP-10 dynamics during TB treatment were studied in extrapulmonary TB 
patients at a tertiary care hospital on Zanzibar, Tanzania. Plasma, dried plasma spots 
and dried blood spots were collected at baseline, 2 months of treatment and end of 
treatment. IP-10 levels were measured by ELISA and compared to clinical 
improvement. 
In paper I, we found that the sensitivity of the MPT64 test for diagnosing 
extrapulmonary TB was lower compared to results obtained in previous studies 
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conducted in TB endemic low-resource settings. The best test performance in our 
setting was demonstrated in formalin-fixed biopsies, where the MPT64 test showed 
an excellent specificity and a sensitivity in the same range as PCR-based tests, but 
lower than culture. The results of paper II indicate that it is possible to reproduce a 
functional polyclonal anti-MPT64 antibody for large-scale use of the MPT64 test, but 
that careful selection of the antigen-adjuvant combination for immunisation and 
comprehensive screening strategies are nessecary to obtain high-performance 
antibodies. In paper III, we found that the overall sensitivity and specificty of Xpert 
Ultra for diagnosing extrapulmonary TB in  low-TB prevalent high-income setting 
were high and close to the performance of culture. In paper IV, we report that a 
significant decline in IP-10 levels in plasma, dried plasma spots and dried blood spots 
during treatment was observed in extrapulmonary TB patients, and the decline was 
significant already after two months in HIV-negative patients. The correlation 
between IP-10 measured in plasma and dried plasma spots or dried blood spots was 
high. 
To conclude, potential new tools for improved diagnosis and treatment monitoring of 
extrapulmonary TB have been identified. Our results indicate that Xpert Ultra can 
contribute to a more rapid diagnosis of extrapulmonary TB in our setting, and that IP-
10 measured in dried blood spots is a promising marker for response to treatment in 
extrapulmonary TB patients. However, further studies with larger sample sizes that 
include relevant negative controls and longer follow-up of patients to evaluate the 
clinical impact of these new tools are needed. The utility of the MPT64 test is likely 
limited in settings with well-functioning culture facilities, but the test can contribute 
to strengthen the TB diagnosis in the event that samples have not been subjected to 
culture. 
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Tuberculosis (TB) is an ancient infectious disease that has plagued humans 
throughout history 1,2. Today, TB is still one of the top 10 causes of death worldwide, 
even though it is both treatable and curable 3. The disease is caused by the bacillus 
Mycobacterium tuberculosis and other species belonging to the M. tuberculosis 
complex. It primarily affects the lungs (pulmonary TB) but can also affect other sites 
of the body (extrapulmonary TB). With falling TB incidence in the early 20th century 
and the discovery of anti-TB chemotherapy in the 1940s, the war on TB was 
considered winnable and the attention to TB gradually decreased 4. However, along 
with downscaling of TB control programs, neglected TB epidemics in resource-poor 
countries, globalisation and the emergence of the HIV/AIDS pandemic, an 
unexpected resurgence of TB occurred in the 1980s and 1990s 5. As a result, TB was 
declared a global emergency by the World Health Organization (WHO) in 1993 5,6, 
and  an internationally recommended TB control strategy, later named DOTS 
(Directly Observed Treatment, Short-Course) 7, was launched in 1994. The DOTS 
strategy, and the following Stop TB Strategy that built on DOTS, have contributed to 
improved national TB control programmes and progress in TB control. Still, these 
efforts have so far only led to gradual reductions in global TB incidence. The new 
End TB Strategy aims at a 90% reduction in TB incidence and a 95% reduction in TB 
deaths by 2035 8. In order to reach these ambitious targets, and to finally end the TB 
epidemic, new diagnostic, treatment and prevention tools are needed. 
1.1 Global tuberculosis epidemiology 
Recent estimates suggest that a quarter of the world’s population is infected with M. 
tuberculosis without showing signs or symptoms of active TB disease (latent TB 
infection 9) 10,11. This number is based on several uncertain assumptions and may be 
overestimated 10-12, but still indicates that a large reservoir of M. tuberculosis exists in 
the human population, and that exposure to TB and TB latency is widespread. Among 
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people infected with M. tuberculosis, approximately 5-10% will develop active TB 
disease within their lifespan 3,13,14. In 2019, there were an estimated 10.0 million new 
cases of active TB disease and 1.4 million deaths caused by TB 3. There are large 
variations in the incidence of TB disease both between countries and different 
populations within countries. Figure 1 shows the geographical distribution of TB 
incidence in 2019. The majority of new TB cases occurred in low- and lower middle-
income countries in the South-East Asian region (44%), followed by the African 
(25%) and Western Pacific (18%) regions 3. India alone accounted for 26% of the 
global total, whereas the highest numbers of incident TB cases relative to population 
size were found in southern African countries, which also had the highest proportion 
of TB cases co-infected with HIV. Within-country variation in TB incidence is 
associated with factors that increase the risk of TB disease and transmission in 
subgroups of the population. Increased exposure to TB bacilli due to limited access to 
health care and crowded and poorly ventilated home and work environments is seen 
in poor communities and among migrants, prisoners and other socially marginalised 
people. Additionally, factors that weaken the immune system, including HIV, 
diabetes, under-nutrition, alcoholism and tobacco smoke are overrepresented in these 
vulnerable groups and also increase the risk of developing TB. 
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Figure 1. Estimated TB incidence rates, 2019. Adapted from: Global 
tuberculosis report 2020. Geneva: World Health Organization; 2020. Licence: 
CC BY-NC-SA 3.0 IGO. 
Global TB incidence rates have been declining in the past decades due to efforts of 
national TB programmes and wide implementation of the cost-effective DOTS 
strategy 15. However, the decline in TB incidence of 1,7% per year from 2000 to 2018 
3 is considered unacceptable low and is not sufficient to achieve the WHO End TB 
strategy milestone of a 20% reduction between 2015 and 2020. Further, the 
emergence of drug-resistant TB has worsened the TB epidemic in many countries due 
to longer and more expensive treatment regimens, more adverse drug side effects and 
low treatment adherence. The low treatment success rate of multidrug- and 
rifampicin-resistant TB threatens global TB control 3. 
1.2 Tuberculosis in Norway 
In Norway, TB mortality peaked around 1900 and TB disease was endemic until the 
1950s 16. With the exception of an increase in TB incidence from the mid-1990s to 
2013, which occurred in parallel with increased immigration from TB endemic areas, 
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the TB incidence rate in Norway has been continuously declining during the last 
century. Norway currently has one of the lowest TB incidence rates in the world with 
4/100 000 per year in 2018 17. Most of the notified TB cases in Norway are found 
among people infected abroad, of which the majority come from the Horn of Africa 
and the Philippines. Like in many other high-income countries, a very low TB rate 
has been achieved in the general non-foreign-born population in Norway. In 2018, the 
TB incidence was 0.7/100 000 in this population, which is at the pre-elimination level 
(<10 notified cases per million population), as defined by WHO 18. Still, occasional 
outbreaks and high TB-prevalence in subgroups of the population, including migrants 
from TB endemic areas, makes TB a persistent public health problem that must be 
addressed.  
1.3 Mycobacteria 
Mycobacteria are aerobic, rod shaped, non-motile bacteria belonging to the genus 
Mycobacterium of the Actinobacteria 19. The bacilli are characterised by a unique, 
thick and protective cell wall rich in mycolic acids and other lipids, which gives the 
bacilli their acid-fastness and contributes to the toughness of the genus 20. The species 
that cause tuberculosis in humans and animals are collectively referred to as the M. 
tuberculosis complex and comprises the exclusively human pathogens M. 
tuberculosis (the major cause of human TB), M. africanum and M. canettii, and 
several animal pathogens with a wide host spectrum, including M. bovis 21. Non-
tuberculous mycobacteria (NTM) include all mycobacteria other than the M. 
tuberculosis complex species and M. leprae 22,23. Albeit most NTM are non-
pathogenic, fast-growing, environmental saprophytes, a few NTM are opportunistic 
pathogens that can cause human disease at a variety of different body sites. 
Immunocompromised, children and people with severe chronic lunge disease are at 
increased risk of NTM infection, particularly with the clinically important M. avium 
complex species, M. kansasii and M. abscessus 24-26. Cervical lymphadenitis caused 
by NTM is relatively common in children 27, and poses diagnostic challenges because 
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the signs and symptoms are similar to TB lymphadenitis. As the treatment of NTM 
disease differs from treatment of TB, it is important to separate these conditions 28.  
1.4 Pathogenesis of tuberculosis 
The success of M. tuberculosis as a human pathogen is based on its extraordinary 
hardiness and capacity to adapt to environmental changes during infection 29, as well 
as the ability to manipulate and take advantage of the host immune system and transit 
into a stage of dormancy 30,31. The disease is airborne and spreads via respiratory 
aerosols produced by an infected host. A new host inhales the aerosols deep into the 
lungs where the bacilli encounter and infect macrophages and other antigen-
presenting cells of the innate immune system 32,33. The bacilli further expand by 
recruiting and infecting additional macrophages, and a localised inflammatory lesion 
consisting of immature granulomas, the primary focus, occurs 34. Actively secreted 
mycobacterial proteins are believed to play an important role in the modulation of 
host immune responses to secure intracellular survival and persistance in this early 
phase of primary TB infection 35. Bacilli from the primary focus are also carried by 
the lymphatic system to the draining regional lymph node during primary infection 36, 
or they may enter the bloodstream and spread to other tissues and organs. Infected 
and activated macrophages present M. tuberculosis antigens to T cells in the draining 
lymph node, thereby inducing the adaptive immune system 37,38. Antigen-specific 
CD4+ T cells are activated and differentiate into effector T-cells that participate in 
the formation of mature primary granulomas 39 and into circulating memory T-cells 
37,40. If the adaptive immune response fails to contain the infection, progression to 
early TB disease (primary TB disease) occurs. Children and individuals with 
weakened immune systems are at higher risk of primary TB disease, and the disease 
spectrum ranges from disseminated TB, TB meningitis, miliary TB, to limited disease 
involving lungs or extrapulmonary organs 41-43. However, in the majority of infected 
individuals the adaptive immune response will contain infection, and more than 90% 
will not develop manifest TB disease after infection 13,14. Still, the immune system is 
not able to eliminate M. tuberculosis, and viable bacilli persist in the body in a non-
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replicating or low-replicating state without causing signs or symptoms of TB disease 
(latent TB infection) 44,45. Little is known about the location or physiological state of 
the bacilli during latency 46-48, or the factors that drive infection towards active TB 
disease 49,50, but in approximately 5% of infected individuals, dormant bacilli will 
reactivate to cause post-primary TB disease 13,14. The risk of reactivation is highest 
within the first two years after infection, and is very low after five years 13,14, albeit it 
can occur even decades later 51,52. Post-primary TB can also be caused by exogenous 
reinfection, which makes an important contribution to TB disease in high endemic 
areas 53. Pulmonary post-primary TB is characterised by caseous pneumonia and 
formation of cavitary lung lesions that results in efficient spread of bacilli through 
coughing 3,43. It accounts for the majority of TB cases worldwide and nearly all TB 
transmission 3. If left untreated, the mortality rate from TB disease is high. Studies 
performed in the pre-chemotherapy era found that 70% of patients with smear 
positive pulmonary TB and 20% of patients with smear negative, culture positive 
pulmonary TB died within 10 years after diagnosis 54. 
1.5 Extrapulmonary tuberculosis 
Extrapulmonary TB is defined by WHO as active TB disease at any other site than 
the lungs 3. In 2019, 16 % of all notified TB cases worldwide were extrapulmonary 3. 
However, the proportion of notified extrapulmonary TB cases varies greatly among 
countries, from 25-35% in most low TB incidence high income countries (and up to 
as much as 40% in the Netherlands, UK and Norway), to 10-20%, or lower, in most 
high TB burden countries 3. In several high-income countries, the relative proportion 
of extrapulmonary TB cases has been continuously increasing over the last decades, 
and the increase has mainly been seen in foreign-born individuals 55-58. The observed 
variation in extrapulmonary TB incidence between countries may reflect true 
differences in epidemiology as extrapulmonary TB prevalence has been linked to 
geography, ethnicity, M. tuberculosis lineage and HIV prevalence 59-64, or may reflect 
differences in screening, diagnosis and reporting of extrapulmonary disease. Whereas 
extrapulmonary TB case notification to national TB programmes can be assumed to 
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provide a good proxy for extrapulmonary TB incidence in most high-income 
countries, more underdiagnosing and underreporting of extrapulmonary TB likely 
occur in many low-resource high-incidence settings because identification of 
contagious pulmonary TB is prioritised over extrapulmonary TB case finding. This 
can lead to underestimated global extrapulmonary TB prevalence estimates. 
The diagnosis of extrapulmonary TB can be challenging due to the non-specific and 
broad spectrum of clinical presentations, difficulties in obtaining specimens from 
various sites of infection, and low sensitivity of diagnostic tests. A significant delay 
in the diagnosis of extrapulmonary TB has been reported in studies from both high 
and low TB burden settings 65-69. TB lymphadenitis and TB pleuritis are the most 
common forms of extrapulmonary disease 70,71, whereas TB meningitis is the most 
lethal form and has a poor prognosis 72. In addition to ethnicity, several other host 
factors are associated with extrapulmonary disease. A higher incidence of 
extrapulmonary TB is reported in females compared to males 55,73, in young children 
41,74,75, and in immunocompromised individuals due to HIV infection, use of steroids 
and tumor necrosis factor-α inhibitors, chronic renal failure and diabetes mellitus 76-
79. Environmental factors, including smoking, alcohol, iron and vitamin D status are 
also associated with extrapulmonary TB, but data is limited 59,80-82. Although the 
extrapulmonary forms of TB are not contagious and therefore considered less 
important compared to pulmonary TB in a public health perspective, they still lead to 
significant morbidity and mortality, especially in vulnerable groups 83-86. Among 
people living with HIV, TB remains the main cause of death, accounting for 1 in 3 
HIV-related deaths 3. 
1.6 Tuberculosis diagnostic tests 
The lack of inexpensive, sensitive and rapid point-of-care tests for diagnosing TB is a 
major obstacle to achieve global TB control. There is still a large gap between the 
estimated global incidence of 10 million new TB cases and the notified 7.1 million 
new TB cases in 2019, which in part is caused by underdiagnosing 3. Moreover, 
among the notified pulmonary TB cases in 2019, only 57% were bacteriologically 
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confirmed 3, and this proportion is assumed to be even lower for extrapulmonary TB 
cases 86,87. The high number of clinically diagnosed TB cases indicates that both 
under- and overdiagnosis of TB occur, leading to delayed or unnecessary initiation of 
TB treatment, both with potentially serious consequences for the patient and 
community. 
1.7 WHO recommended TB diagnostic tests 
M. tuberculosis was first identified by the German scientist Robert Koch in 1882 by 
use of a novel staining technique which was later modified into the well-known 
Ziehl-Neelsen 88 and fluorescence 89 stains for detection of acid-fast bacilli (AFB) by 
microscopy 1. Albeit the method was developed more than 100 years ago and lacks 
both sensitivity and specificity 90, AFB microscopy is still used as the initial test for 
diagnosing TB in many low-resource high TB burden countries 91-93. Hence, a major 
WHO target to improve TB diagnosis is to increase the percentage of 
bacteriologically confirmed cases by scaling up the use of other recommended 
diagnostics that are more sensitive than AFB microscopy 90.  
In addition to AFB microscopy, WHO recommends culture based methods, rapid 
molecular tests, and one antigen-detection based test for detection of 
lipoarabinomannan in urine (Alere Determine TB LAM AG Test)) (Table 1) 90. The 
latter is only recommended for restricted use to assist in detection of M. tuberculosis 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Culture-based methods, including solid Løwenstein-Jensen medium and automated 
liquid culture systems, are still regarded as the reference standard for diagnosing TB 
90. Culture has a relatively high sensitivity and a very high specificity when used in 
combination with antigen-detection rapid tests for species identification. Phenotypic 
drug susceptibility testing is also performed using culture 95,96, and culture is the only 
TB diagnostic test that can separate viable from dead bacilli, which makes it an 
important tool for evaluation of response to TB treatment. However, the reduced 
sensitivity of culture in paucibacillary smear-negative pulmonary TB, childhood TB 
and extrapulmonary TB makes it an imperfect reference standard in these patient 
groups 86. Culture also requires centralised and comprehensive biosafety laboratories, 
and has a relatively long median turnaround time of 1-2 weeks for liquid culture and 
longer for solid culture 97,98, which makes it less suitable for use as the initial 
diagnostic test in low-resource settings.  
Over the last decades, development of new technologies to improve TB diagnosis, 
has mainly been made in the field of rapid molecular tests 94. These tests target 
specific gene sequences in the M. tuberculosis complex genome, by use of 
polymerase chain reaction (PCR) and/or DNA probes, to diagnose TB and genotypic 
drug resistance. WHO recommended rapid molecular tests currently include one 
automated (Xpert MTB/RIF and the new version Xpert MTB/RIF Ultra) and one 
manual PCR-based diagnostic test (TB LAMP), in addition to two line-probe assays 
that are primarily used for genotypic drug susceptibility testing (GenoType 
MTBDRplus version 1 and 2 and Nipro NTM+MDRTB detection kit 2) 99.  
Additionally, data from a prospective multi-centre study coordinated by the 
Foundation for Innovative New Diagnostics (FIND) indicate that another novel 
automated PCR-based test, the TrueNat assays (Molbio Diagnostics, Goa, India) has 
comparable accuracy to Xpert with the advantage of being implementable at the 
point-of-care level 99. The test was endorsed by WHO for initial testing of pulmonary 
TB and detection of rifampicin resistance in July 2020 100,101. Several other rapid 
molecular tests for use in point-of-care settings are currently being developed and 
evaluated 100.  
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Several high-throughput PCR-based test platforms for use at the reference laboratory 
level, including RealTime MTB (Abbott, IL, USA), Roche Cobas MTB (Roche, 
Switzerland), FluoroType MTBDR (Hain Lifescience, Germany) and Max MDR-TB 
(Beckton Dickinson, NJ, USA), are also currently routinely used for the detection of 
M. tuberculosis complex and genotypic drug resistance, especially in high-income 
countries. WHO is undertaking studies to evaluate the clinical validity of these tests 
in reference laboratories in high TB burden settings 90. However, the tests are 
unsuitable for use at lower levels of care and are therefore less relevant for global TB 
control.  
Among these rapid molecular tests, the launch of Xpert MTB/RIF (Xpert) in 2010 
represents the largest global breakthrough for improved TB diagnosis so far. The 
fully automated cartridge-based test system simultaneously detects M. tuberculosis 
complex and genotypic rifampicin resistance within less than two hours and requires 
minimal operational training 102,103. Numerous studies have shown the high sensitivity 
of Xpert to detect M. tuberculosis complex in smear positive sputum specimens, but 
the assay has reduced sensitivity in smear negative samples and limited ability to 
determine some forms of rifampicin resistance 104,105. To overcome these limitations, 
a new version, the Xpert MTB/RIF Ultra (Ultra) was launched in 2017. A large, 
multi-centre non-inferiority study has shown that the sensitivity of Ultra in smear 
negative TB is significantly higher as compared to Xpert 106, and Ultra is now 
recommended by WHO as a replacement for Xpert in all settings 107. The sensitivity 
of Ultra for diagnosing extrapulmonary TB is, however, more variable between 
studies and different types of sample material, and most of the research has been 
conducted in high-TB burden low-resource settings 108-118. There is limited 
knowledge about the usefulness of Ultra in a low-TB-prevalence high-income setting. 
The performance of Ultra compared to routine TB diagnostic tests in high-resource 
setting and the potential of Ultra to contribute to a more rapid diagnosis of 
extrapulmonary TB was investigated in study 3. 
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1.8 Mycobacterial antigens and antigen detection tests 
M. tuberculosis complex protein antigens have been extensively studied over the last 
40 years to discover relevant antigens for use in diagnostic tools and vaccines and to 
better understand the TB host-pathogen interaction. Important secreted 
immunodominant antigens, including the Antigen 85 complex 119,120, MPT64 120,121, 
38 kDa 122, ESAT-6 123,124, CFP-10 125 and TB10.4 126, were discovered in the 1980s 
and 1990s based on classical biochemical analyses of purified M. tuberculosis and M. 
bovis BCG culture filtrates, whereas the sequencing of the M. tuberculosis genome by 
Cole and colleagues 127 resulted in the identification of the latency associated 
antigens, reactivation-associated antigens and resuscitation-promoting factors, 
amongst others 128,129. While the highly immunogenic, and often cross-reactive, 
antigens have been and are being investigated for use in vaccines, the discovery of 
antigens that are specific for M. tuberculosis complex 130 opened up for development 
of antigen-based TB diagnostic tests. Serological tests and antigen detection tests 
have the potential to provide rapid, simple and inexpensive TB diagnosis, and 
antigen-detection tests can also provide direct evidence of active TB disease. 
However, so far few of these tests have made it beyond the stage of development. 
The WHO issued a policy statement in 2011 against the use of serological tests for 
diagnosing TB due to substantial evidence of suboptimal test accuracy 131, and only 
one antigen-detection test (Alere Determine TB LAM AG Test, for detection of 
lipoarabinomannan in urine) is endorsed by the WHO 90. Albeit this test provides 
proof-of-principle that mycobacterial antigens can be detected in easily available 
specimens such as urine 132, the sensitivity is low 133-135. The best test performance is 
found in HIV TB co-infected people with low CD4 counts, presumably due to higher 
systemic antigen load in HIV-associated disseminated TB disease, and the test is 
currently only recommended for TB diagnosis in selected HIV-infected individuals 94. 
Antigen-detection in specimens collected directly from the site of infection is being 
explored as a more sensitive alternative compared to detection in blood and urine, 
because the antigen load is likely to be higher at the site of infection, especially if the 
antigen of interest accumulates. Studies have shown that TB pathology seems to be 
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caused by large amounts of the mycobacterial antigens, despite relative low numbers 
of viable bacilli, causing hypersensitivity reaction and tissue destruction 43, indicating 
the special characteristic of the mycobacterial antigens to accumulate at the site of 
infection.  
The M. tuberculosis complex-specific antigen MPT64 121,136,137 has been detected 
consistently within human macrophages at the site of infection during TB disease in 
several studies despite the absence of viable bacilli 138-144, implying that this antigen 
may accumulate and persist within human macrophages 145-148. This makes it a 
promising target for antigen-detection-based TB diagnostic tests. MPT64 was 
originally identified in M. bovis BCG culture filtrates in the 1980s and named based 
on its relative mobility of 0.64 during polyacrylamide gel electrophoresis 121,149. The 
protein is immunogenic and elicits strong and TB specific delayed type 
hypersensitivity skin responses 121,122,150-152 and T cell interferon-γ production 153-155. 
Its function is unknown, but it has been suggested to play a role in M. tuberculosis 
pathogenesis due to the accumulation within infected human macrophages 145-148 and 
because it is a secreted protein that is relatively abundantly expressed during early 
active cell growth 137,156. Further, the deletion of the Region of Difference 2 genes, 
which encodes the mpt64 gene, from some BCG substrains is associated with reduced 
virulence in animals and decreased vaccine lesions in humans, implying a role in 
virulence 157,158. MPT64 has previously also been studied for use in other types of 
diagnostic tests including hypersensitivity skin tests 151,152, Interferon-γ release assays 
159-161, serological assays 162-165, ELISA 166,167, immunochromatographic lateral flow 
assays 168,169 and PCR 170-173, and as a vaccine candidate to replace the BCG vaccine 
174-177. However, with the exception of the currently commercially available MPT64 
immunochromatographic lateral flow assays for rapid speciation of positive 
mycobacterial cultures, none of these diagnostic tests or vaccines have reached 
clinical trials so far 178. 
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1.9 The MPT64 antigen-detection test 
The MPT64 antigen-detection test (MPT64 test) is an 
immunocytochemistry/immunohistochemistry (ICC/IHC) assay for direct detection of 
MPT64 in extrapulmonary patient samples by use of an in-house polyclonal anti-
MPT64 antibody 179. The method was developed based on previous IHC studies of 
mycobacterial antigen expression in human TB disease 140,147,180 which showed that 
MPT64 was consistently expressed intracellularly in host macrophages with a 
characteristic distribution pattern of staining, while other antigens could not be 
detected or showed a more diffuse distribution pattern. The MPT64-staining was 
present in smear and culture negative samples from clinically diagnosed TB cases, 
indicating that the method could be useful in difficult-to-diagnose paucibacillary TB 
disease. Moreover, the mpt64 gene is specific for M. tuberculosis complex species, 
with the exception of Region of Difference 2 negative BCG substrains, and MPT64 
can thus diffentiate M. tuberculosis from NTM species 121,136,137. These findings led to 
the development of the immunochemistry-based MPT64 test for diagnosing 
extrapulmonary TB. Table 2 shows an overview of the case-control and cohort-based 
diagnostic accuracy studies that have been conducted to evaluate the utility of the test 
in a wide range of clinical extrapulmonary specimens including biopsies, fine-needle 
aspirates and body fluids in different high-TB-burden settings 138-144. The MPT64 test 
has performed well in the studies, being positive in all smear positive and 75-100% of 
culture positive samples. Against clinically or histologically/cytologically diagnosed 
extrapulmonary TB cases, the test had overall sensitivities of 66-100% and 
specificities of 81-100% 138-144, suggesting that the test may improve TB diagnosis 
compared to routine TB diagnostic tests. Moreover, the test method is rapid and 
robust, and can be performed in basic pathology laboratories without need for 
advanced equipment and continuous power supply, making it suitable for 
district/hospital level low-resource settings. These findings indicate that the MPT64 
test is a promising candidate to improve the diagnosis of extrapulmonary TB. The test 
has, however, not been evaluated in a low-TB-burden high-income setting, and the 
performance of the MPT64 test in a clinical routine setting in Norway was evaluated 
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in study 1. Further, the polyclonal anti-MPT64 antibody that is currently used in the 
MPT64 test is in limited supplies. A pre-requisite for further large-scale use of the 
test is reproduction of a functional anti-MPT64 antibody to secure stable supplies and 
batch-to-batch consistency. In study 2, we investigated different strategies to develop 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.10 Assessment of response to anti-tuberculosis treatment 
The WHO End TB Strategy targets a treatment success rate of 90% or more for 
national tuberculosis programs to effectively reduce TB transmission, complications 
and mortality 8. Albeit the global treatment success rate has increased from 82% in 
2016 to 85% in 2017 90, the improvement is still too low. Treatment of TB is lengthy, 
resource-demanding and associated with potentially adverse side-effects. For new 
cases of pulmonary TB, and most types of extrapulmonary TB, the standard treatment 
regimen consists of a 2-month intensive phase with rifampicin, isoniazid, 
pyrazinamide and ethambutol, followed by a 4-month continuation phase with 
rifampicin and isoniazid 181. Smear microscopy or culture status at two months of 
treatment are frequently used to assess treatment response, but have limited ability to 
predict treatment outcomes182-185, and are of no use for treatment monitoring in 
paucibacillary, smear and culture negative forms of TB 186. Clinical assessment is the 
usual way to monitor treatment response in smear and culture negative pulmonary 
and extrapulmonary TB patients, but this is often challenging due to non-specific 
symptoms and findings. Hence, new markers that can predict treatment outcomes 
such as failure, cure and relapse are needed, which is further emphasised by the 
emergence of multidrug-resistant TB 90,187. The widespread use of empirical TB 
treatment in patients with clinically diagnosed extrapulmonary TB also poses a risk of 
overdiagnosis and overtreatment of TB, and a biomarker for early treatment response 
could help identify cases with alternative diagnoses to secure proper management. 
Biomarkers of early treatment response may also provide surrogate end-points in 
clinical trials for faster development of new TB drugs and shorter treatment regimens 
188,189.  
Numerous potential biomarkers for response to TB treatment are being investigated, 
as summarised in several reviews 190-192. Pathogen specific biomarkers that have been 
studied for treatment monitoring include mycobacterial proteins and peptides, DNA 
or RNA fragments, and lipids measured in sputum or urine 193-199, but the sensitivities 
of these markers to predict cure and relapse have been variable and generally low. 
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Measurement of early bactericidal activity against M. tuberculosis in whole blood 
culture after oral dosing of anti-TB drugs appears to be a more promising biomarker 
for cure 198. Early bactericidal activity correlates with culture conversion rate, has 
already been used during development of new anti-TB drugs 200-202, and is currently 
being evaluated in TB host directed therapeutics clinical trials 203. Early bactericidal 
activity is, however, too resource demanding to be used to predict outcomes in 
routine clinical settings. 
Promising host specific biomarkers to monitor treatment and predict cure have 
recently been reviewed 184. These include specific T cell interferon-γ responses to 
stimulation with different M. tuberculosis complex specific antigens 204-209, altered 
expression of cell surface markers for activation and differentiation in subgroups of T 
cells during treatment 210-214, and single-markers or multiple-marker host 
chemokine/cytokine signatures (e.g., interferon-γ-inducible protein 10, C-reactive 
protein, interleukin 6, interleukin 12, interleukin 4, interleukin 10, tumor necrosis 
factor α and interferon γ) 215-221. However, the low concentration in blood of most of 
these markers limits the type of test platforms that can be used for detection, making 
them less suitable as point-of-care tests like immunochromogenic lateral flow assays. 
An important exception is Interferon-γ-inducible protein 10 (IP-10), also known as 
CXCL-10. IP-10 is a pro-inflammatory chemokine produced by macrophages and 
other cells in response to T cell interferon-γ release. Several studies show that plasma 
and serum IP-10 levels decrease upon efficient treatment of TB 222-228, and the decline 
can be detected already after two weeks of therapy both in pulmonary and 
extrapulmonary TB 226. IP-10 is a robust marker expressed at higher levels than many 
other candidate biomarkers 222,229, which enables use of simple test platforms for 
detection. Promising results have been obtained with a quantitative lateral flow assay 
for detection of IP-10 from antigen stimulated blood in TB patients 230,231, indicating 
that IP-10 based assays have the potential to be developed into point-of-care tests. IP-
10 is also stable in dried plasma spots and dried blood spots applied on filter paper 
229,232. Dried plasma spots and dried blood spots are easy methods for storage and 
transport of blood samples at ambient temperatures from peripheral health centres to 
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regional level laboratories for analysis 229,233,234. It has previously been shown that IP-
10 levels in dried plasma spots decline during treatment both in pulmonary and 
extrapulmonary TB patients. However, the potential of IP-10 as a marker for 
treatment response has mostly been investigated in pulmonary TB patients, whereas 
the knowledge about IP-10 response in extrapulmonary TB patients is limited. In 
study 4, we investigated the performance of the IP-10 dried blood spot assay as a 
marker for response to treatment in extrapulmonary TB patients in a low-resource 
setting, by comparing IP-10 measured in dried blood spots and dried plasma spots to 
IP-10 measured directly in plasma during TB treatment. 
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2. Aims 
The overall aim was to investigate new methods for diagnosis and evaluation of 
treatment response in patients with extrapulmonary tuberculosis.  
Specific aims: 
• Study 1 (MPT64 Norway) 
To evaluate the performance of the MPT64 antigen detection test for the 
diagnosis of extrapulmonary tuberculosis in a routine clinical setting in a low-
TB-prevalence high-resource setting. 
• Study 2 (MPT64 Reproducibility) 
To reproduce an anti-MPT64 antibody for large-scale use of the MPT64 
antigen detection test on the biopsy and cytology samples. 
• Study 3 (Xpert Ultra Norway) 
To evaluate performance of the fully automated, rapid molecular assay, Xpert 
Ultra, for the diagnosis of extrapulmonary tuberculosis in a clinical routine 
setting in a low-TB-prevalence high-resource setting. 
• Study 4 (IP-10 treatment response) 
To evaluate the utility of the inflammatory host cytokine IP-10 measured in 
dried blood spots and dried plasma spots as a biomarker to monitor response to 
treatment in patients with extrapulmonary tuberculosis. 
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3. Materials and methods 
 
 
Figure 2 provides an overview of the different studies comprising this thesis. 
Figure 2. Overview of the studies of the thesis. Abbreviations: EPTB, 
extrapulmonary tuberculosis; DPS, dried plasma spot; DBS, dried blood spot; HUH, 
Haukeland University Hospital; SUH, Stavanger University Hospital; OUH, Oslo 
University Hospital; TB, tuberculosis; IP-10, interferon γ-inducible protein 10; 




Studies 1 and 3 were conducted in Norway from January 2015 through January 2016. 
In 2015, Norway had a population of 5.2 million people, a low HIV-prevalence 235 
and an estimated TB incidence of 6 per 100,000 (3.3 per 100,000 in 2019) 3,236,237. 
Thirty percent of all notified TB cases were extrapulmonary in Norway in 2015 236. 
Study 4 was conducted in Zanzibar from August 2014 to September 2015. Zanzibar, 
which is a semi-autonomous region of the United Republic of Tanzania, has a 
population of 1.3 million people 238 and a low adult HIV prevalence of 1% 239. The 
estimated TB incidence in the United Republic of Tanzania was 306 per 100,000 in 
2015 (237 per 100,000 in 2019) 3,240, whereas a national TB survey from 2012 
reported an estimated prevalence of bacteriologically confirmed pulmonary TB in 
Zanzibar of 124 per 100,000 241. Twenty-four percent of all notified TB cases in 
Zanzibar in 2015 were extrapulmonary 242. 
3.2 Study design 
Studies 1, 2 and 3 were diagnostic test accuracy studies. In studies 1 and 3, a single-
gated (cohort selection) cross-sectional study design was used to evaluate the 
accuracy of the MPT64 test (study 1) and the Xpert MTB/RIF Ultra assay (study 3). 
Samples eligible for enrolment were identified at the laboratory level at several 
tertiary care hospitals in Norway, and included all samples received for TB 
diagnostics in a clinical setting at the microbiology laboratory (study 1 and 3) and 
pathology laboratory (study 3). The samples were prospectively and consecutively 
included in study 3. In study 1, the samples were partly prospectively and 
consecutively included, and partly retrospectively included due to logistical issues 
with the prospective inclusion. 
In study 2, a two-gated (case-control selection) cross-sectional study design was used, 
in which the MPT64 test performance was assessed in a study population comprising 
TB samples from both clinically diagnosed and confirmed (culture and/or Xpert 
positive) TB cases and controls with other diseases that were clearly distinct from 
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TB. The study population was nested in the study population of larger 
extrapulmonary TB study conducted in Pakistan 243, and the samples were 
retrospectively included. 
In study 4, a single-gated, cohort study design with prospective and longitudinal data 
collection was used to observe correlation between IP-10 values and TB treatment 
response in a group of TB patients. Patients eligible for enrolment were consecutive 
adults (>18 years) diagnosed with extrapulmonary TB at a tertiary care hospital in 
Zanzibar during the inclusion period. 
3.3 The reference standard 
All the studies in this thesis use a composite reference standard. In study 3, the TB 
case definition was limited to bacteriologically (culture and/or PCR) confirmed TB. 
A composite reference standard that included clinical TB diagnosis in addition to 
culture and PCR status was used in study 1 and 2. In study 1, medical records for all 
patients with culture and PCR negative samples were checked for a clinical TB 
diagnosis 8 months after the inclusion of samples had finished. All clinically 
diagnosed TB patients who responded to treatment, as assessed by the local 
clinicians, were categorised as clinically diagnosed TB cases in the study. In study 2, 
patients with presumptive extrapulmonary TB, histology suggestive of TB, and 
response to treatment, as assessed by the primary investigator, were categorised as 
clinically diagnosed TB cases. In study 4, a composite reference standard consisting 
of culture, Xpert, AFB microscopy, histo/cytopathology, diagnostic imaging status 
and response to treatment was used to categorise patients as confirmed, probable or 
possible TB cases or non-TB cases. The decision to start treatment was done by local 
clinicians, whereas evaluation of response to treatment was mostly done by the 
primary investigator in study 4. For all the studies, the reference standard was 
interpreted without knowledge of the index test results. 
 
 36
3.4 Laboratory methods and assays 
3.4.1 Antigen production 
Detailed protocols and references for culture conditions for mycobacteria, protein 
expression and purification of MPT64 are provided in the manuscript for study 2. The 
rationale for choosing to work with M. bovis BCG and M. smegmatis in study 2 will 
be briefly discussed in the following section. The extremely slow generation time of 
approximately 20 hours for M. tuberculosis, and the biohazard of handling the 
pathogen species, challenges laboratory research with pathogenic mycobacteria. This 
has led to the use of the less virulent M. bovis BCG substrains and the non-pathogenic 
M. smegamtis as common surrogates for M. tuberculosis in TB research.  
The M. bovis BCG substrains are laboratory-derived attenuated strains of M. bovis 
that are primarily used in the live attenuated BCG vaccine, which is currently the 
only licenced vaccine against TB 244,245. The BCG strains are genetically similar to 
the other M. tuberculosis complex species but only require biosafety level 2 
laboratories, which makes them attractive model organisms. However, comparative 
genome studies between M. tuberculosis and BCG strains have revealed numerous 
regions of gene deletions (regions of difference) in the BCG strains that may limit 
their use in research 246,247, and the pattern of deletion also varies between substrains. 
Whereas all the BCG strains lack Region of difference 1, a region that is thought to 
be important for bacterial virulence 248,249, only the so-called late BCG strains 
(Prague, Glaxo, Denmark, Tice, Connaught, Frappier, Phipps and Pasteur) lack 
Region of difference 2, which codes for several antigenic secreted protein, including 
the MPT64 protein. It has been speculated that this deletion has further attenuated the 
late strains compared to the early strains (Russia, Moreau, Tokyo, Sweden and 
Birkhaug) 145,250 thereby contributing to some of the observed heterogeneity in BCG 
vaccine effectiveness 251,252. 
The NTM M. smegmatis is a fast-growing, environmental saprophyte. In laboratory 
research, M. smegmatis is a simple and attractive model organism for mycobacterial 
pathogens because it has a short generation time of 3-4 hours, is non-pathogenic and 
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shares many genetic, structural, and metabolic properties with M. tuberculosis 20. The 
mutant, laboratory-derived M. smegmatis mc2155 strain is particularly useful for 
work with gene expression in mycobacteria as it allows efficient plasmid 
transformation and is readily cultivable in most media 253,254.  
3.4.2 The MPT64 test 
The MPT64 test is an ICC/IHC (immunochemistry)-based test for detection of 
MPT64 in formalin-fixed tissue sections and ethanol-fixed cell smears. 
Immunochemistry is a type of immunostaining in which specific antibodies are used 
to identify antigens (mostly proteins) in cells or tissues. For IHC, the method also 
provides information about the distribution and quantity of the antigen in the tissue. 
Immunochemistry is a routine method that is widely used both in diagnostic and 
research laboratories worldwide. The MPT64 test uses a two-step indirect staining 
method, which means that an unlabelled primary antibody binds the MPT64 protein 
in the tissue before labelled secondary antibodies bind the primary antibody. The 
secondary antibody is labelled with an enzyme, horseradish peroxidase, that reacts 
with a chromogenic substrate to yield a red brownish colour precipitate that can be 
visualised by light microscopy (Fig. 3). This method is more sensitive than direct 
one-step immunochemistry due to the signal amplification provided by binding of 
several secondary antibodies to one primary antibody. 
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Figure 3.  The immunohistochemistry-based MPT64 antigen detection test. 
Abbreviations: HRP, horseradish peroxidase. 
The MPT64 test method has been optimised and validated in previous studies 140-142, 
and previously developed standard of operation was adhered to for all 
immunostaining runs in studies 1 and 2. In both studies, the same operator performed 
all runs. Initially, limited validation runs were performed, in which multiple staining 
runs were performed on serial sections from a small number of positive and negative 
controls. Based on a subjective evaluation of the consistency in staining patterns in 
these controls, intra- and inter-run staining variability for the assay was found to be 
acceptable. For all later runs during the studies, a positive control sample (smear 
positive confirmed TB tissue section) and a negative control (tissue section from 
patient with other disease than TB) were included as quality control, in addition to a 
negative control including no primary antibody.  
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In study 1, the MPT64 test was interpreted by a designated pathologist with 
experience in evaluating the test, according to previously developed scoring 
guidelines 139. As the study was performed in a clinical setting, clinical information 
about the patient and results of routine diagnostic tests were sometimes available for 
the pathologist. In study 2, a pathologist without previous experience with the MPT64 
test interpreted the samples after being trained in evaluating the test. 
3.4.3 The Xpert Ultra assay 
The next-generation Xpert MTB/RIF Ultra assay is a semi-quantitative, real-time 
PCR in-vitro diagnostic test for simultaneous detection of M. tuberculosis complex 
species and rifampicin resistance. Compared to the original Xpert MTB/RIF assay, 
Ultra includes two new multi-copy amplification targets (IS6110 and IS1081) in 
addition to the original single-copy rpoB target, fully nested nucleic acid 
amplification, and a larger PCR reaction chamber to improve detection and increase 
the sensitivity of the assay compared with Xpert 255. The increased sensitivity offered 
by the multi-copy targets has resulted in the new semi-quantitative category “MTB 
detected, trace” (trace), which represents the lowest detectable bacillary load. Initial 
validation of Ultra has shown a limit of detection of 15.6 colony forming units/mL 
for Ultra versus 112.6 colony forming units/mL for Xpert in M. tuberculosis spiked 
sputum 255. Additionally, the accuracy of rifampicin resistance detection is increased 
by incorporating melting temperature-based analysis of the four molecular beacon 
probes that identify resistance mutations in the rpoB gene, instead of the former real-
time PCR-based analysis. The test is almost fully automated, requires minimal 
training of laboratory personnel, and provides results within less than 80 minutes. 
Quality control is incorporated in each test cartridge and includes a sample processing 
control (non-infectious spore), which verifies adequate processing of DNA and 
detects possible PCR inhibition, and a probe check control, which measures the 
fluorescence signal from the probes before the start of the PCR reaction. The results 
of Ultra are generated automatically by the GeneXpert Instrument system from 
measured fluorescent signals and embedded calculation algorithms.  
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In study 2, frozen specimens were used for Ultra, and the same operator performed all 
the runs. 
3.4.4 The Dried plasma spot/Dried blood spot IP-10 ELISA test 
Preparation of plasma, dried plasma spots and dried blood spots were performed 
according to previously described methods 229,234. The filter paper cards were 
transported at room temperature and the plasma samples on dry ice to Bergen, 
Norway, for analysis. 
A previously developed ELISA protocol was used for detection of IP-10 in plasma 
and eluates from dried plasma spots and dried blood spots 229,234. The assay is a direct 
sandwich ELISA, in which two antibodies specific for different epitopes on IP-10 are 
used. This method can be highly specific and sensitive and is suitable to detect 
substances in complex samples. A murine anti-IP-10 capture antibody was used to 
bind IP-10 to the wells of a microtiter plate, and a second horseradish peroxidase -
conjugated rat anti-IP-10 detection antibody that binds a different epitope on the IP-
10 protein, was used to detect IP-10. Visualisation was performed by adding a 
substrate to the wells, and a coloured precipitate developed when the substrate 
reacted with horseradish peroxidase. The presence and quantity of IP-10 was 
subsequently calculated based on the colour intensity in the wells, as measured by an 
automated spectrometer. 
ELISA characteristics of the test including intra- and inter-run imprecision, IP-10 
recovery, linear range, dynamic range, limit of detection and lower limit of 
quantification, have previously been assessed in an initial validation study 229. Based 
on this study, a standard curve that covered the linear range of the assay was included 
in triplicates in all runs in our study. The blank sample in the standard curve 
functioned as a negative control and the samples containing recombinant IP-10 
functioned as positive controls. The intra-run imprecision of each ELISA run was 
found to be acceptable if the coefficient of variation of the triplicates of the standard 
curve was <15%. The ELISA assay was manually performed, and the same operator 
performed all the runs. The operator was blinded to clinical patient information.  
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3.5 Statistical analyses 
In studies 1, 2 and 3, 2x2 cross-tabulation was used to calculate sensitivity, specificity 
and accuracy against the reference standard. Calculation of 95% confidence intervals 
for sensitivity and specificity was performed with the exact Clopper-Pearson method.  
In study 4, statistical analyses were performed using SPSS Statistics V25 (IBM). 
Non-parametric statistical methods were applied. Wilcoxon Signed Ranks test was 
used for repeated measurements to evaluate changes in IP-10 levels at different time 
points during treatment. For comparison of differences in IP-10 levels in independent 
groups at baseline, Mann Whitney U test was applied when the groups compared 
consisted of more than 5 individuals per group. Correlation analyses were performed 
using Spearman’s Rank Correlation Coefficient. A significance level of 0.05 was 
used.  
3.6 Ethical considerations 
Ethical clearance was obtained from the Regional Committee for Medical and Health 
Research Ethics, Western Norway (studies 1, 2, 3 and 4), the Institution review board 
and ethical Committee, Gulab Devi Educational Complex, Lahore, and the National 
Bioethics Committee Pakistan (study 2), and the Zanzibar Medical Research and 
Ethics Committee (study 4) before conducting the studies. All methods were carried 
out in accordance with the relevant guidelines and regulations. For studies 1 and 3, an 
exemption from informed consent from the participants was granted as the study only 
included residual material from samples sent for TB diagnostics in a clinical setting. 
For studies 2 and 4, all patients provided informed written consent. Permission to 
export plasma, dried plasma spots and dried blood spots out of Tanzania was 
approved by the Zanzibar Medical Research and Ethics Committee (Ministry of 
Health, Zanzibar), Mnazi Mmoja Hospital and the study participants. 
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4. Results 
In study 1, the diagnostic accuracy of the MPT64 test for diagnosing extrapulmonary 
TB in low-TB-incidence high-income setting was evaluated against a composite 
reference standard that included clinically diagnosed TB cases. In formalin-fixed 
biopsies, the sensitivity of the MPT64 test was 37%, compared to 20%, 37% and 50% 
for AFB microscopy, PCR-based tests pooled, and culture, respectively. The MPT64 
test was positive in 5/7 PCR-positive biopsies, whereas none of the PCR-negative, 
culture positive, biopsies were positive with the MPT64 test. The specificity of the 
MPT64 test in formalin-fixed biopsies was excellent (99%) and the test was negative 
in all NTM cases. The test performance in fine-needle aspirates, pus and fluid 
samples was generally lower and variable, with sensitivities and specificities between 
0-100% and 50-80%, respectively. 
Different strategies to reproduce the MPT64 antibody for the MPT64 antigen 
detection test were investigated in study 2. Several functional polyclonal antibodies 
were obtained after immunisation of rabbits with a combination of recombinant 
MPT64 antigen and TiterMax Gold adjuvant through a process of negative screening 
of pre-immune sera and positive screening of antisera in IHC. By pooling the 
functional antisera that performed well individually but still displayed slight 
differences in sensitivity and specificity, we obtained a large volume of a functional 
antibody with stable performance. The validation of this final antibody in the patient 
samples showed a high performance with sensitivity in the same range as the 
reference antibody, but a somewhat lower specificity. We were not able to develop a 
monoclonal anti-MPT64 antibody applicable in IHC on the formalin-fixed paraffin 
embedded biopsies with sensitivity and specificity in the same range as the reference 
antibody. 
The diagnostic accuracy of the WHO endorsed rapid molecular test Xpert MTB/RIF 
Ultra (Ultra) for diagnosing paucibacillary extrapulmonary TB was assessed in a low-
prevalence high-income setting in study 3. Using culture and routine-PCR as 
reference standard, the overall sensitivity and specificity of Ultra were 90% (95% CI 
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56-100) and 99% (95% CI 93-100), respectively. Ultra was positive in 6/7 smear 
negative confirmed TB samples. Semi-quantitation of bacillary load by Ultra showed 
that none of the samples has a high bacillary load and two of the samples were in the 
new category of “trace” positive samples. The genotypic rifampicin resistance results 
from Ultra were in concordance with phenotypic drug susceptibility test results. 
In study 4, the potential of using IP-10 measured in dried plasma spots and dried 
blood spots as a biomarker for response to treatment in extrapulmonary TB patients 
in a TB endemic low-resource setting was investigated. Detectable levels of IP-10 
were found in unstimulated plasma, as well as in dried plasma spots and dried blood 
spots from all of the extrapulmonary TB patients. There was a significant decline in 
IP-10 levels from baseline to end of treatment in plasma, dried plasma spots and dried 
blood spots both in extrapulmonary and pulmonary TB patients. For HIV negative 
patients, the decline was observed already after 2 months of treatment. There was a 
high correlation between IP-10 measured in plasma and dried plasma spots and dried 






In this project we have studied new methods to improve diagnosis and treatment 
monitoring of extrapulmonary TB. We evaluated the performance of the MPT64 
antigen detection test and the Xpert Ultra assay for diagnosing extrapulmonary TB in 
a high-income low-TB-prevalence setting. The potential of reproducing and 
improving the MPT64 test was also investigated. Further, the biomarker IP-10 was 
studied as a marker for response to treatment in extrapulmonary TB. 
5.1 Methodological considerations 
5.1.1 Study design 
The cross-sectional study design used in studies 1, 2 and 3 is considered a valid study 
design for clinical assessment of diagnostic accuracy. However, based on several 
factors such as study setting, study population, sample selection and choice of 
reference standard, this study design can provide more or less generalisable findings 
256,257. In order to reduce the risk of bias and ensure more complete and transparent 
reporting of diagnostic test accuracy studies, a quality assessment tool (QUADAS-2) 
258 and a guideline for reporting of diagnostic test accuracy studies (STARD) 257 have 
previously been developed. These guidelines can be of use both when designing and 
interpreting results of diagnostic test accuracy studies.  
In study 2, the case-control selection of samples is likely to have introduced a 
spectrum bias that can lead to over-estimated test accuracy estimates of the index test. 
However, in an early exploratory phase of test development, it can be appropriate to 
initially use a small case-control selection to save time and resources 259. If the test 
cannot discriminate between clearly diseased and non-diseased cases, there is no need 
to perform larger cohort studies in clinical settings. 
The cohort selection used in studies 1 and 3 is considered superior to a case-control 
selection because the index test is evaluated in a population that better reflects the 
patients that will be tested in clinical practice, and the characteristic of diseased and 
controls are more similar. In our cohort, samples received for TB diagnostics in a 
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clinical setting at the laboratories in several tertiary care hospitals in Norway were 
enrolled, which represents a highly relevant study population reflecting the true test 
population. The prospective and consecutive inclusion of samples also reduces the 
risk of sampling bias. However, in study 1, samples were also partly retrospectively 
collected, which may have introduced a sampling bias. Still, the point of 
identification of samples was the same as in the prospective and retrospective 
inclusion (any sample received for TB diagnostics at the microbiology and/or 
pathology laboratory during the inclusion period), which makes it more likely that the 
retrospectively included samples were also representative of the true test population. 
The single-gated, cohort study design with prospective and consecutive inclusion of 
participants used in study 4 is a valid study design to provide longitudinal data that 
can be used to observe correlation between IP-10 values and TB treatment response 
in TB patients. The study population represented a clinically relevant patient group, 
as both clinically diagnosed, and microbiologically confirmed TB patients were 
included. 
5.1.2 Sample size 
A major limitation of the studies in this thesis is the small sample size. Study 2 was 
an exploratory case-control study, and a calculation of sample size was not 
performed. The study populations in studies 3 and 4 were nested within the study 
populations of study 1 and a similar study conducted in Zanzibar (the Zanzibar-study) 
139), respectively. A sample size calculation was performed both for study 1 and the 
Zanzibar-study but was not performed for the individual subpopulations in study 3 
and 4. However, we were not successful in recruiting the targeted number of 
participants in neither study 1 nor the Zanzibar-study within the inclusion period. 
This was mainly due to the study design, where inclusion of presumptive 
extrapulmonary TB patients in routine clinical practice was planned for one year, and 
it was expected to reach the targeted sample within this period. However, during the 
implementation, several logistical difficulties were faced, and the number of enrolled 
patients were less than expected. Scarce sample material and poor sample processing 
at the laboratories further reduced the sample size. The resulting small sample sizes 
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led to imprecise estimates of accuracy with wide confidence intervals around them, 
and also limited the possibility to provide stratified accuracy estimates for key 
subpopulations (e.g., based on HIV and smear status). However, the samples used in 
the studies reflect the real-life situation and may be more generalizable in routine 
clinical practice as compared to the carefully selected samples for a study.  
 
5.1.3 The MPT64 test 
The reproducibility of ICC/IHC is influenced by several pre-analytic, analytic and 
post-analytic factors that may introduce variability. Variation in tissue preparation, 
uneven fixation and antigen retrieval methods are preanalytical factors that can affect 
the availability and quality of the epitopes of interest. In study 1, we could not control 
the process of cell smear preparation at the microbiology laboratories, which we think 
may have been suboptimally performed for some of the included samples (long time 
before fixation). Analytical factors of variability include incubation time and 
temperature and concentration of reagents, in addition to operator variation. These 
factors may be more pronounced when the staining is manually performed, as in our 
study, in contrast to on environmentally controlled automated platforms. However, 
the same operator performed all runs in our study, which reduces operator variation. 
Positive and negative controls were included in all runs for quality control. As the 
same positive control was used in most of the runs in the study, inter-assay variation 
was continuously evaluated based on the staining pattern and intensity in the positive 
control. The same operator performed all runs in our studies, and inter-operator 
variation was, thus, not investigated. 
Post-analytic factors that can affect reproducibility are related to interpretation of test 
result. The MPT64 test was interpreted according to previously developed scoring 
guidelines, but still requires some degree of subjective assessment by the reader, 
which makes the test sensitive to inter- and intra-observer variability. Observer 
variability has not been systematically evaluated in studies 1 and 2. Clinical 
information about the patient and results of routine diagnostic tests were sometimes 
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available for the pathologist who interpreted the MPT64 test in study 1, which may 
have introduced a bias. However, the pathologist was blinded during interpretation of 
all the retrospectively included biopsies, and almost all biopsies were retrospectively 
included. The best performance of the test was observed in biopsies, indicating that 
confirmation bias during interpretation was less likely to occur.   
5.1.4 The Xpert Ultra assay 
Pre-analytical factors that reduce the number of intact bacilli in the patient samples, 
such as improper sample collection, sample storage or insufficient concentration of 
starting material may contribute to test variability. Thirty-two out of 86 specimens in 
study 3 had a starting volume below the WHO recommended volume requirement for 
biopsy specimens for Xpert (0.7 mL) 260. However, cerebrospinal fluid volumes as 
low as 0.1 mL are recommended for use with Xpert, and specific volume 
requirements for other extrapulmonary sample materials have not been made, 
indicating that more knowledge is needed before final sample volume 
recommendations can be given. Moreover, 30/32 specimens with a low volume in our 
study had volumes greater than 0.5 mL, which is relatively close to the WHO 
recommendation. The use of frozen sample material may also have affected the 
performance of Ultra due to reduced sample quality. However, in previous studies, 
this effect has been reported to be small 104,105,112,261, and our samples were only 
subjected to one freeze-thaw cycle before analysis, and we therefore believe this is of 
less relevance in our study. 
Other observed pre-analytic factors that affected the performance of the assay 
included suboptimal homogenisation of biopsies, which led to clogging and high 
pressure in the cartridges from particulate matter (ERROR run), and PCR inhibition 
by blood in the sample (INVALID run).  As the test is fully automated, analytic 
factors that may lead to variability will not be further discussed. The results of Ultra 
are generated automatically by the GeneXpert Instrument system from measured 
fluorescent signals and embedded calculation algorithms. Thus, post-analytic factors 
that can lead to variability are less likely to be an issue with this assay. Still, the 
 48
investigator who performed the assay in our study, was blinded to the results of the 
reference tests. 
5.1.5 The Dried plasma spot/Dried blood spot IP-10 ELISA test 
Sample collection, handling and transportation were mostly performed according to 
the study protocol, and we believe that pre-analytical factors that can lead to 
variability is of less importance in study 4. However, long storage time of dried 
plasma spots and dried blood spots before analysis may lead to degradation of IP-10 
in the samples. Albeit a previous validation study has shown that IP-10 is stable in 
dried plasma spots after four weeks of storage at 37°C 229, our samples were stored 
for several months before analysis (mostly at -20°C), which may have reduced IP-10 
concentration and affected the sensitivity of the assay. The ELISA assay was 
manually performed, and analytic factors that can cause variability are related to 
operator (e.g., pipetting accuracy) and environment (incubation temperature and 
time). The intra-run imprecision of all ELISA runs, as assessed by the coefficient of 
variation of the standard curve triplicates in each run, was found to be acceptable. 
Inter-run imprecision was not evaluated in our study but was of less importance 
because all samples from the same patient were run together on the same plate. The 
operator was blinded to clinical patient information when performing the assay. Post-
analytical factors that can cause variability are less relevant for this assay, as the 
results are based on automated read-out of light absorbance and require no 
interpretation. 
 
5.1.6 The reference standard 
The lack of a true gold standard for the diagnosis of TB is a major challenge for 
validation of new diagnostic tests. With its high specificity and relatively high 
sensitivity, automated liquid culture is recommended as the primary reference 
standard in diagnostic accuracy studies on smear-replacement tests 262. However, the 
limited sensitivity of culture can lead to misclassification bias. This can result in 
overestimated sensitivity of the index test because of false negative culture samples, 
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and underestimated specificity of the index test if it is more sensitive than culture. As 
a result, many studies use composite reference standards that include not only culture 
status, but also PCR and/or smear status and/or clinical TB diagnosis, to better 
determine true disease status. This is particularly important in paucibacillary TB 
disease, including paediatric and extrapulmonary TB. 
In study 3, the TB case definition was limited to bacteriologically (culture and/or 
PCR) confirmed TB, which represents an extreme case definition as only clearly 
diseased cases are classified as TB cases. This may be problematic because the 
reference standard is not likely to correctly classify all the TB cases in the cohort. The 
reason for still choosing this reference standard is because information about clinical 
TB diagnosis was not available for all the study participants. An advantage of using 
bacteriologically confirmed TB as case definition is that it enables comparison of 
results between studies and inclusion of data in meta-analyses. There is, however, a 
risk of overestimating index test sensitivity due to false negative culture samples. 
Composite reference standards that included clinical TB diagnosis were used in 
studies 1, 2 and 4. These composite reference standards are likely to correctly classify 
more true TB cases as compared to the reference standard in study 3 but may also 
incorrectly classify some non-TB cases as TB cases due to the low specificity of a 
clinical TB diagnosis. In order to reduce the problem of low specificity, response to 
treatment was required to be classified as a clinically diagnosed TB case in the 
studies. A limitation of including clinical TB diagnosis in the reference standard is 
that the criteria used to define a clinically diagnosed TB case often vary greatly 
between studies, making it difficult to compare results. 
In study 1, routine TB diagnostic tests were performed as part of normal clinical 
practice at the inclusion sites, and the types of TB diagnostic tests performed varied 
somewhat based on type of sample material, pre-test probability of TB and specific 
requests from clinicians. As a consequence, not all patients received the same 
reference standard. However, the choice to use different diagnostic tests for different 
samples was not dependent on index test results as the index test was performed after 
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the reference standard tests, and an introduction of partial or differential verification 
bias is therefore less likely. 
 
5.1.7 Selection bias 
Diagnostic accuracy estimates may be biased if not all eligible participants undergo 
the index test and the reference standard. In studies 1 and 3, any cell-rich non-sputum 
sample received for TB diagnostics at the microbiology laboratory (and pathology 
laboratory, study 1) at tertiary care hospitals were eligible for inclusion. These 
samples are the same samples that will be tested for TB in a clinical setting, and thus 
reflect the true test population very accurately. However, not all eligible samples 
underwent the index test or the full reference standard. An evaluation at one of the 
inclusion sites (Haukeland University Hospital) of the eligible samples that had not 
been included in the study, showed that at the microbiology department, many lymph 
node FNAs and biopsies were not included because no sample material was left after 
routine TB diagnostic tests had been performed. All samples were subjected to 
culture as a minimum, whereas smear microscopy was only performed if clinical 
information indicated a high pre-test probability of TB, and routine-PCR was only 
performed if smear microscopy was positive, or if the clinician specifically requested 
these tests. Thus, clinically relevant samples (TB lymphadenitis constituted 50% of 
all notified extrapulmonary TB cases, and 15% of all TB cases in Norway in 2015 236) 
were at higher risk of not being included because of 1) generally low sample volumes 
of FNAs and biopsies, and 2) an even lower sample volume left after routine 
diagnostics of the samples with the highest pre-test probability of TB. Firstly, this 
may have introduced a sampling bias; the proportion of biopsies and FNAs compared 
to other extrapulmonary sample types was lower in studies 1 and 3 compared to in a 
routine setting, and, hence, does not fully represent a random sample of the 
population. Secondly, a disease spectrum bias may also have been introduced. 
Assuming that samples with higher pre-test probability of TB are more likely to 
represent true TB and maybe also more severe TB disease, the proportion of TB (and 
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severe TB disease) in our sample material may have been lower than in a routine 
setting.  
Another group of samples that were eligible for inclusion, but that were not correctly 
prospectively included in study 1, were formalin-fixed biopsies at the pathology 
laboratories. A retrospective evaluation showed that many of these samples were 
missed from inclusion because clinical information stating that TB was a differential 
diagnosis was often lacking, even when the same sample had been sent for TB culture 
at the microbiology department in parallel. Based on cross-checking of data on 
biopsies received for TB diagnostics at the microbiology laboratories with biopsies 
received at the pathology laboratories, most of the formalin-fixed biopsies that were 
missed during prospective inclusion were identified and retrospectively included. 
However, a selection bias was introduced during retrospective inclusion because an 
extended set of exclusion criteria was applied. Biopsies with a histopathological 
diagnosis other than TB (e.g., malignancy) or no pathological findings were excluded 
to narrow down the number of irrelevant non-TB samples included. The use of 
different eligibility criteria changed the disease spectrum and possibly also increased 
the TB prevalence in the group of biopsy specimens, but we find it less likely that this 
selection bias is clinically relevant because these excluded samples with a definite 
diagnosis other than TB would not have been subjected to TB specific tests at the 
pathology laboratory in a routine setting.  
A selection bias was also introduced in study 3, as pleural fluid samples with a low 
pre-test probability of TB were excluded. According to local guidelines, many pleural 
fluid samples are routinely sent for TB diagnostics in our setting, even when the pre-
test probability of TB is very low. We therefore only included pleural fluids if TB 
was mentioned as a diffential diagnosis on the request form or in patient records. This 
may have changed the disease spectrum in the group of included pleural fluids, but 
we believe that our selection is in line with the intended use of Ultra, and, thus, 
represents a clinically relevant cohort.  
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In study 4, patients eligible for inclusion were prospectively included, thus reducing 
the risk of selection bias. Subgroup analysis of the patients who refused to participate 
has not been performed. During the study period, the samples from the study 
participants who were lost to follow-up due to death ( n = 4), transfer-out (n = 3), 
refused to give blood (n = 2) and unknown (n = 3) were not available. This may give 
biased results if the IP-10 levels are different in the group lost-to-follow-up compared 
to in the group of included participants. Evaluation of the participants lost-to-follow 
up for other reasons than death did not identify any uniform characteristics with 
regard to disease severity, age, co-morbidities or outcome, and we think it is less 
likely that these incomplete datasets have introduced biased results. The patients that 
were lost-to-follow up due to death presented with more severe disease at baseline 
(based on patient journals) and had a poorer outcome than the other participants. 
Hence, a bias may have been introduced by including these incomplete datasets in 
analysis, but we do not know in which direction such a bias influences the results.  
5.1.8 Sample flow between reference tests and index test 
There can be large variations in bacillary load both between specimens and within 
specimens from the same patient. For studies 1, 2 and 3 the index test and the 
reference standard tests were performed on the same specimen, which reduces 
random variability and provides the best evidence on comparative accuracy 256. Still, 
within-specimen variation in bacillary load, due to non-uniform distribution of bacilli, 
always represents a risk of noise during interpretation, particularly in paucibacillary 
specimens. A large sample size would have reduced this noise but was not possible to 
achieve in our studies for reasons explained elsewhere.  
5.1.9 Modifiers of test accuracy 
Clinical characteristics such as gender, age, co-morbidities and spectrum of disease 
were not available in studies 1 and 3 due to a limited ethical clearance to obtain this 
information. Some of these characteristics may affect test accuracy in subgroups of 
the study population. It is possible that not only disease prevalence but also disease 
spectrum is different in a high-income versus low-income settings. The clinical 
setting in studies 1 and 3 was tertiary care hospitals, and the patients included in the 
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study were therefore selected by referral based on symptoms and findings suggestive 
of TB (or other serious diseases), implying that the test has been assessed in more 
advanced disease. On the other hand, referral to a hospital may happen at an earlier 
time point during disease development, i.e., less advanced disease, in high-income 
settings because of better access to health care system as compared to low-income 
settings, making it more challenging to compare disease spectrum between our study 
and previous study settings. 
Another potential confounder in study 1, 2 and 3 is HIV TB co-infection, because 
HIV infection changes immune cell function, bacillary distribution and the 
histopathology of TB disease, which may potentially also affect the test performance 
of the MPT64 test and Ultra. Still, in the Norwegian material, the proportion of HIV 
TB co-infection is believed to be very low. In 2016, HIV status was known for 
254/289 TB cases in Norway, of which 10 cases were HIV infected (4%) 263. HIV TB 
co-infection is, thus, most likely not a very relevant confounder. 
In study 4, clinical characteristics including age, gender and HIV-status were 
available. HIV TB co-infection was also identified as a potential confounder in this 
study. Indeed, stratified analysis based on HIV status showed a clearer association 
between changes in IP-10 levels and response to treatment in the HIV negative group 
as compared to the HIV infected group. However, the number of HIV infected 
participants was small, which gives uncertain estimates. 
5.2 The MPT64 test for diagnosing extrapulmonary TB 
Ideally, a new test for diagnosing TB should be simple, low-cost and require little or 
no instrumentation to make it suitable and sustainable for use at a point-of care level 
in the low-resource settings with high TB burden. However, low test sensitivity is a 
major issue in TB diagnostics, indicating that a more complex test for use at reference 
centre or district/hospital levels may be considered as a valid alternative to a point-of-
care test, if it can significantly increase the currently low case detection rate of smear 
negative TB and reduce empirical treatment which is bound to cause over-treatment 
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in a substantial proportion of patients. Previous studies performed in low-resource 
settings suggest that the MPT64 test can play such a role 139-141,143. In most of these 
studies, the MPT64 test had a higher sensitivity than conventional smear and culture, 
and correctly diagnosed a high proportion of clinically diagnosed TB cases. 
 In study 1, we found that the sensitivity of the MPT64 test for diagnosing 
extrapulmonary TB was low compared to results obtained in previous studies, both 
against a composite reference standard that included clinical TB diagnosis, and 
against culture as reference standard. We believe that the MPT64 accuracy estimates 
presented in our study are clinically relevant because the study population is 
representative for the intended test population in a high-income setting, including 
difficult-to-diagnose paucibacillary TB cases. The discrepant results between study 1 
and the previous MPT64 validation studies may be related to differences in study 
setting, disease spectrum, relative proportion of the different sample types and 
composition of reference standard among the studies. The disease spectrum is not 
fully described in any of the MPT64 diagnostic accuracy studies conducted, including 
study 1, but it is likely that the study populations in the studies conducted in low-
resource settings have more severe disease and higher bacillary load at the time of 
diagnosis as compared to our study population, because patients in a high-resource 
setting have access to free health services and presumably seek health care at an 
earlier time during disease progression. This may lead to higher sensitivity of the 
MPT64 test in low-resource settings as compared to high-resource settings.  
The proportion of culture confirmed TB cases also substantially differed between the 
previous studies conducted in low-resource settings (5-30%) and study 1 (62%). 
Theoretically, this could reflect more severe disease and a higher bacterial load in our 
setting, but we find this less likely. As discussed above, the disease spectrum is 
expected to include fewer cases with severe disease in a high-resource setting, and we 
have also identified a possible selection bias in our study that led to inclusion of 
fewer specimens from clearly diseased TB cases. More importantly, the culture 
procedures used in our setting favour higher bacilli recovery rates and detection rates, 
which will increase the sensitivity of culture.  
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Firstly, pre-treatment of samples with N-acetyl-L-cysteine-sodium hydroxide 
decontamination, which reduces viability, was used more selectively in our setting as 
compared to previous studies where it was used on all samples. Secondly, most of the 
previous studies used one solid Lowenstein-Jensen culture per sample, whereas 
multiple cultures, including both solid and liquid culture of decontaminated and/or 
non-decontaminated material, was used for a large proportion of the samples in our 
study. Fully automated liquid culture systems are regarded as superior to solid culture 
for detection of isolates 186, and the combination of liquid culture and conventional 
solid culture has been found to provide the highest recovery rates for mycobacteria 
264. Multiple cultures per sample compared to one culture per sample is likely to 
increase the sensitivity of culture, especially in paucibacillary specimens with non-
uniform distribution of bacilli. Thirdly, pre-laboratory factors including long sample 
transportation time before culture, which reduces viability, and apportioning of scarce 
sample material between several different tests could also have contributed to 
reduced sensitivity of culture in previous studies. In our study, many FNAs and 
biopsies that were eligible for inclusion, were not included because no sample 
material remained after routine diagnostic tests had been performed. In the previous 
studies, on the other hand, sample material was distributed equally among all the 
different TB diagnostic tests that were compared, irrespective of total sample volume. 
This may lead to insufficient in-put sample volumes for routine diagnostic tests, 
thereby reducing their sensitivity. Taken together, these methodological differences 
indicate that culture had a higher sensitivity in our setting, which reduced the 
sensitivity of the MPT64 test compared to culture. This is further supported by using 
nested-PCR (targeting IS6110) instead of culture as a comparator between the 
previous studies and study 1. The sensitivity of the MPT64 test was 71% against 
nested-PCR positive samples in our study, which is comparable to previous results 
(72-100%). Nested-PCR was however, only performed on a limited number of 
samples in our study, and the findings should be interpreted with caution. In contrast 
to previous studies that only included nested-PCR positive TB samples for validation 
of the MPT64 test 138,140-144, our study also included several PCR negative, but culture 
positive TB samples, and all of these samples were negative with the MPT64 test. 
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Assuming that PCR negative, culture positive samples have lower bacillary load as 
compared to PCR and culture positive samples, these findings imply that our study 
has included cases with less severe and paucibacillary disease and that the MPT64 
test is not sensitive enough to detect M. tuberculosis complex in these samples. The 
benefit of using the MPT64 test as an add-on test for case detection in a setting with 
optimal culture methodology is therefore most likely limited, although the test may 
provide more rapid results than culture. However, study 1 revealed that some tissue 
samples from patients with symptoms and findings suggestive of TB were not sent 
for culture in parallel to histopathological examination, presumably due to low TB 
suspicion or awareness in our setting. In the absence of culture, the MPT64 test may 
complement other available TB diagnostic tests including AFB microscopy and 
nested-PCR. Further, M. tuberculosis complex specific nested-PCR on formalin-fixed 
biopsies is not available in all routine pathology laboratories, whereas IHC is. 
In low-resource settings with limited culture facilities, the potential of the MPT64 test 
to improve TB diagnosis is promising 138-144. Before the potential of the MPT64 test 
in these settings can be investigated in larger clinical diagnostic test accuracy studies, 
the issue of test reproducibility must be assessed. This was done in study 2. Test 
reproducibility and stable antibody supplies are known challenges for tests based on 
polyclonal antibodies. A common strategy to improve reproducibility and secure 
infinite supplies of antibodies for antibody-based tests is to replace the polyclonal 
antibody with a monoclonal antibody. Despite using different combinations of 
antigen/adjuvants and several screening strategies during hybridoma production, none 
of the generated monoclonal antibodies in study 2 were fully functional in IHC, albeit 
they showed good reactivity in ELISA. ELISA was, thus, not an optimal method to 
select clones that were functional in IHC. Formalin fixation and other tissue 
processing steps prior to IHC alter epitopes 265, and the antibodies with the strongest 
binding in ELISA may be non-functional in IHC and vice versa. Important clones for 
IHC may have been lost in the initial experiments where IHC was not used for 
screening. However, even after comprehensive screening in IHC in the later 
experiments, the resulting few monoclonal antibodies that showed some specific 
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staining in IHC also displayed cross-reactivity, indicating that their target epitopes 
were not unique to the MPT64 protein. It is possible that our choice of antigen was 
not optimal to generate antibodies against unique epitopes 266, for instance if the less 
specific epitopes were more immunogenic than the epitopes of interest 266. However, 
as long as the target epitope or epitopes of the MPT64 test are not identified, it is 
difficult to pin-point the factors that need to be addressed during future antibody 
production. 
When it is not possible to replace a polyclonal antibody with a monoclonal antibody, 
an alternative strategy to increase both reproducibility and the total volume of the 
polyclonal antibody is to pool several individual functional antisera, as investigated in 
study 2. After immunisation of several rabbits with MPT64 antigen to produce 
MPT64 specific antisera, we observed that the performance of the MPT64 test varied 
greatly between the different antisera, even when the same batch of MPT64 antigen 
and immunisation protocol was used. This posed a challenge for reproduction of 
functional polyclonal antibodies for the MPT64 test, and immunisation and screening 
of a large number of animals was necessary to identify a sufficiently large number of 
functional individual antisera. Candidate animals were selected by repeated screening 
of sera in IHC, both before immunisation to select out sera with non-specific staining, 
and during immunisation to find the antibodies with the strongest specific staining. 
Albeit not systematically evaluated, our findings also suggest that the choice of 
adjuvant and method for production of MPT64 antigen was of importance for 
obtaining functional antibodies for the MPT64 test. The combination of TiterMax 
adjuvant and recombinant MPT64 antigen produced in a mammalian cell line vector 
system resulted in the strongest and most specific immunostaining patterns in IHC 
among the combinations tested. After pooling the best individual antisera, the 
antibody test performance in IHC remained similar, which makes this a valid 
alternative when it is not possible to change to monoclonal antibodies. The diagnostic 
test accuracy of the final pooled functional polyclonal antibody was assessed in a 
small number of cases and controls, and the results indicated that the sensitivity was 
similar, but specificity was somewhat lower compared to the reference antibody. 
Further modification of the protocol, e.g., optimisation of the blocking of the non-
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specific binding sites and increased number of washing steps during IHC has 
overcome this challenge. However, ongoing studies on a larger cohort will be able to 
fully evaluate the performance of the new polyclonal antibody in clinically relevant 
populations.  
In addition to reproducibility of the antibody, several other factors related to 
implementation and quality control of the MPT64 test remain to be more thoroughly 
investigated. The test requires basic laboratory facilities and trained personnel and is 
therefore not implementable at a point-of-care level, as is the case with most of the 
WHO endorsed rapid molecular tests. However, compared to rapid molecular tests, 
the MPT64 test is less complex, not prone to contamination and can be performed at 
ambient temperatures using low-cost basic laboratory equipment, which are all 
advantages in low-resource settings. Still, operational factors including total cost per 
test, total hands-on time during test performance, test capacity per operator per day, 
and overall turnaround time for the test (time from the sample is taken to the results 
are reported back to the clinician) must be evaluated in a real-life setting. Albeit 
performance of the test itself requires less than one working day, pre-test processing 
of sample material for biopsies by formalin-fixation, paraffin embedding, and 
sectioning of slides are all time consuming procedure. Lack of qualified personnel to 
perform the test or interpret the immunostained sections may also be a limiting factor 
in some settings. Time needed to train personnel must be investigated, and inter- and 
intra-operator and -observer variability must also be assessed. Finally, the clinical 
impact of the MPT64 test remains to be investigated in a so-called phase IV 
diagnostic study 259. Will introduction of the test result in earlier diagnosis and earlier 
initiation of treatment, and if so, will this affect TB mortality and morbidity rates. 
Also, the use of the test in patients previously treated for TB must be established. It is 
unknown if MPT64 remains detectable after treatment, and if so, for how long. If 
MPT64 would prove to be a marker that is only present in active disease, the test 
could provide very important information.  
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5.3 The Xpert Ultra assay for diagnosing extrapulmonary 
tuberculosis in high-resource settings 
In study 3, we found that the test performance of Ultra was very good in 
extrapulmonary samples. With a sensitivity that was almost as high as culture, and a 
laboratory turnaround time of less than two hours for results, the test may contribute 
to a more rapid TB diagnosis in a high-resource setting compared to other routine TB 
diagnostics. Moreover, the high specificity of the test (99%) in our study, indicates 
that it may be suiteable for use in low TB prevalence countries, where the majority of 
samples tested would be non-TB. There are, however, issues related to the specificity 
of Ultra that remain to be explored.  
Despite a generally high performance of Ultra for the diagnosis of extrapulmonary 
TB in previous studies 108-114,117,118,267, several studies report that the specificity of 
Ultra is slightly reduced compared to Xpert against culture as a reference standard 
109,113,114,116,267. In a low TB prevalence setting, even a small reduction in specificity 
may have clinical implications, and it is not given that the advantage of earlier 
diagnosis and treatment of a few extrapulmonary TB cases outweights the 
disadvantages of inappropriate TB treatment of several false positive cases. 
Moreover, as culture is known to be an imperfect reference standard, it is not clear if, 
or under which conditions, Ultra positive, but culture negative, samples should be 
interpreted as false positive or true positive. In patients recently treated for TB, Ultra 
positive, culture negative samples may represent detection of non-viable bacilli left 
after treatment, and not relapse of active TB disease. This is a well-known issue for 
all tests based on detection of DNA, and they are concidered less suiteable for 
diagnosis of TB relapse. However, Ultra may also have limited usefullness for 
detection of TB reinfection, even many years after TB treatment, as shown in a study 
by Dorman and collegues 106. They found that the specificity of Ultra compared to 
Xpert was reduced up to seven years after treatment in patients previously treated for 
pulmonary TB, possibly due to the presence of non-viable or non-replicating bacilli 
several years after treatment. It has also been speculated that Ultra positive culture 
negative samples could represent non-replicating or non-viable bacilli from patients 
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with self-contained/cured minor TB disease or latent TB infection in the lower end of 
the TB disease spectrum, which raises issues about how, or if, these cases should be 
treated 268. In the study by Dorman and colleagues, clinical follow-up of a subgroup 
of patients with Ultra positive, culture negative samples who had not started TB 
treatment, showed improvement or resolution of symptoms in 17/18 patients after 2 
months, further questioning the relevance of an isolated positive Ultra test result. As 
many of these presumed false positive Ultra samples were categorised as trace, the 
authors suggested repeated testing, or the use of various algorithms that categorise all 
or some trace positive samples as non-TB cases to improve the specificity of the 
assay (with some loss of sensitivity), a strategy which has later been used in other 
Ultra studies.  
Updated WHO guidelines now state that trace positive samples should be considered 
true positive among people with presumptive extrapulmonary TB, children and 
people living with HIV, whereas repeated testing is recommended in other patient 
groups 107. This strategy is considered a trade-off between increased numbers of false 
positives and maximisation of case detection in patient groups that will potentially 
benefit most from Ultra. These recommendations are, however, based on a low level 
of evidence. Modelling studies performed by WHO show that replacement of Xpert 
with Ultra will lead to 49 incremental unnecessary treatments per incremental death 
averted in an Indian TB centre setting, 10 unnecessary treatments per TB death 
averted in a South-African HIV clinic setting, and as much as 501 unnecessary 
treatments per death averted in a Chinese primary care setting 107. These data suggest 
that the consequences of implementing Ultra will vary greatly depending on the 
clinical setting and TB prevalence, and that more setting specific approaches to 
implementation may be necessary for Ultra. We followed the WHO recommendation 
to categorise trace positive samples from patients with presumptive extrapulmonary 
TB as Ultra positive in study 3, and we still obtained a high specificity. However, as 
clinical information about previous history of TB was not available, the high 
specificity may reflect that our study population included few patients previously 
treated for TB. Previous history of TB is an important confounder for Ultra 
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specificity in pulmonary TB that should be systematically assessed, alongside other 
potential confounders, in further studies of extrapulmonary TB.  
In addition to a high test performance, the simple and automated design of Ultra is 
one of its main advantages, whereas the high price is a major limitation. The price is 
currently reduced to US$9.98 per cartridge in eligible high burden low- and middle-
income countries as a result of the 2012 donor-negotiated concessional pricing 
program 269, but it is substantially higher in high-income countries including Norway. 
Compared to the cost of reagents and equipment required for the MPT64 test, Ultra is 
much more expensive. On the other hand, the total cost of a test also includes labour 
cost, and the MPT64 test requires specially trained personnel to perform the test and 
interpret the results, while the fully automated Xpert/Ultra offers low personell cost 
(very short laboratory hands-on time for sample preparation, followed by automated 
sample analysis and reporting of results, and hence low use of “scarce” labour 
resources). In settings where the availability of trained personnel is limited and/or 
salary costs are high, labour cost may be of great importance and possibly outweight 
the high cost of the Ultra cartridge itself. Still, despite the user-friendly design of 
Ultra, there are operational challenges related to the roll-out of Xpert/Ultra worldwide 
118. According to a 2017 Médecins Sans Frontières report, nationwide implementation 
of Xpert as the initial TB diagnostic test is lagging behind. Only 15/28 high TB 
burden countries evaluated in the report had guidelines that recommended use of 
Xpert as the initial test, out of which only 7 countries had implemented the policy 
widely 93. Some of the main challenges for implementation and sustaineability were 
unstable power supplies and temperature control, and lack of resources for cartridges, 
calibration and repair of the machines, which are all factors that are of less concern 
with the MPT64 test. Further, several studies that evaluate outcome of Xpert 
implementation have shown that Xpert testing does not increase the number started 
on treatment and does not greatly impact TB mortality and morbidity rates 270-272. 
This may be partly explained by non-functional health care systems and pre-treatment 
delays. Similarly to the MPT64 test, Xpert/Ultra is performed at the district/hospital 
level far away from the patient, which leads to delays before the patient receives the 
test results. The low clinical impact of introducing Xpert/Ultra may also partly be 
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explained by the fact that many patients are started on empirical TB treatment before 
test results are available. The recently released GeneXpert Edge machine, and the 
soon expected GeneXpert Omni machine, which are portable and battery-operated 
smaller systems that can be used at a rural point-of care level, are very promising and 
may overcome some of these implementational challenges of Xpert/Ultra in low-
resource settings 273-275.  In high-income countries with functional health care 
systems, low risk of pre-treatment delays and sufficient funding for cartridges and 
machine maintenance, these implementational issues of Ultra are of less concern, and 
the potential clinical impact of introducing a sensitive and more rapid test can, hence, 
be larger. While the clinical usefullness of the MPT64 test in a high-resource setting 
is limited due to its low sensitivity compared to culture, our results suggest that 
implementation of Ultra as an add-on test will most likely be beneficial and lead to 
earlier diagnosis of extrapulmonary TB for the majority of culture positive patients in 
our setting. However, the clinical impact on diagnostic delay, TB morbidity and 
mortality should be investigated to ensure that implementation of a new and 
expensive test is actually cost-effective. As discussed above, the issue with reduced 
specificity must also be handled, and only selected samples from patients with a high 
pre-test probability of extrapulmonary TB should be subjected to Ultra. 
Finally, other potential serious consequences of Ultra implementation that need to be 
addressed, are the down-scaling or replacement of microscopy and culture facilities 
and networks due to increased use of Ultra. Ultra is not suitable for monitoring 
treatment response, and before better methods are developed, culture and or smear 
microscopy is still needed for this purpose. Reduced access to microscopy and/or 
culture may threaten the quality of other important parts of TB care, including 
treatment monitoring and drug susceptibility testing. Ideally, these effects of Ultra 
implementation should be studied alongside clinical impact on TB mortality and 
morbidity in further clinical phase IV diagnostic accuracy studies of Ultra. 
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5.4 Biomarkers for response to treatment in extrapulmonary 
tuberculosis 
Development of alternative methods that can replace culture and smear for evaluation 
of treatment response in extrapulmonary TB patients is needed for timely and proper 
management, as many of these patients are started empirically on treatment due to the 
low sensitivity of the conventional tests. A new marker for treatment response should 
detect treatment failure, e.g., caused by drug-resistant TB, low adherence to treatment 
or substandard/counterfeit tuberculosis drugs, and ideally should also be able to 
predict relapse-free cure. In study 4, we found that IP-10 levels significantly decline 
after two months of treatment and upon completion of successful treatment in HIV 
negative extrapulmonary TB patients, which is in accordance with several other 
studies that evaluate IP-10 response during treatment of TB 219,221,224-227. However, the 
small sample size in our study gives reduced power to the estimates. Detectable IP-10 
levels were present in both dried plasma spots and dried blood spots prepared from 
unstimulated blood samples, indicating that the concentration of the marker is 
sufficiently high in whole blood to allow for direct detection (as opposed to sample 
processing with antigen stimulation to increase cytokine responses). Moreover, taking 
a whole blood sample from a finger prick is an easily available sample material that 
can be stored and transported as dried blood spots at ambient temperatures to 
regional/hospital level laboratories for analysis, making it suitable for low-resource 
settings. Dried blood spots are already being used worldwide for newborn screening 
of congenital diseases276, and has also been tested for HIV screening and viral load 
monitoring277,278. 
A weakness of study 4 is that it did not include a control group of non-responders. As 
a consequence, our study only shows that there is a correlation between declining IP-
10 levels and response to treatment, and we cannot assess if IP-10 levels remain 
unchanged or increase during treatment failure or progression of disease, albeit 
limited data from previous studies suggest that this does occur 227,279. In one of these 
studies, a higher level of IP-10 at 2 months of treatment was found in pulmonary TB 
patients with high risk of treatment failure as defined by a positive sputum smear at 2 
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months and cavitations on initial chest x-ray227. However, the utility of IP-10 
monitoring to detect treatment failure is potentially much larger in smear negative 
pulmonary and extrapulmonary TB, but this remains to be investigated. As our cohort 
was only followed until end of treatment, it is not possible to evaluate the role of IP-
10 kinetics as a predictor for relapse-free cure. 
The low specificity of IP-10 is an issue that can affect interpretation, as observed in 
our study. Unstimulated IP-10 is a non-specific and dynamic marker of inflammation 
vis-à-vis C-reactive protein. High levels of IP-10 are not only associated with several 
infections 280-283, but also observed in a variety of inflammatory diseases 284-286 and 
other conditions that lead to changes in cytokine profiles 287. IP-10 levels may also 
vary between subgroups of TB patients. Studies in cell-models288,289 and humans290 
have shown that antibiotics can affect cytokine production, and TB patients on 
various drug regimens may show different cytokine patterns during treatment 
depending on the antibiotics used, albeit this has not been specifically studied for IP-
10. For TB HIV co-infected patients, changes in IP-10 levels may be influenced not 
only by response to TB treatment, but also by changes in CD4 cell count and 
immunomodulatory effects of antiretroviral drugs. It has also been reported that drug 
resistant strains can cause other immune responses than drug sensitive strains 291,292, 
which could be of importance if cytokines, including IP-10, are used to monitor 
treatment response in MDR-TB patients. IP-10 must, thus, be interpreted in a clinical 
context. Still, a non-specific marker may be useful during treatment monitoring, 
which is best exemplified by C-reactive protein. C-reactive protein is conventionally 
used to monitor treatment response in numerous infectious diseases, and albeit non-
specific, a decline in the marker during treatment indicates improvement. Of note, C-
reactive protein has also been shown to significantly decrease at two months of 
treatment in TB patients with clinical response 293,294. However, the marker may not 
be sensitive enough to monitor treatment response as detectable levels of C-reactive 
protein are not found in all patients at baseline 295. In contrast, detectable levels of IP-
10 were found for all the participants in our study, indicating that IP-10 may be a 
more sensitive marker. However, apparent stable or weakly fluctuating low levels of 
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plasma IP-10 (< 300 pg/mL) throughout treatment were observed in a few 
extrapulmonary TB patients despite good clinical response. TB patients represent a 
heterogenous group of patients, both in terms of infection sites and variation in 
systemic inflammation. Thus, low systemic plasma IP-10 levels in some patients 
could reflect low disease activity already at baseline, or compartmentalized 
production and degradation of cytokines at the site of infection, both limiting the use 
of the assay in the subgroups of extrapulmonary TB patients. This remains to be 
further examined. 
In the study, we found a high positive correlation between IP-10 measured in plasma 
and IP-10 extracted from dried plasma spots and dried blood spots. However, 
discordant results between the three methods were observed for some patients, mostly 
HIV-infected. This may be related to assay variability, even though the coefficient of 
variation for the standard curve triplicates in all runs was low, indicating a high intra-
assay precision. Still, coefficient of variation could not be calculated for individual 
patient samples, because the patient samples were assayed as singlets due to limited 
sample material. The use of triplicates in further studies would provide important 
information about whether assay varability or some other factor is causing discordant 
results between the methods. 
Empirical treatment of extrapulmonary TB and smear negative pulmonary TB is 
extensively used globally, particularly in low-resource settings 86,90. A biomarker that 
can predict treatment response at an early time point would be very useful for timely 
management of patients with presumptive TB in order to reduce overtreatment. A 
limitation of our study was that it did not include assessment of IP-10 treatment 
response at earlier time points than 2 months. Changes in immune responses, 
including IP-10, have been reported to occur as early as one week after start of 
treatment228,296, albeit the correlation between the early decline in IP-10 levels and 
clinical outcomes including treatment failure and successful treatment were not 
assessed in the studies. These data suggest that it may be possible to evaluate 
response to treatment at very early time points, but this remains to be investigated. 
The need for new biomarkers for assessment of treatment response is lower in high-
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income settings compared to low-resource settings because of reduced risk of failure 
to treatment caused by drug-resistant TB and overtreatment (more patients are culture 
confirmed before initiation of treatment), lower risk of non-adherance (stricter 
regimens of direct observed treatment), and extensive use of diagnostic imaging 
modalities to aid in clinical evaluation of treatment response. Still, as much as 29% of 
patients diagnosed with extrapulmonary TB in Norway in 2018 were not culture 
confirmed 17, indicating an uncertain diagnosis in a substantial proportion of patients 
with extrapulmonary disease even in high-income settings. Evaluation of IP-10 
response during treatment would be particularly usefull in these patients and should 




• The usefulness of introducing the MPT64 test as an add-on test for diagnosing 
extrapulmonary TB in a high-resource setting with optimal culture 
performance is limited due to low sensitivity compared to culture. However, 
the test may provide an earlier TB diagnosis as compared to culture and may 
be a useful tool in the absence of culture. 
• Acceptable reproducibility of a polyclonal antibody for the MPT64 test can be 
achieved through comprehensive screening of individual pre-immune sera and 
antisera from immunised rabbits, followed by pooling of the best functional 
antibodies to provide large volume of antibodies with stable performance. The 
choice of adjuvant and method for antigen production is also likely to affect 
the performance of the antibodies. 
• The use of Xpert Ultra as an add-on test may lead to earlier diagnosis of 
various forms of extrapulmonary TB in a high-resource setting, and may also 
provide earlier information about drug resistance. Caution must be made when 
interpreting Ultra trace positive results, particularly in patients with a previous 
history of TB which can give false positive results. 
• IP-10 levels measured in plasma, dried plasma spots and dried blood spots 
during TB treatment have the potential to serve as a biomarker for treatment 
response in extrapulmonary TB patients. However, further studies are needed 
to evaluate IP-10 responses during treatment failure and relapse and the low 
specificity of the marker may be an issue.  
• Dried blood spots represent an easy method for collection, storage and 
transportation of patient samples that can contribute to better sample flow in 
TB care in rural low-resource settings. 
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7. Future perspectives 
Even though the sensitivity of the MPT64 test in our study was low compared to 
culture, the results are uncertain, and a more controlled study with a larger sample 
size and complete reference standard data for all samples is needed to fully evaluate 
the test performance in our setting. Several other test issues including operator and 
observer variability, total test cost (including labour cost), overall turnaround time for 
test results, test capacity per day, time needed to train personnel and pathologist, and, 
finally, the clinical impact on TB morbidity and mortality, must also be determined 
before the cost-effectiveness of the MPT64 test can be compared to other tests.  
Further validation studies in different settings with head-to-head comparison with the 
reference antibody are also needed to confirm the non-inferiority of the new 
polyclonal antibody for the MPT64 test. An ongoing validation study of the new 
antibody in a clincally relevant study population is currently being undertaken in a 
high TB burden low-resource setting. 
Our findings indicate that Xpert Ultra has the potential to provide earlier diagnosis 
for extrapulmonary TB patients in a low-prevalent high-resource setting, but larger 
studies in similar settings are needed to confirm this. Further, the test is expensive, 
and cost-effectiveness analyses that include evaluation of the clinical impact of Ultra 
on diagnostic delay, morbidity, and mortality for extrapulmonary TB patients must be 
performed. The issue of reduced specificity of Ultra in patients with a previous 
history of TB warrants additional TB diagnostic testing in this group of patients to 
avoid overdiagnosis. 
In order to fully evaluate IP-10 as marker for response to treatment in extrapulmonary 
TB patients, further studies must include control groups of treatment failure and 
relapse. Patient samples should also be collected at earlier time points during 
treatment to explore the marker’s potential for early prediction of relapse-free cure. 
Further, IP-10 kinetics including normal variation in IP-10 levels in healthy controls, 
clinically significant cut-off levels and clinically significant changes in IP-10 levels 
during TB treatment needs to be determined.  
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Abstract
Background: Extrapulmonary tuberculosis (EPTB) poses diagnostic challenges due to the paucibacillary nature of
the disease. The immunochemistry-based MPT64 antigen detection test (MPT64 test) has shown promising results
for diagnosing EPTB in previous studies performed in low-resource settings, with higher sensitivity than microscopy
and culture. The aim of this study was to investigate the performance of the MPT64 test in a routine clinical setting
in a high-income low TB prevalence country.
Methods: Extrapulmonary samples sent for TB diagnostics to microbiology and pathology laboratories at three
regional tertiary care hospitals in Norway in a one-year period were included and subjected to the MPT64 test in
parallel to the routine TB diagnostic tests.
Results: Samples from 288 patients were included and categorised as confirmed TB cases (n = 26), clinically
diagnosed TB cases (n = 5), non-TB cases (n = 243) and uncategorised (n = 14), using a composite reference
standard (CRS). In formalin-fixed biopsies, the sensitivity (95% CI) of the MPT64 test, microscopy, PCR-based tests
pooled, and culture was 37% (16–62), 20% (4–48), 37% (16–62) and 50% (23–77), respectively, against the CRS. The
MPT64 test showed a good positive predictive value (88%) and an excellent specificity (99, 95% CI 92–100) in
formalin-fixed biopsies. In fine-needle aspirates, pus and fluid samples, the test performance was lower.
Conclusions: The MPT64 test was implementable in pathology laboratories as part of routine diagnostics, and
although the sensitivity of the MPT64 test was not better than culture in this setting, the test supplements other
rapid diagnostic methods, including microscopy and PCR-based tests, and can contribute to strengthen the
diagnosis of EPTB in formalin-fixed biopsies in the absence of culture confirmation.
Keywords: Extrapulmonary tuberculosis, Diagnostic test, Immunohistochemistry, MPT64, Antigen detection test
Background
While tuberculosis (TB) remains a global health problem,
the incidence in Norway and many other high-income
countries is low [1]. Still, diagnosis and control of TB dis-
ease poses significant challenges in high-income settings.
Although TB rates have been continuously declining in
the Norwegian-born population since the middle of the
past century, the overall TB incidence in Norway and
other high-income countries has remained relatively stable
over the last years because of immigration from TB preva-
lent countries [2–5]. Several studies also report that the
increase in foreign-born TB cases is associated with a rise
in the proportion of extrapulmonary TB (EPTB) [3, 5–7].
In the European region, EPTB has increased from 16,4%
of all TB cases in 2002 to 22,8% in 2016 [6, 8]. In the
Netherlands, England, Australia and Norway, EPTB cur-
rently accounts for as much as 40% of all TB cases [1, 2].
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The diagnosis of EPTB is challenging. Clinical and
radiological findings are often non-specific and the sen-
sitivity of routine TB diagnostic tests, including micros-
copy for acid fast bacilli (AFB) and culture, is low in
paucibacillary disease [9]. Culture also requires advanced
laboratory facilities, and results could be delayed up to 8
weeks. Globally, the use of rapid molecular tests for
detection of TB is increasing, albeit most commercially
available PCR-based tests are only approved for pulmon-
ary TB. The only World Health Organization (WHO)
endorsed PCR-based test for diagnosing EPTB, Xpert
MTB/RIF (Cepheid, Sunnyvale, CA), has shown variable
sensitivity in extrapulmonary samples [10] and is only
recommended for subgroups of EPTB [11]. A recently
launched new version, Xpert MTB/RIF Ultra (Xpert
Ultra), performs better in smear negative, culture posi-
tive sputum samples [12], but so far, few studies have
investigated its use in EPTB [13–18]. Histopathological
findings suggestive of TB may support the EPTB diagno-
sis, but these are also present in other diseases including
sarcoidosis and non-tuberculosis mycobacteria (NTM)
infections. The incidence of NTM infections is also
increasing in western countries [19–22]. Due to these
diagnostic challenges, a definite diagnosis of EPTB is
often difficult to obtain. Many EPTB patients are diag-
nosed clinically and EPTB is associated with diagnostic
delay [23–25]. Thus, better diagnostic tests are needed
to improve early case detection and management of
EPTB patients.
An immunochemistry-based test for detection of the
mycobacterial secreted protein MPT64 (MPT64 test)
from biopsies, fine-needle aspirates (FNAs) and fluid
samples has shown high sensitivity for diagnosing EPTB
in previous studies compared to culture and a TB spe-
cific nested-PCR [26–31]. The MPT64 test is robust and
fast, and can differentiate between NTM and TB disease,
as the MPT64 protein is specific for Mycobacterium
tuberculosis complex (MTBC) species, and not found in
NTM [32–34]. A recent study conducted in Zanzibar,
Tanzania, has also shown that the MPT64 test is imple-
mentable in a routine TB diagnostic setting in a TB
high-endemic low-resource country [35]. However, the
performance of the MPT64 test has not yet been evalu-
ated in a routine clinical setting in a low TB burden
high-income country. The objective of the study was to
evaluate performance of the MPT64 test and whether
the test would provide an added value to EPTB diagnos-
tics when implemented in routine TB diagnostics in the
high-resource health care system in Norway.
Methods
Sample inclusion
Formalin-fixed biopsies, FNAs and fluid samples sent for
TB diagnostics to microbiology and pathology laboratories
at three regional tertiary care hospitals (Haukeland Univer-
sity Hospital (HUH), Oslo University Hospital (OUH) and
Stavanger University Hospital (SUH)) from January 2015
until January 2016 were prospectively included in the study,
provided there was enough material left after routine diag-
nostics to prepare a minimum of one cell smear or tissue
section for the study (Fig. 1). Acellular fluid samples and all
samples from patients that had received TB treatment dur-
ing one year prior to the study, were excluded.
Because very few formalin-fixed biopsies from patients
with presumptive TB had been prospectively included, a
retrospective inclusion of biopsy specimens was also per-
formed. At HUH and SUH, all samples included in the
study from the microbiology laboratories were cross-
checked with the pathology laboratory registers to see if
the same sample, or a different sample material collected
from the same location at the same time, had been sent
to the pathology laboratories. At OUH, a list of all biop-
sies sent for TB diagnostics to the microbiology labora-
tory during 2015 was cross-checked with the pathology
register to find the samples that had been sent for both
departments. Based on these searches, formalin-fixed
biopsies from the pathology departments were included
if they showed any type of inflammation or necrosis.
Biopsies with a histopathological diagnosis other than
TB (e.g. malignancy) or no pathological findings were
not included as these samples will not be subjected to
TB specific tests at the pathology laboratory in a routine
clinical setting.. Additionally, all formalin-fixed biopsies
that had been subjected to a TB specific nested-PCR as
part of routine diagnostics at Department of Pathology
at HUH, were retrospectively included.
Sample processing and routine TB diagnostic procedures
All samples were subjected to routine TB diagnostics at
the inclusion hospitals according to local diagnostic
algorithms. At the microbiology laboratories, FNAs in
saline and fluid samples were used unconcentrated if
volume < 10mL and concentrated by centrifugation
before resuspension of sediment in saline if the sample
volume was > 10 mL. Biopsy specimens were mechanic-
ally homogenized and resuspended in saline. Cell smears
were stained using the Ziehl-Neelsen or Auramine
method for detection of AFB. For the study, a minimum
of one cell smear from fluid samples was prepared on a
Superfrost glass, air-dried for 20 min, fixed in absolute
ethanol for 20 min and stored at room temperature. A
standard NALC-NaOH decontamination procedure was
performed on the remaining sample material if the sample
was non-sterile, before appropriate sample volumes were
seeded in liquid medium (BACTEC MGIT), and for most of
the samples, also onto solid medium (Lowenstein-Jensen).
At HUH, all lymph node specimens, sterile fluids and aspi-
rates and most biopsies were cultured both before and after
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NALC-NaOH decontamination, and lymph node specimens
were also cultured at 28 °C. If PCR was requested by the
clinician, a 1-step PCR-based tests (1-step PCR) including
Cobas Taqman MTB (Roche, Switzerland) at OUH, Abbott
Real Time MTB (Abbott, United States) at SUH and Geno-
type MTBDR plus (Hain Lifescience, Germany) at HUH,
was performed. All samples with a remaining volume of >
0.5mL, were stored at − 80 °C for later analysis with Xpert
Ultra.
At the pathology laboratories, biopsy specimens were
routinely fixed in PBS buffered formalin and embedded
in paraffin before tissue sections were prepared for hist-
ology. Fine-needle aspiration from lymph nodes was
performed by local clinicians or pathologists and cell
smears for cytology were directly prepared and fixed
after sample collection. If microscopy for AFB was
requested by the pathologist, the Ziehl-Neelsen (HUH,
SUH), Auramine (OUS) or Fite Faraco [36] (OUS) method
was used. Additionally, a previously developed in-house
nested-PCR (n-PCR) for detection of the MTBC-specific
IS6110 sequence in DNA extracted from archived material
[37] was also performed on the samples as part of routine
diagnostics at HUH only, if requested by the pathologist.
Xpert ultra
Xpert Ultra was performed on all the frozen sample ma-
terial during the autumn 2018, except for pleural fluid
samples, which were only subjected to Xpert Ultra if TB
was mentioned as a differential diagnosis on the request
form or in patient records. This was done to exclude
clinically irrelevant samples, as many pleural fluid sam-
ples are routinely sent for TB diagnostics, even when the
Fig. 1 Flow chart of study design and sample inclusion. Abbreviations: TB, tuberculosis; PCR, polymerase chain reaction; AFB, acid fast bacilli.
1Uncategorised cases included 3 patients who died, 2 patients that did not show for clinical controls, 8 patients that had not been given a
definite diagnosis 8 months after inclusion of samples ended, but for whom TB could not be ruled out either because they have previously been
treated for TB or because histopathology showed necrotising granulomas and giant cells in the samples included. The last patient was given a
clinical TB diagnosis, but the sample included in the study showed no pathology and may be non-representative of the site of infection
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pre-test probability of TB is very low. Samples were
thawed at room temperature and processed according to
the manufacturer’s protocol. All but two samples (both
volume 0.25 mL) had a sample volume of minimum 0.5
mL. Samples with volume < 0.7 mL (n = 20) were added
sample reagent to sample in a 3:1 ratio, whereas a ratio
of 2:1 was used for samples with a volume of 0.7 mL or
more (n = 28).
Immunostaining with MPT64
The MPT64 test was performed by a laboratory technician
in parallel to routine TB diagnostics at Department of
Pathology at HUH. The request form with clinical infor-
mation, sometimes including results of TB diagnostic
tests, was available to the technician. The test was per-
formed using an in-house polyclonal rabbit anti-MPT64
antibody at 1:250 dilution together with the Dako Envision
+ System-HRP kit (Agilent, Santa Clara, CA), according to
the manufacturer’s protocol with some modifications as
earlier described [26, 28]. Briefly, tissue sections were
deparaffinized with xylene, before tissue sections and cell
smears were rehydrated through decreasing grades of al-
cohol. Microwave antigen retrieval in citrate buffer, pH
6.2, was then performed on tissue sections only. Further,
tissue sections and cell smears were washed in distilled
water for 10min and incubated with hydrogen peroxide
for 20min. The primary anti-MPT64 antibody was applied
and the slides were incubated for 60min, before horse-
radish conjugated secondary anti-rabbit antibody was
applied for 45min. Thereafter, the substrate (3-amino-9-
ethylcarbazol) was added to the slides for 10min for
smears and 15min for biopsies, followed by counterstain-
ing with Mayer’s haematoxylin and mounting with Immu-
Mount (Thermo Fisher Scientific, United States). Slides
were washed with wash buffer (0.05mol/L Tris/HCl buff-
ered saline with 0.05% Tween 20, pH 7.6) between incuba-
tion steps.
Evaluation of immunostaining
A laboratory technologist was trained to screen the
MPT64 test stained cell smears prepared from fluid
samples. Screening was performed at a total magnifica-
tion of 200x and more detailed evaluation at 400x. Fluid
samples screened possibly positive were examined by a
designated pathologist, who also evaluated all biopsies
and FNAs, according to a previously developed guideline
for interpretation [35]. Briefly, a sample was positive if a
minimum of two granular red-brown coloured spots,
either observed intracytoplasmic in inflammatory cells
or extracellularly in necrotic material, were present in
the sample. If only one typical spot was present, or if the
staining was not strongly granular, the test was evaluated
as weakly positive. No staining, nuclear staining or extra-
cellular granular staining in non-necrotic areas were
interpreted as negative. Clinical information on the
request form, which sometimes included information
about results of routine TB diagnostics, was available to
the pathologist.
Categorisation of samples and patients according to a
composite reference standard
A composite reference standard (CRS), including both
microbiologically confirmed TB and clinically diagnosed
TB, was used to define a TB case. Results of routine TB
diagnostic tests and cyto/histopathological examination
were obtained from the laboratory information systems.
Medical records for all patients with culture and PCR
negative samples were checked for a clinical TB diagno-
sis 8 months after the inclusion of samples had finished.
According to the CRS, a patient was defined as a con-
firmed TB case if a culture and/or PCR (1-step PCR
and/or n-PCR) positive sample was registered during the
inclusion period or on a repeat sample until 8 months
afterwards. Culture and/or PCR positive samples were
classified as confirmed samples from confirmed TB cases,
whereas culture and PCR negative samples from patients
that were diagnosed with microbiologically confirmed
TB within 8 months after end of inclusion, were classi-
fied as unconfirmed samples from confirmed TB cases. A
patient that had been given a clinical TB diagnosis and
successfully completed a full course of TB treatment,
was defined as a clinically diagnosed TB case. Patients
with culture and PCR negative samples that improved
without treatment, or were given a diagnosis other than
TB, or had a negative interferon-gamma-release assay, or
had stable symptoms and negative results of TB diagnos-
tics at repeated controls until 8 months after the inclu-
sion had finished, were defined as non-TB cases. Patients
that did not fit into any of these categories were classi-
fied as uncategorised cases.
Statistical analysis
Test performance was evaluated using one sample per
case. When multiple samples were included from one
case, the first sample collected from non-TB cases and
the first confirmed TB sample collected from TB cases
was chosen for analysis. For TB cases with multiple
unconfirmed samples included, the sample with cyto/
histopathological findings most strongly suggestive of
TB was chosen. Sensitivity, specificity and accuracy were
calculated using the CRS as reference method.
Results
Clinical samples
A total of 465 samples received for TB diagnostics at the
inclusion hospitals were consecutively sent to the HUH
during the study period (Fig. 1). Additionally, 97 samples
were retrospectively included from the same hospitals.
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After exclusion of 202 samples for various reasons, the
remaining 360 samples from 288 patients were classified
using the CRS. Twenty-six patients were confirmed TB
cases, 5 clinically diagnosed TB cases, 243 non-TB cases
and 14 uncategorised cases. Uncategorised cases were
excluded, leaving samples from 274 patients for analysis.
Clinical characteristics for the included samples are
shown in Table 1. Pleural fluid was the most common
sample type. The MPT64 test was performed on all
samples, whereas the type and number of routine TB
diagnostic tests performed on the samples varied. HIV
status was unknown for the study participants.
Among the 97 retrospectively included formalin-fixed
biopsies, 13 biopsies were included because they had
been subjected to a TB specific n-PCR at the pathology
laboratory at HUH, due to histopathological findings
suggestive of TB. These samples had not been sent for
TB diagnostics at the microbiology laboratory and TB
was not mentioned as a differential diagnosis on the
request form. Four of 13 samples were n-PCR positive,
and TB was thus, an unexpected finding in these cases.
MPT64 test performance compared to routine TB
diagnostics and Xpert ultra
Biopsy specimens
Using the CRS, the sensitivity (95% CI) of the MPT64 test
in formalin-fixed biopsies was 37% (16–62), compared to
20% (4–48), 37% (16–62) and 50% (23–77) for micros-
copy, PCR-based tests pooled and culture respectively
(Tables 2 and 3). Against PCR (1-step PCR and n-PCR
pooled) as a reference standard, the sensitivity of the
MPT64 test was 71% (5/7, 95% CI 29–96). However, in
PCR negative, culture positive biopsies (n = 6), the MPT64
test was negative in all samples. One of the 69 non-TB
biopsies was MPT64 test positive, yielding a positive pre-
dicitive value of 88% (7/8 MPT64 test positive biopsies
were from TB cases) and an excellent specificity of 99%
(95% CI 92–100). Granulomatous inflammation with
necrosis, the most specific histopathological finding sug-
gestive of TB, was present in 13/19 biopsies from TB cases
and 13/69 non-TB biopsies (Table 4). This gives histo-
pathology a sensitivity, specificity and positive predicitive
value of 68% (43–87), 81% (70–90) and 50% (36–64) re-
spectively against the CRS. Among biopsies from non-TB
cases, 5 samples were bacteriologically confirmed NTM
infections and another 3 samples came from patients with
a probable, though not confirmed, NTM infection. The
MPT64 test was negative inn all these samples.
Fine needle-aspirates and fluid samples
Abundant non-specific staining was observed in the cell
smears prepared from FNAs, pus and fluid samples, and
the MPT64 test performance was lower in these materials
compared to the biopsies. Using the CRS, the sensitivity
and specificity of the MPT64 test in lymph node FNAs
was 29% (95% CI 4–71) and 50% (95% CI 7–93) respect-
ively. Cytopathological findings suggestive of TB had low
Table 1 Characteristics of samples included (one sample per patient)
TB cases1 non-TB cases
n = 31 n = 243
Sample material
Lymph node aspirates 7 4
Lymph node biopsies 7 17
Other biopsies 12 52
Pus 2 13
Pleural fluid 3 133
Ascites 0 8
Pericardial fluid 0 3
Synovial fluid 0 10
Other fluids 0 3
Number of samples
per patient2
1 sample 24 200
2 samples 6 33
3 samples 0 6
4 samples 1 3





n = 88 n = 11 n = 175




Microscopy3 59 9 43
1-step PCR 32 6 8
Nested-PCR 12 4 1
Culture 68 9 83
Sample only sent to the
microbiology laboratory
N/A N/A 92
Microscopy N/A N/A 51
1-step PCR N/A N/A 12
Culture N/A N/A 92
Sample only sent to the
pathology laboratory
20 2 N/A
Microscopy 4 0 N/A
Nested-PCR 17 1 N/A
Abbreviations: TB, tuberculosis; PCR, polymerase chain reaction, N/A, not applicable
1Includes 5 clinically diagnosed patients
2Number of samples per patient included at different time points. Patients
with the same material from the same site (n = 27), different material from the
same site (n = 13), material from different locations (n = 6), material from different
locations, multiple samples collected from some of these locations (n = 4)
3Microscopy performed at pathology and/or microbiology laboratory. A
sample with discordant microscopy results between the laboratories (n = 2) is
registered as positive
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sensitivity and specificity for diagnosing TB. In pus and
fluid samples, the sensitivity of all tests methods was diffi-
cult to evaluate due to few TB cases. All three pleural
fluids from TB cases were culture positive and negative
with all other tests. Two pus samples from TB cases were
included. One was microscopy negative and positive with
culture, 1-step PCR, Xpert Ultra and the MPT64 test,
whereas the other sample was negative with all tests.
Many non-TB pus and fluid samples were interpreted as
weakly positive (n = 33) or positive (n = 3), and the specifi-
city of the MPT64 test was 80% (95% CI 72–86) and 69%
(95% CI 39–91) in fluid and pus samples, respectively.
Head-to-head comparison of various diagnostic methods
As the number of TB diagnostic tests performed on the
samples varied greatly, the diagnostic performance of
the different tests was also evaluated based on head-to-
head comparisons (Table 5). There was no difference in
the overall test performance between microscopy and
the MPT64 test, which both detected the same number
of TB cases as 1-step PCR, and fewer TB cases than n-
PCR, Xpert Ultra and culture. Further, the subgroup
comparisons of culture, 1-step PCR, microscopy and the
MPT64 test showed that some samples were positive in
one test and negative in the other and vice versa. The
MPT64 test was positive in 4 microscopy negative sam-
ples, 2 1-step PCR negative samples and 3 culture negative
samples, indicating added value of combining various TB
diagnostic tests.
Discussion
This is the first study in which the MPT64 test, an
immunochemistry-based test for diagnosing EPTB, has
been implemented in parallel to routine TB diagnostics
in a low TB prevalence country with a high-resource
health care system. Using a CRS that included clinically
Table 2 Results of routine TB diagnostic tests, Xpert Ultra and the MPT64 test performed on samples
Positive samples/total samples (%)
Number of cases Micro-scopya Culture 1-step PCR Nested-PCR Xpert Ultra MPT64 test
TB cases
All samples 31 6/27 (22) 16/26 (62) 6/18 (33) 7/11 (64) 4/7 (57) 10/31 (32)
Lymph node biopsies 7 1/6 (17) 2/6 (33) 0/5 (0) 2/2 (100) N/A 3/7 (43)
Other biopsies 12 2/9 (22) 5/8 (63) 1/7 (14) 4/6 (67) N/A 4/12 (33)
Pus samples 2 0/2 (0) 1/2 (50) 1/1 (100) N/A 1/2 (50) 1/2 (50)
Lymph node aspirates 7 3/7 (43) 5/7 (71) 4/4 (100) 1/3 (33) 3/4 (75) 2/7 (29)
Fluid samples 3 0/3 (0) 3/3 (100) 0/1 (0) N/A 0/1 (0) 0/3 (0)
Confirmed TB case -confirmed sample 22b 5/19 (26) 16/17 (94) 6/13 (46) 7/9 (78) 4/5 (80) 8/22 (36)
Culture positive sample 16 4/16 (25) 16/16 (100) 5/12 (42) 2/4 (50) 4/5 (80) 3/16 (19)
Culture positive, PCR positive sample 6 3/6 (50) 6/6 (100) 5/5 (100) 2/2 (100) 3/3 (100) 3/6 (50)
Culture positive, PCR negative sample 8 1/8 (13) 8/8 (100) 0/7 (0) 0/2 (0) 1/2 (50) 0/8 (0)
1-step PCR positive sample 6 4/6 (67) 5/6 (83) 6/6 (100) 1/1 (100) 3/3 (100) 4/6 (67)
Nested-PCR positive sample 7 1/4 (25) 2/2 (100) 1/1 (100) 7/7 (100) 1/1 (100) 5/7 (71)
Confirmed TB case -unconfirmed sample 4 0/3 (0) 0/4 (0) 0/3 (0) N/A N/A 2/4 (50)
Clinically diagnosed TB case 5 1/5 (20) 0/5 (0) 0/2 (0) 0/2 (0) 0/2 (0) 0/5 (0)
Non-TB cases
All samples 243 7/139 (5) 0/226 (0) 0/40 (0) 0/24 (0) 1/41 (2) 39/243 (16)
Lymph node biopsies 17c 1/13 (8) 0/14 (0) 0/4 (0) 0/4 (0) 0/2 (0) 0/17 (0)
Other biopsies 52d 2/35 (6) 0/40 (0) 0/16 (0) 0/17 (0) 1/8 (13) 1/52 (2)
Pus samples 13e 3/13 (23) 0/13 (0) 0/4 (0) 0/1 (0) 0/8 (0) 4/13 (31)
Lymph node aspirates 4f 1/2 (50) 0/2 (0) 0/2 (0) 0/2 (0) 0/1 (0) 2/4 (50)
Fluid samples 157 0/76 (0) 0/157 (0) 0/14 (0) N/A 0/22 (0) 32/157 (20)
Abbreviations: TB, tuberculosis; PCR, polymerase chain reaction
aMicroscopy performed at microbiology laboratory and/or pathology laboratory. A sample with discordant microscopy results between the laboratories (n = 2) is
registered as microscopy positive
bOne of the nested-PCR positive patients was not started on TB treatment, and only followed by controls
c6 cases of NTM infection (2 NTM culture positive, 1 NTM specific PCR positive, 3 given a clinical diagnosis)
d2 cases of NTM infection (2 NTM specific PCR positive)
e3 cases of NTM infection (3 microscopy and NTM culture positive)
f1 case of NTM infection (microscopy, NTM culture and NTM specific PCR positive. This case was also MPT64 positive)
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diagnosed TB cases, the test had a sensitvity (95% CI) of
37% (16–62) in formalin-fixed biopsies, compared to
37% (16–62) and 50% (23–77) for PCR-based tests
pooled and culture, respectively. The specificity of the
test was excellent (99, 95% CI 92–100) in formalin-fixed
biopsies. In cell smears prepared from FNAs, pus and
fluid samples, the test performance was low. Culture was
found to be the most sensitive method for diagnosing
TB in the study, with a disadvantage of long turnaround
time. The study revealed that in this low TB incidence
setting, many EPTB cases are incidentally detected based
on histopathological findings in biopsy specimens that










All samples (n = 274)
Microscopy 166 22 (9–42) 95 (90–98) 83
Culture 252 62 (41–80) 100 (98–100) 96
PCR (1-step PCR and n-PCR pooled) 87 44 (26–65) 100 (94–100) 83
Xpert Ultra 48 57 (18–90) 98 (87–100) 92
MPT64 test 274 32 (17–51) 84 (79–88) 78
Lymph node biopsies (n = 24)
Microscopy 19 17 (0–64) 92 (64–100) 68
Culture 20 33 (4–78) 100 (77–100) 80
PCR (1-step PCR and n-PCR pooled) 15 29 (4–71) 100 (63–100) 67
Xpert Ultra 2 N/A 100 (16–100) –
MPT64 test 24 43 (10–82) 100 (80–100) 83
All biopsies (n = 88)
Microscopy 63 20 (4–48) 94 (83–99) 76
Culture 68 50 (23–77) 100 (93–100) 90
PCR (1-step PCR and n-PCR pooled) 57 37 (16–62) 100 (91–100) 79
Xpert Ultra 10 N/A 90 (56–100) –
MPT64 test 88 37 (16–62) 99 (92–100) 85
Lymph node aspirates (n = 11)
Microscopy 9 43 (10–82) 50 (1–99) 44
Culture 9 71 (29–96) 100 (16–100) 78
PCR (1-step PCR and n-PCR pooled) 9 67 (22–96) 100 (29–100) 78
Xpert Ultra 5 75 (19–99) 100 (3–100) 80
MPT64 test 11 29 (4–71) 50 (7–93) 36
Pus samples (n = 15)
Microscopy 15 0 (0–84) 77 (46–95) 67
Culture 15 50 (1–99) 100 (75–100) 93
PCR (1-step PCR and n-PCR pooled) 6 100 (3–100) 100 (48–100) 100
Xpert Ultra 10 50 (1–99) 100 (63–100) 90
MPT64 test 15 50 (1–99) 69 (39–91) 67
Fluid samples (n = 160)
Microscopy 79 0 (0–71) 100 (95–100) 96
Culture 160 100 (29–100) 100 (98–100) 100
PCR (1-step PCR and n-PCR pooled) 15 0 (0–98) 100 (77–100) 93
Xpert Ultra 23 0 (0–98) 100 (85–100) 96
MPT64 test 160 0 (0–71) 80 (72–86) 78
Abbreviations: PCR, polymerase chain reaction; CI, confidence interval
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have not been sent for culture in parallel. Histopatho-
logical findings alone cannot confirm a TB diagnosis, and
in these cases, the MPT64 test can supplement other rapid
tests, including microscopy and n-PCR. This test is less
prone to contamination than PCR and, in contrast to
microscopy, can differentiate between MTBC and NTM
infections. Thus, the MPT64 test may strengthen the TB
diagnosis in a pathology laboratory in the absence of cul-
ture confirmation.
The MPT64 test performance was lower in the present
study compared to previous studies [28–30, 35]. Against
a CRS, the overall sensitivity was 32% (95% CI 17–51)
for the MPT64 test, compared to 67–100% in previous
studies [28–30, 35]. The use of different composite refer-
ence standards and variable TB prevalence across the
studies may contribute to this variation. All previous
studies were conducted in high TB burden settings, in
which a higher pre-test probability of TB combined with
potentially more advanced stage of TB disease at the
time of diagnosis, may lead to higher test sensitivity. Still,
also when using culture as a reference standard, the overall
MPT64 test sensitivity was lower (19, 95% CI 4–46)
compared to previous studies (75–100%) [26, 28, 30, 35,
37]. This could partly be explained by different procedures
for culture used across the studies. Apportioning of smaller
sample volumes for culture and long transportation time to
the TB laboratory, potentially reducing the viability of the
bacilli, may have reduced the sensitivity of culture in previ-
ous studies [35]. In most of the previous studies, all samples
were decontaminated and seeded onto only 1 tube of solid
medium, whereas 2–8 culture tubes per sample were used
for most samples in the present study, including culturing
of material not treated with NALC-NaOH for many
samples. These factors can lead to increased sensitivity of
culture in our study, especially in paucibacillary specimens
with non-uniform distribution of bacilli. Further, the use of
different reference standards makes it challenging to com-
pare the studies. For validation of the MPT64 test, n-PCR
has been used as a reference standard in most previous
studies, yielding a sensitivity of 72–100% [26–29, 31, 35]. In
the present study, n-PCR was only performed on a sub-
group of samples and could not be used for validation
alone. However, when using n-PCR as a reference standard
in this subgroup, the sensitivity of the MPT64 test was 71%
Table 4 Cyto/histopathological findings in biopsy and fine-needle aspirate samples
TB cases Non-TB cases
Confirmed sample Unconfirmed sample Clinically diagnosed sample Total TB cases
Histomorphology, biopsies (n = 88) n = 13 n = 3 n = 3 n = 19 n = 69
Granulomatous inflammation
with necrosis
9 3 1 13 13
Granulomatous inflammation
without necrosis












Foreign body granuloma 1
Lymph node hyperplasia 1
Mesothelial proliferation 1
No pathology 1




Abundant necrosis 3 3 1
Fluid background, mostly RBCs 1 1 1
Subacute or chronic inflammation 1 1 1
Acute inflammation 1 1
Abbreviations: TB, tuberculosis; FNA, fine-needle aspirate
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(95% CI 29–96). This is close to previous findings. More-
over, all culture positive samples were n-PCR positive in
previous studies, whereas the present study included several
culture positive, but PCR negative samples (n = 8). The
MPT64 test was negative in all these culture positive, PCR
negative samples. Assuming that culture positive, PCR
negative samples have a lower bacterial load than culture
positive, PCR positive samples, these results indicate that
the MPT64 test is not sensitive enough to detect samples
with very low bacterial load. However, the long turnout
time of culture does not help clinicians to make a timely
diagnosis. Further, although culture performed under opti-
mal conditions is the most sensitive method for diagnosing
EPTB in the present study, TB culture facilities are not
available in most TB endemic areas, in which TB diagnos-
tics are most needed.
The specificity of the MPT64 test in biopsy specimens
was very high and comparable to results observed in
previous studies, whereas the specificity in cell smears
prepared from FNAs, pus and fluid samples was lower.
In lymph node FNAs, the specificity was only 50%, How-
ever, this was based on only two MPT64 test positive
non-TB cases of a total of four non-TB cases, which
gives low power to the estimate. In pus and fluid sam-
ples, non-specific false positive staining was observed in
a large proprotion of the smears and made interpretation
challenging. The non-specific staining may have been
caused by suboptimal sample handling at the microbiol-
ogy laboratories where samples could be stored cold for
more than one day before preparation of smears, as indi-
cated by cell lysis in many samples. Long storage time
may have affected the antigen integrity and increased non-
specific binding. In contrast, smears in previous studies
were prepared immediately after sample collection.
The low specificity of the test in cell smears has a
greater impact in this low prevalence setting compared
to a high prevalence setting because more false positive
cases and unecessary treatment must be accepted for
every true positive case detected. Thus, the results of the
present study indicate that the MPT64 test is not useful
for diagnosis of EPTB in cell smears. In biopsy speci-
mens, on the other hand, the test was highly specific. It
was negative in clinically relevant non-TB samples with
various types of inflammation and in all samples from
patients with NTM infections. NTM infection is an
important differential diagnosis to EPTB, as 31% of the
microbiologically confirmed mycobacterial infections
were NTM in the present study.
There are limitations to the study. The low number of
TB cases gives low power to sensitivity estimates.. Fur-
ther, the exlusion of culture and PCR negative samples
because information about clinical TB diagnosis was not
available (Fig. 1), in addition to the exclusion of biopsies
with a histopathological diagnosis other than TB or no
pathological findings, leads to a selection bias in favour
of samples with a higher pre-test probability of TB,
which could affect specificity estimates. As the study was
designed to evaluate the MPT64 test performance in a
routine setting, we did not intervene in sample handling
or TB diagnostic algorithms at the inclusion sites, lead-
ing to many suboptimally prepared samples for the
MPT64 test. Samples from patients with presumptive






















Nested-PCR+ Nested-PCR- Culture + Culture -
n = 10 n = 21 n = 6 n = 21 n = 6 n = 12 n = 7 n = 4 n = 16 n = 10
Microscopy + 2 4
Microscopy - 4 17
1-step PCR + 4 2 4 2
1-step PCR - 2 10 2 9
Nested-PCR + 5 2 1 3 1 0
Nested-PCR - 0 4 0 4 0 1
Culture + 3 13 4 12 5 7 2 2
Culture - 3 7 2 7 1 5 0 2
Xpert Ultra + 2 2 2 2 3 0 1 1 4 0
Xpert Ultra - 0 3 0 3 0 1 0 1 1 2
Abbreviations: TB, tuberculosis; PCR, polymerase chain reaction
1TB cases include both microbiologically confirmed TB cases (n = 26) and clinically diagnosed TB cases (n = 5)
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EPTB were often not sent for TB diagnostics both to
microbiology and pathology laboratories, as would have
been expected according to good clinical practice. Not
only may this lead to diagnostic delay since the available
diagnostic tools are not fully utilized in difficult-to-
diagnose cases, but it also makes it difficult to compare
test performance in the present study because the types
and number of tests performed per sample varied
greatly. Hence, more controlled validation studies with
larger cohorts are needed to fully asses MPT64 test per-
formance in a low TB incidence high-resource setting.
Conclusions
The diagnosis of EPTB is challenging in a high-resource,
low-TB incidence country. The awareness of TB is often
low and routine TB diagnostic tests are not able to iden-
tify all EPTB cases. The MPT64 antigen detection test
has a good positive predictive value and an excellent
specificity in formalin-fixed biopsies and is implementa-
ble in pathology laboratories. In the absence of culture,
the MPT64 test may contribute to strengthen the TB
diagnosis in formalin-fixed biopsies when used in com-
bination with microscopy and PCR-based tests, and thus,
has an added value in TB diagnostics in this setting.
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Abstract: Tuberculosis (TB) is a global health problem. The 17 
immunohistochemistry (IHC)-based MPT64 antigen detection test has shown 18 
promising results for diagnosing extrapulmonary TB in previous studies. 19 
However, the anti-MPT64 antibody currently used in the test is in limited 20 
supply, and reproduction of a functional antibody is a prerequisite for further 21 
large-scale use. Various antigen-adjuvant combinations and immunisation 22 
protocols were tested in mice and rabbits to generate monoclonal and 23 
polyclonal antibodies. Antibodies were screened in IHC, and the final new 24 
antibody was validated on clinical human specimens. We were not able to 25 
generate monoclonal antibodies that were functional in IHC, but we obtained 26 
multiple functional polyclonal antibodies through careful selection of 27 
antigen-adjuvant and comprehensive screening in IHC of both pre-immune 28 
sera and antisera. To overcome the limitation of batch-to-batch variability 29 
with polyclonal antibodies, the best performing individual polyclonal 30 
antibodies were pooled to one final large-volume new anti-MPT64 antibody. 31 
The sensitivity of the new antibody was in the same range as the reference 32 
antibody, while the specificity was somewhat reduced. Our results suggest 33 
that it possible to reproduce a large-volume functional polyclonal antibody 34 
with stable performance, thereby securing stable supplies and reproducibility 35 
of the MPT64 test, albeit further validation remains to be done.  36 
Keywords: extrapulmonary tuberculosis; diagnostics; antigen detection; MPT64; 37 
immunohistochemistry; polyclonal antibody; monoclonal antibody. 38 
 39 
1. Introduction 40 
Tuberculosis (TB) is a global health problem with an estimated 10 million 41 
new cases and 1.4 million deaths in 2019 (1). Approximately one third of the 42 
estimated new TB cases each year are not diagnosed or reported. 43 
Extrapulmonary TB (EPTB), which is more common in children and people 44 
with HIV (2-6), pose a special diagnostic challenge due to the paucibacillary 45 
nature of the disease. This leads to variable and generally low sensitivity of 46 
routine microscopy, PCR and culture (1, 7), and new improved diagnostic 47 
tests are needed. Tests based on detection of mycobacterial antigens are of 48 
special interest as they have the potential to provide rapid and direct evidence 49 
of active TB disease (8). Two antigen-detection tests for TB diagnosis are 50 
currently commercially available (Alere Determine TB LAM and Fujifilm 51 
SILVAMP TB LAM, both detecting lipoarabinomannan in urine) but their 52 
clinical use is restricted due to suboptimal sensitivity (9, 10). The novel MPT64 53 
antigen-detection test (the MPT64 test) for the diagnosis of EPTB, which is 54 
based on detection of the mycobacterial antigen MPT64 in tissue samples from 55 
the site of infection, has shown promising results in previous validation 56 
studies (11-18), with higher sensitivity than routine smear and culture in high 57 
TB incidence settings (12-17). The test is feasible to implement in the low-58 
resource setting and can contribute towards timely and accurate diagnosis of 59 
EPTB (16). These results warrant further research to evaluate the diagnostic 60 
test accuracy in larger cohorts and to investigate the potential for large-scale 61 
use and clinical roll-out of the test. However, the in-house polyclonal rabbit 62 
anti-MPT64 antibody used in the test so far is in limited amount, and 63 
reproduction of an antibody with stable performance, which is a pre-requisite 64 
for large-scale use, can be challenging due to batch-to-batch to variations in 65 
polyclonal antibodies (19). The aim of the study was to develop an anti-66 
MPT64 antibody to secure stable supplies and performance of the MPT64 test. 67 
Here, we describe different aspects to be considered when developing 68 
antibodies for use in immunohistochemistry (IHC), the challenges faced with 69 
the production of a monoclonal antibody and strategies to make large 70 
volumes of a functional polyclonal antibody. 71 
2. Materials and Methods 72 
Production of MPT64 antigen 73 
Several strategies were used to produce MPT64 antigen for 74 
immunisation. Native MPT64 was produced because the conformational 75 
epitopes, which may be important targets in IHC, are conserved in native 76 
proteins. Native MPB64 protein was obtained from cultures of Mycobacterium 77 
bovis bacillus Calmette-Guérin Moreau (BCG Moreau), according to 78 
previously developed protocols for culturing and purification (20-22), with 79 
some modifications (Supplementary text). MPB64 is homologous to the M. 80 
tuberculosis derived MPT64 protein used as an antigen when the reference 81 
anti-MPT64 antibody was generated (23), and the two proteins are hereafter 82 
collectively referred to as MPT64. Because production of native MPT64 is 83 
time-consuming due to the slow growth of the bacilli and the resulting low 84 
yield of MPT64 protein, we also produced recombinant MPT64 antigen in 85 
several expression systems. In our laboratory, untagged recombinant MPT64 86 
protein was expressed in the non-pathogenic, fast-growing M. smegmatis 87 
mc2 155 (24) transformed with the mycobacterial plasmid (pUV15tetORm 88 
(25)) modified to contain the mpb64 gene with its predicted secretion signal 89 
sequence (GenBank Accession No. AM412059.2; BCGM locus 1981c), 90 
according to previously developed protocols (25-27), (Supplementary text, 91 
figure S1). His-tagged recombinant MPT64 was produced in E. coli (by 92 
Trenzyme Life Science Services, Konstanz, Germany) and in a mammalian cell 93 
line (by InVivo Biotech Services, Berlin, Germany), based on the MPT64 94 
amino acid sequence from M. bovis BCG Moreau without the signal sequence 95 
(Supplementary text). Table 1 shows the predicted amino acid sequence of the 96 
different MPT64 proteins that were used as antigens in the study. 97 
 98 
Table 1. Amino acid sequence of the various forms of MPT64 protein used as antigen in the study. The native MPT64 99 
sequence is derived from M. bovis BCG Moreau and includes a N-terminal cleavable protein secretion signal sequence 100 
(bold), which is not present in the final, secreted form of the protein. The sequence of the recombinant protein produced 101 
in Escherichia coli (E. coli rMPT64) includes a C-terminal Thrombin-cleavable 8XHis-tag (underlined) to simplify 102 
purification. The sequence of the recombinant protein produced in human HEK cells (mammalian rMPT64) includes a 103 
N-terminal HSA signal peptide (bold) to secrete the protein, and a C-terminal 6XHis-tag (underlined) to simplify 104 
purification. 105 
Protein Amino acid sequence 
















Development of a monoclonal anti-MPT64 antibody 108 
Monoclonal antibodies from mice were generated by hybridoma 109 
technology according to standard methods (28) by commercial companies 110 
(Biogenes, PharmAbs and InVivo). Four different strategies to develop a 111 
functional monoclonal antibody for the MPT64 test were investigated (mAb 112 
experiment 1-4, figure 1). Different combinations of MPT64 antigen and 113 
adjuvants were tested, and an increasing number of screening steps in IHC 114 
were added in subsequent experiments. Antibodies were screened in parallel 115 
in indirect enzyme-linked immunosorbent assay (ELISA) by the commercial 116 
companies, and in IHC at our laboratory, to identify the hybridomas that 117 
produced MPT64-specific antibodies. Antibody performance in IHC was 118 
assessed in positive and negative control tissue sections using serial dilution 119 
to find the optimal working dilution, by several readers (T.M. and I.M.H.). 120 
Several antigen retrieval methods were tested to optimise the MPT64 test 121 
protocol for murine monoclonal antibodies (Supplementary text). Figure 2 122 
provides an overview of the different stages of hybridoma production and 123 
target points for screening of clones for monoclonal antibodies.  124 
 125 
 126 
Figure 1. Overview of the different strategies used to develop monoclonal and polyclonal anti-MPT64 antibodies. 127 
Abbreviations: d, day; IFA, incomplete Freund adjuvant, IHC, immunohistochemistry; mod, moderate; NSS, non-128 
specific staining; SS, specific staining; rMPT64, recombinant MPT64. 129 
 130 
 131 
Figure 2. The steps of hybridoma production and different target points for screening of clones during development 132 
of monoclonal antibodies. Abbreviations: ELISA, enzyme-linked immunosorbent assay, IHC, immunohistochemistry; 133 
mAb, monoclonal antibody. 134 
Development of polyclonal rabbit anti-MPT64 antibodies 135 
Immunisations 136 
Immunisation of rabbits to produce polyclonal anti-MPT64 antibodies 137 
was performed by commercial companies (Biogenes, PharmAbs and InVivo). 138 
Figure 1 shows the four different strategies for development of polyclonal 139 
MPT64-antibodies that were investigated (pAb experiment 1-4). In 140 
experiments 1-2, the original protocol for development of the reference anti-141 
MPT64 antibody was followed (29), with the exception that the antigen was 142 
not immunoprecipitated with polyclonal rabbit anti-MPT64 antibodies before 143 
immunisation. In brief, outbred female rabbits were immunised 144 
intradermally with native MPT64 emulsified in incomplete Freund adjuvant 145 
(IFA) using a standard immunisation protocol. In later experiments, 146 
recombinant MPT64 and other adjuvants were also tested, rabbits whose pre-147 
immune sera gave non-specific staining were excluded from immunisation, 148 
and the immunisation protocols were longer for rabbits whose antisera tests 149 
bleeds gave particularly strong specific staining (figure 3). In all experiments, 150 
pre-immune sera were collected at baseline, antisera test bleeds were collected 151 
seven days after the second or third immunisation, and the final bleed was 152 
taken seven days after the last immunisation. Pre-immune sera and all 153 
individual bleeds were tested by indirect ELISA by the companies, and in IHC 154 
in our laboratory on positive and negative control tissue sections. The staining 155 
in IHC was evaluated by several readers (T.M., I.A.M.A. and I.M.H.). The 156 
optimal working dilution was determined using serial dilution.  157 
 158 
 159 
Figure 3. Flow chart showing immunisation protocols, screening and pooling strategies used to develop the new 160 
polyclonal antibody (polyclonal antibody experiment 4). Abbreviations: d, day; IHC, immunohistochemistry; mod, 161 
moderate; NSS, non-specific staining; SS, specific staining.  162 
 163 
Selection and pooling of MPT64 specific antibodies 164 
The performance of the different bleeds in IHC were evaluated according 165 
to previously developed guidelines for interpretation of the MPT64 test (16). 166 
The antibodies were categorised as 1) strong specific staining (SS) and low 167 
non-specific staining (NSS), 2) moderate SS and low NSS, 3) moderate to 168 
strong SS and moderate to strong NSS, and 4) not functional, defined as no or 169 
weak SS and various degrees of NSS. In order to reduce batch-to-batch 170 
variation and to enable large-scale use of the polyclonal antibodies, the bleeds 171 
were pooled. Different combinations of pooled bleeds were tested in IHC 172 
(figure 3), and the combination of bleeds with the best sensitivity and 173 
specificity in IHC, hereafter referred to as the new polyclonal antibody, was 174 
chosen for further experiments. 175 
 176 
Background blocking and antibody absorption experiments 177 
Blocking experiments were performed to reduce the non-specific binding 178 
of the new polyclonal antibody. Before application of the MPT64-antibody, 179 
the tissue sections were incubated with blocking solutions containing either 180 
1) bovine serum albumin and serum free protein block with casein (Dako, 181 
Agilent), or 2) normal goat serum, or 3) recombinant Fc domain protein (Hu 182 
Fc block pure, BD, Becton Dickinson). Table 2 provides an overview of the 183 
different dilutions, incubation times and combinations of blocking solutions 184 
that were tested. Experiments with negative absorption were carried out at 185 
our laboratory by mixing the new polyclonal antibody with different 186 
proteinaceous solutions to allow non-specific antibodies or antibodies with 187 
cross-reactivity to bind proteins in the solutions and precipitate 188 
(Supplementary text). 189 
  190 
 191 
 192 
Table 2. Strategies employed to reduce non-specific staining in immunohistochemistry with the new polyclonal 193 
antibody. 194 
 Level of non-specific staining 
Strategy Positive TB 
control 
Negative non-TB control 
Blocking experiments   
Serum free block (12 min, 30 min, 60 min, or 
overnight) 
- - 
BSA 3% or 10% and NGS 10% (60 min), followed by 
serum free block (60 min)  
-/↓ -/↓ 
BSA 3% or 10% and NGS 10% (overnight), followed 
by serum free block (12 min) 
↓↓ ↓↓ 
Fc block  - - 
Absorption experiments   
M. bovis BCG Copenhagen, culture filtrates -/↓ -/↓ 
M. bovis BCG Copenhagen, cell sonicate - - 
Homogenised non-TB lung and lymph node tissue 
sections (deparaffinised and hydrated) 
- ↑ 
Abbreviations: TB, tuberculosis; BSA, bovine serum albumin; NGS, normal goat serum; NSS, non-





Immunohistochemistry (the MPT64 test) 197 
The MPT64 test was performed using the Dako Envision + System-HRP 198 
kit (Agilent, Santa Clara, CA), according to the manufacturer’s protocol with 199 
some modifications. Briefly, 4 µm thick tissue sections on Superfrost Plus 200 
slides (Thermo Fisher Scientific, MA) were deparaffinized with xylene and 201 
rehydrated through decreasing grades of alcohol. When rabbit antibodies 202 
were used as primary antibody, heat induced antigen retrieval (HIER) was 203 
performed by microwave boiling the sections in citrate buffer at pH 9, for 20 204 
minutes. For murine antibodies, HIER was performed by pressure cooker 205 
boiling at 125°C in TE-buffer at pH 9, for 1 min. The sections were left to cool 206 
for 20 minutes at RT, washed in distilled water for 10 minutes and incubated 207 
with peroxidase block for 20 minutes. For IHC with the new polyclonal 208 
antibody, an additional protein blocking step was then added to the protocol, 209 
in which a combination of 10% normal goat serum and 3% bovine serum 210 
albumin was applied to the sections overnight at 4°C, followed by serum-free 211 
protein block (Dako) for 12 minutes at RT the next day. The primary antibody 212 
was applied, and the slides were incubated for 60 minutes, before horseradish 213 
peroxidase conjugated secondary anti-rabbit antibody was applied for 45 214 
minutes. Thereafter, the substrate (3-amino-9-ethylcarbazol) was added to the 215 
slides for 15 minutes, followed by counterstaining with Mayer’s haematoxylin 216 
and mounting with Immu-Mount (Thermo Fisher Scientific, United States). 217 
Slides were washed with wash buffer (0.05 mol/L Tris/HCl buffered saline 218 
with 0.05% Tween 20, pH 7.6) between all incubation steps. In each IHC run, 219 
tissue sections from known TB and non-TB cases were added as controls. In 220 
addition, the primary antibody was substituted with antibody diluent on one 221 
non-TB tissue section, to assess any non-specific binding of the secondary 222 
antibody or other reagents during IHC.  223 
 224 
Validation of the new polyclonal antibodies 225 
Human clinical samples were used for the validation of the new anti-226 
MPT64 polyclonal antibody. Twenty extrapulmonary biopsies from TB cases 227 
with a confirmed (culture and/or Xpert MTB/RIF positive) or clinical TB 228 
diagnosis (defined as patients with presumptive extrapulmonary TB, and 229 
histology suggestive of TB, and response to treatment, as assessed by the 230 
primary investigator) were used. These materials were collected as part of 231 
another project where the clinical samples were obtained from a cohort of 232 
EPTB patients (30). Twenty-four non-TB samples with histopathological 233 
diagnoses other than TB were used as controls. The immunostaining was 234 
screened at a total magnification of 200x and evaluated in detail at 400x by 235 
one designated reader (S.I.) according to previously developed guidelines for 236 
interpretation of the MPT64 test (16). Briefly, a sample was positive if a 237 
minimum of two granular red-brown coloured spots, either observed 238 
intracytoplasmic in inflammatory cells or extracellularly in necrotic material, 239 
were present in the sample. No staining, nuclear staining or extracellular 240 
granular staining in non-necrotic areas were interpreted as negative. 241 
 242 
Statistical methods 243 
The sensitivity and specificity of the new polyclonal antibody were 244 
calculated using 2x2 cross-tabulation against a reference standard that 245 
included culture, Xpert MTB/RIF and clinical TB diagnosis. 246 
 247 
3. Results 248 
3.1. Production of MPT64 antigen 249 
During a period of one year, 156 litres of BCG Moreau culture filtrates 250 
were produced and subsequently purified by chromatography (figure S2), 251 
resulting in a yield of approximately 15 mg MPT64 protein with a purity of > 252 
90%, based on visual evaluation of Coomassie stained SDS-PAGE gels (figure 253 
S3). Untagged recombinant MPT64 was expressed in M. smegmatis at our 254 
laboratory, and the presence of MPT64 in the cultures was confirmed by 255 
positive MGIT TBc identification test. No band of the expected size of MPT64 256 
was found on Coomassie stained SDS-PAGE gel, neither from the 257 
concentrated culture filtrate nor cell lysate solution, but both solutions gave a 258 
band of the right size in Western blot. This indicated that soluble MPT64 had 259 
been expressed, but in low quantities. Purified HIS-tagged recombinant 260 
MPT64 protein from E. coli (Trenzyme) and mammalian HEK-cells (InVivo) 261 
were provided from commercial companies.  262 
 263 
3.2. Development of monoclonal MPT64 antibody 264 
Figure 1 provides the results from the four strategies that were tested to 265 
develop a monoclonal anti-MPT64 antibody. Monoclonal antibodies that 266 
were functional in ELISA were obtained with all the strategies, but most of 267 
these antibodies gave no specific staining in IHC. As ELISA was not suitable 268 
to select clones that were functional in IHC, we included earlier and more 269 
frequent screening in IHC in the latter experiments (figures 1 and 2). In 270 
experiment 2-4, only mice whose antisera showed strong SS in IHC were used 271 
for fusion, and we observed that the combination of mammalian recombinant 272 
MPT64 and Titer Max Gold adjuvant resulted in particularly good polyclonal 273 
antisera in the mice (SS in 9/9 mice), as compared to native MPT64 and IFA 274 
(SS in 1/10 mice), or E. coli recombinant MPT64 and IFA (SS in 4/9 mice). 275 
However, hybridoma cultures from mice with particularly good antisera did 276 
not result in more SS on IHC despite very good reactivity on ELISA. The few 277 
clones that gave possible SS with IHC, also displayed cross-reactivity, and 278 
development of a monoclonal antibody was not further pursued after the 279 
fourth experiment.  280 
 281 
3.3. Development of a polyclonal antibody 282 
The results from the four strategies used to develop a polyclonal 283 
antibody are summarised in figure 1. Based on the results from experiment 1-284 
2 where non-specific staining and weak specific staining were observed in the 285 
majority of antibodies, the strategy of screening was modified in experiment 286 
3-4 (figures 1 and 4). To minimize non-specific binding, we adopted a strategy 287 
of only selecting the rabbits whose pre-immune sera showed minimal or no 288 
staining in IHC for further immunisations. Additionally, the adjuvant was 289 
changed to Titer Max Gold together with mammalian recombinant MPT64 as 290 
antigen in experiment 4, as particularly good polyclonal antisera had been 291 
obtained with this combination in mice during development of monoclonal 292 
antibodies. Further, the rabbits whose antisera gave particularly strong 293 
specific staining in IHC in experiment 4, were selected for a longer 294 
immunisation protocol (90 days) to generate larger volumes of antisera (figure 295 
3). Using this strategy, a total of 38 rabbits were immunised in experiment 4 296 
(whereas 142 rabbits were excluded after screening of pre-immune sera and 297 
released for other projects within the company), resulting in 55 bleeds from 298 
25 animals that were functional in IHC (figure 3). These bleeds were further 299 
pooled in different combinations (combination 1-5), to increase the total 300 
antibody volume and reduce batch-to-batch variation. Combination 2 and 3 301 
gave the best results in IHC, both showing strong SS that was comparable to 302 
the staining from the reference antibody in the positive control, and weak 303 
NSS. Combination 3 was chosen as the new polyclonal antibody because of 304 
the larger volume as compared to combination 2, making it suitable for future 305 
large-scale use. Among the various strategies employed to reduce NSS in the 306 
new polyclonal antibody, blocking with bovine serum albumin 3% and 307 
normal goat serum 10% overnight, followed by serum-free block for 12 min 308 
gave the best results with clearly reduced NSS (table 2). This blocking step 309 
was incorporated into the MPT64 test protocol for the new polyclonal 310 
antibody. Negative absorption of the new antibody with different 311 
proteinaceous solutions, including M. bovis BCG Copenhagen components, 312 
did not reduce NSS. 313 
 314 
3.4. Validation of the new polyclonal antibody 315 
Validation of the new polyclonal antibody was performed on human 316 
clinical extrapulmonary specimens, including 20 biopsies from confirmed or 317 
clinically diagnosed TB cases and 24 biopsies from non-TB cases. In the TB 318 
samples, the sensitivity of ZN, Xpert, Culture and the new polyclonal MPT64 319 
antibody was 11% (1/9), 67% (6/9), 40% (6/15) and 95% (19/20), respectively 320 
(table 3). The new polyclonal antibody was positive in all the culture and/or 321 
Xpert positive TB samples (n = 12), and positive in 7/8 samples from clinically 322 
diagnosed TB cases. Non-specific staining was observed in 4/24 non-TB 323 
samples with the new polyclonal antibody, yielding an overall specificity of 324 
83%. 325 
 326 
Table 3. Results of routine diagnostic tests and the MPT64 test performed on clinical TB and non-TB samples. 327 
    
Routine diagnostic tests 
Positive/total (%) 
The MPT64 test 
Positive/total (%) 





New polyclonal MPT64 
antibody 
TB cases total 20 1/9 (11) 6/9 (67) 6/15 (40) 19/20 (95) 
Lymph node biopsies 14 1/6 (17) 3/4 (75) 6/12 (50) 14/14 (100) 
Other biopsies 6 0/3 (0) 3/5 (60) 0/3 (0) 5/6 (83) 
            
Confirmed TB cases 12 0/5 (0) 6/6 (100) 6/11 (55) 12/12 (100) 
Clinically diagnosed TB 
cases 
8 1/4 (25) 0/4 (0) 0/3 (0) 7/8 (88) 
Non-TB cases total 24 N/A N/A N/A 4/24 (17) 
Lymph node biopsies 7 N/A N/A N/A 2/7 (29) 
Other biopsies 17 N/A N/A N/A 2/17 (12) 
Abbreviations: LJ, Lowenstein Jensen; TB, tuberculosis. 
 328 
4. Discussion 329 
In this study we have investigated different strategies to develop a new 330 
functional antibody for use in the TB diagnostic MPT64 test, which has shown 331 
promising results for diagnosing EPTB in low-resource settings (11-17). The 332 
test uses an in-house polyclonal antibody for detection of the mycobacterial 333 
antigen MPT64, but the antibody is in limited supply and further large-scale 334 
use of the test requires reproduction of the antibody. Despite generation of 335 
several monoclonal anti-MPT64 antibodies with good reactivity in ELISA, 336 
none of the antibodies were fully functional in IHC. We therefore opted for 337 
development of polyclonal antibody. By careful selection of animals for 338 
immunisation, optimal antigen-adjuvant combination, screening of 339 
antibodies in IHC and pooling of the best performing individual antibodies, 340 
generation of a sensitive new polyclonal antibody in a large volume was 341 
achieved. The new antibody was more sensitive than routine microscopy, 342 
Xpert and culture when validated on a small number of clinical samples, 343 
albeit a reduced specificity warrants more work with background reduction.  344 
The choice of antigen and adjuvant can greatly affect the performance of 345 
the resulting antibody (31-34). We used native MPT64 as antigen in the initial 346 
experiments because the conformational epitopes, which may be important 347 
targets in IHC (35), are conserved in native proteins. However, as the resulting 348 
antibodies were neither sensitive nor specific in IHC, and the production of 349 
native MPT64 was time-consuming, we changed to recombinant MPT64 in 350 
the latter experiments. Recombinant protein expression allows for rapid 351 
production but may alter conformational epitopes depending on the choice of 352 
host system. Recombinant MPT64 from E. coli has been reported to elicit 353 
weaker immune responses than native MPT64 and recombinant MPT64 from 354 
M. smegmatis (36), possibly due to different post-translational modification 355 
systems (37-43), suggesting that important MPT64 epitopes can be affected by 356 
the host system. Despite this possible drawback, immunisation of mice with 357 
recombinant MPT64 from both E. coli and mammalian cells resulted in 358 
polyclonal antisera with as strong, or stronger, specific staining in IHC as 359 
compared to immunisation with native MPT64 (strong specific staining was 360 
observed in 9/9, 4/9 and 1/10 murine antisera with mammalian MPT64, E. coli 361 
MPT64 and native MPT64 as antigen, respectively). Several adjuvants, which 362 
can enhance and prolong the immune response (33, 34), were also tested in 363 
the study (fig 2). Based on the particularly strong specific staining obtained 364 
after immunisation of mice with mammalian recombinant MPT64 and Titer 365 
Max Gold adjuvant, we chose to change to this antigen-adjuvant combination 366 
in rabbits as well. This resulted in some of the best individual antisera in our 367 
study, with almost as strong specific staining as the reference antibody, and 368 
low non-specific staining. 369 
The main reason for choosing monoclonal antibodies in a diagnostic test 370 
is to avoid batch-to-batch variability, thereby securing reproducible test 371 
performance. Still, polyclonal antibodies offer some important advantages 372 
(19). Development of polyclonal antibodies is relatively simple, fast and 373 
inexpensive and can results in highly sensitive antibodies because several 374 
epitopes are recognised simultaneously, leading to efficient signal 375 
amplification and improved detection. High test sensitivity is of great 376 
importance in TB diagnostics, as the sensitivity of routine TB diagnostic tests 377 
is low in paucibacillary EPTB disease (44). Further, the biological diversity of 378 
polyclonal antibodies allows for use under a wide range of chemical 379 
conditions and temperatures, which is an advantage in low-resource settings. 380 
Thus, as long as batch-to-batch consistency is managed through standardised 381 
validation of all new batches, or through creation of a large batch as in this 382 
study, polyclonal antibodies may be used, and are being used, for diagnostic 383 
purposes (45-47). Still, cross-reactivity is a common issue with polyclonal 384 
antibodies, and antibody purification or background blocking is often 385 
required. Surprisingly, negative absorption with BCG Copenhagen culture 386 
filtrate proteins, which successfully reduced non-specific staining in the 387 
reference antibody, had no effect on the new polyclonal antibody. We 388 
experienced that a combined strategy of careful selection of animals for 389 
immunisation and optimised background blocking prior to IHC were the 390 
most effective measures to reduce non-specific staining. The specificity of the 391 
new antibody is still not optimal, but ongoing work indicates that increased 392 
duration of the washing steps in IHC removes the non-specific staining 393 
without reducing the specific staining of the antibody. This will be further 394 
explored in an up-coming validation study.  395 
The development of monoclonal antibodies for use in IHC can be 396 
challenging, as demonstrated in our study. The screening of hybridoma 397 
cultures in ELISA was not an optimal method to select clones that are 398 
functional in IHC. Clones with high performance in ELISA may not detect 399 
relevant epitopes in IHC, because formalin fixation prior to IHC can mask or 400 
alter the three-dimensional conformation of the epitopes that were exposed 401 
during ELISA (48). Antigen retrieval partly reverses these alterations, but the 402 
effect varies between epitopes, and antibody screening should therefore 403 
preferably be performed directly in IHC. This was done in the latter 404 
experiments but is more time-consuming than ELISA and requires large 405 
numbers of positive control tissue sections. In the latter experiments, antisera 406 
from several immunised mice gave relatively strong specific staining in IHC, 407 
but the resulting few monoclonal antibodies that showed some specific 408 
staining also displayed cross-reactivity, indicating that their target epitopes 409 
were not unique to the MPT64 protein. We may have lost clones that 410 
recognised unique MPT64 epitopes during fusion or hybridoma selection, 411 
especially in the initial experiments where IHC was not used for screening. 412 
Another possible explanation is that our choice of antigen was not optimal to 413 
generate antibodies against unique epitopes (49). If the less unique epitopes 414 
are immunodominant, most of the antibodies in the mice will be generated 415 
against these, whereas less immunogenic, but unique epitopes could be 416 
missed by the immune system. To avoid this, so-called subtractive 417 
immunisation techniques can be applied, in which the undesirable antibodies 418 
are used to mask their epitopes on the antigen before immunisation, so that 419 
antibodies are only generated against other epitopes (49). This remains to be 420 
explored during further development of monoclonal MPT64-antibodies for 421 
IHC. 422 
5. Conclusions 423 
Reproduction of a functional polyclonal MPT64 antibody for large-scale 424 
use of the TB diagnostic MPT64 test was achieved through a combination of 425 
careful selection of antigen-adjuvant for the immunisation protocol, 426 
comprehensive screening in IHC of both pre-immune sera and antisera to find 427 
the best performing antibodies, followed by pooling the best individual 428 
antisera to obtain a large volume of polyclonal antibodies with stable 429 
performance, thereby securing stable supplies and reproducibility of the 430 
MPT64 test. Further validation of the new polyclonal antibody in clinically 431 
relevant larger populations remains to be done.  432 
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Supplementary text 
Detailed protocols for production and purification of MPT64 antigen, development of 
antibodies, and immunohistochemistry background reduction 
Production of native MPT64 protein 
The Brazilian BCG vaccine strain M. bovis bacillus Calmette-Guérin Moreau (BCG Moreau) was 
used for production of endogenous, native MPB64 protein. Briefly, lyophilised BCG cells were 
suspended in isotone saline and inoculated onto Lowenstein-Jensen slants and subsequently 
onto wholly synthetic Sauton’s liquid medium to be grown as surface pellicles at 37°C without 
shaking. The cultures were harvested after three weeks, as the peak concentration of secreted 
MPT64 protein from in vitro grown M. tuberculosis is obtained at this time point (20). The bacilli 
were removed with paper filter from the culture filtrates which were sterile filtered (0.2 µm) 
before further use. 
Purification of native MPT64 protein 
The methods for protein purification were based on previous protocols (21, 22), with some 
modifications. To concentrate the proteins in the culture filtrates, solid ammonium sulphate 
was added to 80% saturation (533 g/L at 4°C). Proteins were left to precipitate overnight, 
followed by centrifugation at 10,000 x g at 4°C for 45 minutes. The protein pellet was 
resuspended in phosphate-buffered saline (PBS) and dialysed against PBS. Protein concentration 
was measured on Direct Detect Spectrometer (Merck Millipore, MA, USA). 
In order to purify the untagged, native MPT64 protein (nMPT64) to the required level of purity 
for antibody production (80-90%), a three-step chromatography strategy, carried out under 
native conditions, including ion-exchange chromatography (IEX), hydrophobic interaction 
chromatography (HIC) and size exclusion chromatography (SEC), was used. All purification steps 
were performed on fast liquid protein chromatography (FPLC) machines (Äkta Explorer or 
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Purifier) at room temperature (RT), using filtered (0.45 µm) and degassed buffers and protein 
samples. The pH of all buffers was adjusted at RT.  
Before the first step IEX, the protein concentrate was dialysed against IEX binding buffer (20 
mM Tris-HCl, pH 8.3), and loaded onto a Q Sepharose Fast Flow XK 50/20 column that was 
subsequently washed with binding buffer until unbound proteins were removed. For elution, a 
linear gradient of 0 to 0.3 M NaCl in 20 mM Tris-HCl, pH 8.3, was applied, and 10 mL fractions of 
the eluate were consecutively collected. Between each chromatography step the collected 
fractions were subjected to SDS-PAGE under non-reducing conditions and Western blot with 
polyclonal rabbit anti-MPT64 antibody to assess purity and identify MPT64. MPT64 positive 
fractions were pooled and concentrated by ultrafiltration (Amicon Ultra spin-filter, molecular 
weight cut-off 3000, Merck, Germany) at 3200 x g for 25 minutes at RT. To prepare the sample 
for the intermediate HIC step, the sample buffer was exchanged to HIC binding buffer (20 mM 
Tris-HCl, 1.7 M ammonium sulphate, pH 7.5) by adding HIC binding buffer to the concentrated 
protein sample in the spin-filter, followed by ultrafiltration. This procedure was repeated twice. 
The protein sample was then loaded onto a Phenyl HP HiTrap column (1 mL bed volume) in HIC 
binding buffer. The column was washed with binding buffer until unbound proteins were 
removed, followed by elution of bound proteins by applying a linear gradient of 0-100% elution 
buffer (20 mM Tris-HCl, pH 7.5). 2 mL fractions of the eluate were collected during the run, and 
the fractions containing MPT64 were further pooled. Concentration and buffer exchange to SEC 
buffer (20 mM Tris-HCl, 0.3 M NaCl, pH 7.5) of the pooled protein sample were carried out by 
ultrafiltration as described above. For the final SEC polishing step, the protein sample was 
loaded onto a Superdex 75pg HiLoad 26/600 column in SEC buffer, separated according to 
molecular size as the sample passed through the medium over a volume of 400 mL SEC buffer at 
a flow rate of 2,5 mL/min, and collected as 5 mL fractions. The level of purity in the fractions 
containing MPT64 was visually evaluated in Coomassie stained SDS-PAGE gels. Fractions with a 
purity of approximately >90% were selected for later use as antigen. Endotoxin levels were 
measured (Pierce LAL chromogenic endotoxin quantitation kit, ThermoFisher Scientific) before 
and after endotoxin affinity purification (Pierce high capacity endotoxin removal spin columns, 
ThermoFisher Scientific). Protein concentration was measured by Direct Detect. The samples 
were stored at -80°C. 
 
Production of recombinant MPT64 protein 
Mycobacterial vector system 
All laboratory kits were used according to the manufacturer’s recommended protocols, unless 
otherwise stated. Genomic DNA from BCG Moreau was prepared using FastDNA SPIN Kit (MP 
Biomedicals, OH, USA). An 888 bp segment of genomic DNA containing the mpb64 gene with its 
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predicted secretion signal sequence (GenBank Accession No. AM412059.2; BCGM locus 1981c), 
was amplified using KAPA HiFi HotStart Readymix PCR kit (Roche) and the primers mpt64UP1 5’-
ATCGCGGCAATCCAATCTCC-3’ and mpt64LP1 3’-TCTCTAGCGACGATTCTTGAGC-5’ (Initial 
denaturation 3 min 95°C. 30 amplification cycles: 20 sec 98°C, 15 sec 63°C, 20 sec 72°C. Final 
extension 1 min 72°C). Following purification with UltraClean 15 DNA Purification kit (MO BIO 
Laboratories), the PCR product was used as template to amplify an 853 bp segment containing 
the mpt64 coding region with PacI and PstI restriction sites, using the primers mpt64adaptUP1 
5’-GCTTAATTAACTACTCCCGGAGGAA-3’ and mpt64LP1 3’-TCTCTAGCGACGATTCTTGAGC-5’ with 
the same PCR and purification protocols. The purified PCR product and the mycobacterial 
inducible plasmid pUV15tetORm were separately digested with PacI and PstI (New England 
BioLabs, MA, USA) and purified. Cloning was performed by incubating the plasmid backbone 
and insert (insert:backbone ratio 5:1), T4 DNA ligase and T4 DNA Ligase Buffer (Invitrogen) at 
4°C overnight. Correct insertion was controlled by sequencing. Figure S1 shows the final plasmid 
construct and table 1 shows the predicted amino acid sequence of the expressed protein. 
Chemically competent E. coli cells (One Shot TOP10, ThermoFisher Scientific, MA, USA) were 
transformed with the plasmid by heat shock, plated on selective Luria Bertani (LB) agar, 
expanded in selective liquid LB medium (both containing 200 mg/L hygromycin (ThermoFisher 
Scientific)) and purified using QIAprep Spin Miniprep Kit (QIAGEN, Netherlands). 
Electrocompetent M. smegmatis mc2 155 was cultured in Middlebrook 7H9 supplemented with 
OADC, 0.05% Tween-80 and 0.2% glycerol, and prepared for transformation in glycerol as 
described by Goude and colleagues (26). The pUV15tetORmMpt64 plasmid was transformed 
into M. smegmatis mc2 155 by electroporation (Bio-Rad Gene Pulse II) in a 0.2 cm gap 
electroporation cuvette subjected to one single pulse of 2,5kV, 25µF, with the pulse-controller 
resistance set at 1000Ω. After 3 hours cell recovery in 7H9 without antibiotics, the cells were 
harvested by centrifugation at 3000 x g for 10 minutes and plated out in suitable dilutions on 
Middlebrook 7H10 agar plus 50 mg/L hygromycin. At day 3, transformant colonies were used to 
inoculate 5 mL 7H9 plus 50 µg/mL hygromycin and incubated on a shaker (100 rpm) at 37°C to 
reach logarithmic phase (OD600 0.8-1). The culture was then inoculated into 200 mL 7H9 plus 
50µg/mL hygromycin and 200ng/mL anhydrotetracycline, to induce expression of rMPT64 (27), 
and was incubated on a shaker (100 rpm) at 37°C for 3 days. Expression of rMPT64 was 
confirmed by subjecting 10µL of the culture diluted in 90 µL 7H9, to the MGIT TBc identification 
test (Becton Dickinson, NJ, USA), a rapid lateral-flow immunochromatographic assay normally 
used for detection of MPT64 antigen in MTBC cultures. 
To assess if soluble rMPT64 had been expressed, the protein content in culture filtrates and cell 
sonicates were analysed. Culture filtrate was prepared from half of the culture as previously 
described. The other half was centrifuged at 3000 x g for 10 min at 4°C to pellet out bacterial 
cells. The bacteria were dissolved in PBS and probe sonicated in bursts of 30 sec over 10 
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minutes in a rosette cooling cell in an ice bath. The resulting cell lysate was centrifugated at 
3000 x g for 10 min at 4°C and the supernatant was sterile filtered. Solid ammonium sulphate 
was added to 80% saturation (533 g/L at 4°C) to the culture filtrate and cell lysate supernatant 
and gently mixed by stirring. Proteins were left to precipitate overnight, followed by 
centrifugation at 10,000 x g at 4°C for 45 minutes. Each protein pellet was resuspended in 2 mL 
PBS, and 10 µL of the solution was analysed by SDS-PAGE and Western blot with polyclonal 
rabbit anti-MPT64 antibody to identify any rMPT64 protein bands. 
To avoid protein contamination of the antigen from the culture medium, transformant colonies 
were also cultured in protein-free, wholly synthetic Sauton’s medium instead of 7H9, otherwise 
using the same protocol as described above. 
E. coli vector system 
A recombinant MPT64-His protein was produced in an E. coli expression system (E. coli rMPT64) 
by Trenzyme Life Science Services (Konstanz, Germany). The E. coli rMPT64 was designed based 
on the MPT64 amino acid sequence from M. bovis BCG Moreau without the signal sequence and 
with a C-terminal 8xHis-tag (table 1). Cloning, transformation of E. coli and expression of the 
protein was performed according to standard protocols. The rMPT64 was purified under non-
denaturing conditions using affinity chromatography, followed by dialysis against tris-buffered 
saline (TBS), pH 7.5. Purity (> 98%) was measured by densitometry of Coomassie stained SDS-
PAGE gel. Endotoxin content was measured by LAL before and after endotoxin removal by 
affinity purification. The protein was stored at -80°C. 
Mammalian cell line vector system 
A recombinant MPT64 protein expressed in a human cell line (mammalian rMPT64) was 
produced by InVivo Biotech Services (Berlin, Germany). The mammalian rMPT64 was made 
based on the MPT64 amino acid sequence from M. bovis BCG Moreau without the signal 
sequence, with an HSA signal peptide at the N-terminal and a 6xHis-tag at the C-terminal (table 
1) using an expression vector that was expanded in E. coli and then transfected into HEK cells, a 
cell line derived from human embryonic kidney cells, to express recombinant protein. Affinity 
chromatography was used to purify the rMPT64, followed by dialysis against TBS, pH 7.4. A 
purity of >90% was obtained, as determined by analysis of Coomassie-stained SDS-PAGE. 
Endotoxin levels were measured by LAL. The protein was stored at 2-8° C. 
Development of a monoclonal and polyclonal anti-MPT64 antibody 
Antigen retrieval experiments 
Tissue sections were subjected to several antigen retrieval protocols prior to IHC to optimise the 
MPT64 test protocol for murine monoclonal antibodies. After deparaffinisation with xylene and 
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rehydration through decreasing grades of alcohol, the positive control tissue section were 
treated with 1) proteinase K digestion for 5 min, 2) heat induced epitope retrieval (HIER) in 
microwave oven in citrate buffer, pH 9, 20 min, 3) HIER in pressure cooker at 125°C in Tris-EDTA 
buffer, pH 9, for 1 min, and 4) no retrieval. The method that resulted in the strongest specific 
staining was used in further IHC experiments with monoclonal antibodies.  
Background blocking experiments 
In addition to the blocking of endogenous peroxidase, which is part of the original MPT64 test 
protocol, further blocking experiments were performed to reduce non-specific binding to tissue 
components when the new polyclonal antibody was used. Before application of the primary 
antibody, the tissue sections were incubated with different blocking solutions containing 1) 
proteins that bind readily to non-specific sites, including bovine serum albumin (BSA) and serum 
free protein block with casein (Dako, Agilent), 2) normal goat serum (NGS), in which antibodies 
in non-immune serum bind non-specific sites in the tissue, and 3) recombinant Fc domain 
protein (Hu Fc block pure, BD, Becton Dickinson) to block Fc receptors on immune cells in the 
tissue sections which could otherwise bind the Fc domain of the primary antibodies. Table 2 
provides an overview of the different dilutions, incubation times and combinations of blocking 
solutions that were tested. 
Absorption experiments 
Experiments with negative absorption were carried out at our laboratory by mixing the new 
polyclonal antibody with different proteinaceous solutions to allow non-specific antibodies or 
antibodies with cross-reactivity to bind proteins in the solutions and precipitate. The new 
polyclonal antibody was mixed with 1) culture filtrates (3 mg/mL) from M. bovis BCG 
Copenhagen, a BCG sub-strain that lacks Region of Difference 2 and therefor does not express 
MPT64 protein, in ratio 1:1, or 2) BCG Copenhagen cell sonicate and antibody in ratio 1:5, or 3) 
homogenised non-TB lung and lymph node tissue sections (deparaffinised and hydrated) in PBS 
in ratio 1:1. The mixture was gently vortexed and left overnight at 4°C. The absorbed antibodies 
were then carefully pipetted off the precipitated antibody-antigen complexes and tested in IHC.  
Protocol for preparation of homogenised tissue solutions 
Formalin-fixed and paraffin-embedded non-TB lung and lymph node biopsies were selected for 
absorption experiments because the new polyclonal antibody showed a high degree of non-
specific staining in these biopsies. Six 10 µm thick sections from each biopsy were placed in a 
tube, deparaffinized with xylene and rehydrated through decreasing grades of alcohol. After 
three minutes in distilled water, the tubes were centrifuged, the water pipetted off and 1 mL 
PBS was added to each tube. The tissue/PBS mixture was transferred to a lysing matrix tube A 
(MPbio.com) containing garnet matrix and ¼ ceramic sphere and homogenized for 40 seconds 
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by a Fastprep-24-5G homogenizer. The lysed tissue mixture was subsequently used directly for 
absorption experiments as described above. 
 
Figure S1. The completed vector construct, pUV15tetORmMpt64, expressing MPT64 protein. 
An 800 bp fragment containing the gene encoding the MPT64 protein, including its secretion 
signal sequence, was inserted between the PacI and PstI sites of the pUV15tetORm plasmid, a 





Figure S2. Chromatograms from the three-step chromatography purification strategy applied 
to purify native MPT64 protein. The elution pattern from the first step separation of culture 
filtrate proteins from M. bovis BCG Moreau by anion exchange chromatography on a Q 
Sepharose Fast Flow column is shown in (A). Fractions containing MPT64 were pooled and 
further purified in the intermediate hydrophobic interaction chromatography step on a Phenyl 
HP HiTrap column (B), before the final polishing step size exclusion chromatography (C) on a 
Superdex 75pg HiLoad column. Fractions of the eluate were consecutively collected during all 
runs and subjected to SDS-PAGE and Western blot to identify the MPT64 containing fractions. 





Figure S3. Overview of purity of the MPT64 containing fractions after each step of 
chromatography. The figure shows the purity of the fractions containing MPT64 protein in 
Coomassie-stained SDS-PAGE after (A) ion exchange chromatography, (B) hydrophobic 
interaction chromatography and (C) size exclusion chromatography. (D) shows concentrated 
culture filtrates from M. bovis BCG. Molecular mass is given for the bands in the standard 
(SeeBlue Plus2, Invitrogen, CA, USA) at the left in (A). The MPT64 band is located at 
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Xpert MtB/Rif ultra for rapid 
diagnosis of extrapulmonary 
tuberculosis in a high‑income 
low‑tuberculosis prevalence setting
ida Marie Hoel1, Heidi Syre2, ingerid Skarstein3 & tehmina Mustafa1,4*
the diagnosis of extrapulmonary tuberculosis (eptB) is often challenging due to paucibacillary 
nature of the disease. Xpert MtB/Rif Ultra (Ultra) has been developed to improve detection of 
Mycobacterium tuberculosis complex (Mtc) in paucibacillary specimens. the objective of the study 
was to assess the performance of Ultra for the diagnosis of eptB in a high‑income low tB prevalence 
country. extrapulmonary samples received for tB diagnostics at two hospitals in norway between 
January 2015 and January 2016 were prospectively and consecutively included. Defrosted samples 
were subjected to Ultra. Culture and routine PCR tests were used as reference standard. A total of 82 
samples, 10 culture and/or routine PCR positive (confirmed TB) samples and 72 culture and routine 
PCR negative samples were included in analysis. The overall sensitivity and specificity of Ultra were 
90% (9/10, 95% CI 56–100) and 99% (71/72, 95% CI 93–100), respectively. Ultra was positive in 6/7 
smear negative confirmed TB samples. To conclude, Ultra showed a high sensitivity and specificity in 
extrapulmonary specimens and may contribute to a rapid diagnosis of eptB in a low tB prevalence 
setting.
Tuberculosis (TB) is a global health  problem1. Extrapulmonary TB (EPTB) accounts for approximately 15% of 
notified TB cases  globally1, whereas as much as 40% of TB cases are extrapulmonary in several high-income 
countries, including  Norway1,2. Due to paucibacillary nature of the disease, the diagnosis of EPTB is often chal-
lenging. The worldwide roll-out in 2010 of the new PCR-based assay, Xpert MTB/RIF (Xpert; Cepheid, Sunny-
vale, CA), represented a breakthrough in TB  diagnostics3. The rapid and fully automated assay simultaneously 
detects Mycobacterium tuberculosis complex (MTC) species, the causative agents of TB, and rifampicin resistance 
(RIF-R), and has a high sensitivity for diagnosing pulmonary TB (PTB) in smear positive sputum  samples4. 
However, the sensitivity of Xpert in paucibacillary specimens, including smear negative PTB and many forms 
of EPTB, is  limited4–6. To improve the performance of Xpert in smear negative samples, an upgraded version 
of the assay, Xpert MTB/RIF Ultra (Ultra), has been  developed7. Ultra was launched in 2017 and is recom-
mended by the World Health Organization as a replacement for Xpert in all  settings8. The increased sensitivity 
of Ultra is achieved by incorporation of two new PCR assays targeting the multicopy genes IS6110 and IS1081 
for the diagnosis of TB, a larger DNA reaction chamber and transformation from hemi-nested to fully nested 
PCR  reactions7. A number of studies report increased sensitivity of Ultra compared to Xpert in smear negative 
 PTB9–16, and several studies also show promising results for diagnosing  EPTB11,14,15,17–25. However, most of the 
studies that investigate Ultra for diagnosing EPTB have been conducted in low-resource settings with high TB 
incidence. The aims of the present study were to (1) evaluate the diagnostic accuracy of Ultra for diagnosing 
EPTB compared to routinely used culture and PCR tests in a clinical setting in the high-income low TB preva-
lence country  Norway26, and (2) investigate the potential of Ultra as an add-on test to the existing routine tests 
to improve the rapid diagnosis of EPTB.
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Methods
Sample inclusion. The present study was performed on frozen specimens that had been collected as part of 
a larger prospective study conducted at Haukeland University Hospital, Bergen, Norway, between January 2015 
and June  201627. The study includes 47 specimens that were also included in the larger study, and 39 additional 
specimens that did not meet the inclusion criteria in the larger study. The eligibility criteria and reference stand-
ard were designed prior to Ultra testing. Samples eligible for inclusion were identified at the microbiology labo-
ratories at two regional tertiary care hospitals, Haukeland University hospital and Stavanger University hospital. 
All consecutive extrapulmonary samples received for TB diagnostics from patients of all ages were included 
during the study period, provided there was enough material left after routine diagnostics. As the diagnosis of 
EPTB almost always requires invasive sample collection, which is only performed on symptomatic patients with 
abnormal tissue masses or fluids, we assumed that the pre-test probability of TB was generally quite high in these 
samples. One exception was pleural fluid samples, which accounted for a large proportion of the samples, but 
often had a very low pre-test probability for TB because most of the samples were malignant pleural effusions 
routinely sent for TB diagnostics before initiation of cancer chemotherapy. Hence, pleural fluid samples were 
only included and subjected to Ultra if TB was mentioned as a probable differential diagnosis on the request 
form, whereas all other sample types were included without selection. Multiple samples were taken from some 
patients, and individual patients were allowed to contribute to the dataset multiple times. Results of routine 
TB diagnostic tests were obtained from the microbiology laboratory information systems. A microbiological 
reference standard was used in this study. Culture and/or routine PCR test positive samples were categorised as 
confirmed TB samples, and culture and routine PCR test negative samples were categorised as non-TB samples. 
Because information about clinical TB diagnosis was not available for all the samples in the cohort, we could 
not include a clinical TB diagnosis as part of the reference standard, and any sample included from a clinically 
diagnosed TB case was therefore categorised as a non-TB sample in this study.
Sample processing and routine tB diagnostic procedures. Laboratory personnel at the inclusion 
hospitals performed routine TB diagnostics according to local diagnostic algorithms. They were blinded to Ultra 
results. Fine needle aspirates (FNAs) and fluid samples with a volume of < 10 mL were used unconcentrated, 
whereas samples with a volume of > 10 mL were concentrated by centrifugation (3,800×g for 15 min) before 
resuspension of the sediment in saline. Biopsy specimens were mechanically homogenized and resuspended 
in saline. The Ziehl–Neelsen (ZN) method was used for detection of acid fast bacilli by smear microscopy. 
At Haukeland University hospital, a standard NALC-NaOH decontamination procedure was performed if the 
sample was assumed to be non-sterile, before seeding of appropriate sample volumes in liquid medium (BAC-
TEC MGIT) and solid medium (Lowenstein-Jensen containing glycerol and sodium pyruvate). All lymph node 
specimens, sterile fluids and aspirates and most biopsies were cultured both before and after NALC-NaOH 
decontamination, and lymph node specimens were also cultured at 28  °C. At Stavanger University hospital, 
most extrapulmonary samples were NALC-NaOH decontaminated and only cultured on liquid medium (Bactec 
MGIT 960; Becton Dickinson, Towson, MD). If the clinician requested PCR, appropriate sample volumes were 
further used for Cobas Taqman MTB (Roche, Switzerland), Abbott Real Time MTB (Abbot, Des Plaines, IL) or 
Genotype MTBDR plus (Hain Lifescience, Nehren, Germany), hereafter collectively referred to as routine PCR. 
Any remaining sample material was stored at − 80 °C for later analysis with Ultra.
Xpert ultra. We performed Xpert ultra on the frozen sample material during the autumn 2018, blinded for 
results of routine TB diagnostics and clinical information. Samples were thawed at room temperature and pro-
cessed according to the manufacturer’s protocol. All but two samples (both volume 0.25 mL) had a sample vol-
ume of minimum 0.5 mL. In samples with volume < 0.7 mL (n = 32), sample reagent was added in a 3:1 reagent 
to sample ratio, whereas a ratio of 2:1 was used for samples with a volume of 0.7 mL or more (n = 54).
Statistical analysis. Sensitivity, specificity and accuracy were calculated using culture and routine PCR as 
the reference standard. A minimum of one valid (positive or negative) culture result and a valid Ultra result were 
required to include a sample in this analysis. Calculation of 95% confidence intervals for sensitivity and specific-
ity was performed with the exact Clopper-Pearson method.
ethical considerations. The study was approved by the Regional Committee for Medical and Health 
Research Ethics of Western Norway (REK Vest), (2014/46/REK vest), and carried out in accordance with rel-
evant guidelines and regulations. REK Vest granted an exemption from informed consent from the patients, as 
the study only included residual material from samples sent for TB diagnostics in a clinical setting.
Results
Figure 1 provides the study overview. Frozen material was available from a total of 177 samples received for TB 
diagnostics during the study period, and comprised 21 biopsies, 16 lymph node FNAs, 16 pus samples and 124 
fluid samples. Pleural fluid samples accounted for more than half of all the specimens (n = 109), but TB was only 
mentioned as a probable differential diagnosis on the request form for 18/109 samples. We excluded the 91 pleural 
fluids with assumed low pre-test probability of TB and analysed the remaining 86 extrapulmonary samples (from 
80 cases) with Ultra. All these samples had a minimum of one valid culture result (positive or negative) available. 
Four samples were excluded from further analysis due to invalid Ultra result (ERROR).
The type and number of routine TB diagnostic tests performed on the analysed samples varied (Table 1). All 
samples were subjected to culture, 85% to ZN microscopy (n = 70) and 24% to a routine PCR (n = 20). MTC was 
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detected in ten samples (positive culture and/or routine PCR), hereafter called confirmed TB samples, while 72 
samples were culture and routine PCR negative (Table 1). HIV status was unknown for all cases.
test performance of ultra compared to routine tB diagnostic tests. Using culture and/or routine 
PCR as reference standard, Ultra was positive in 9 of 10 confirmed TB samples, giving an overall sensitivity 
of 90% (95% CI 56–100) (Table 2). Among the nine culture positive TB samples, Ultra was positive in eight 
(Fig. 2). All the smear positive (3/3) and 6/7 (86%) smear negative confirmed TB samples were Ultra positive. 
Semi-quantitation of bacillary load by Ultra categorised the TB samples as medium (n = 3), low (n = 3), very 
low (n = 1) and trace (n = 2). None of the TB samples had a high bacillary load. Among the 8 culture and Ultra 
positive samples, genotypic RIF-R was detected by Ultra in two samples, not detected in four samples and inde-
terminate in the two samples semi-quantitated as “trace”. The genotypic RIF-R results were in concordance with 
the phenotypic drug susceptibility test (DST) results. The two samples with indeterminate RIF-R by Ultra were 
both sensitive to first line TB drugs in phenotypic DST.
One of the 72 culture and routine PCR negative samples was Ultra positive, yielding an overall specificity of 
99% (95% CI 93–100) for Ultra. This sample was a lymph node biopsy from a patient with lymphadenitis fol-
lowing BCG vaccination. The lymphadenitis healed spontaneously and was eventually interpreted as an immune 
reaction to the vaccine. Among the culture and routine PCR negative samples were also three non-tuberculous 
mycobacteria (NTM) culture positive samples, identified as Mycobacterium avium. All three were Ultra negative.
Discussion
In the present study we have investigated the performance of Ultra compared to routine TB diagnostic tests for 
diagnosing EPTB in a small cohort of prospectively collected extrapulmonary specimens in a high resource set-
ting with a low TB prevalence. Using culture and/or routine PCR as reference standard, we found that Ultra had 
an overall sensitivity and specificity of 90% (95% CI 56–100) and 99% (95% CI 93–100), respectively. In smear 
negative confirmed TB samples, the sensitivity of Ultra was 86% (95% CI 42–100).
Several studies have been published on the diagnostic accuracy of Ultra in extrapulmonary 
 specimens11,14,15,17–25,28,29. Most of the studies were performed in TB endemic  settings14,17,19–25,28,29, and only three 
studies have investigated Ultra test performance in low TB prevalence  settings11,15,18. However, two of these stud-
ies were retrospective and performed on selected sample material. A strength of our study is that it is a prospec-
tive cohort study with consecutive inclusion of samples in a clinical routine setting, and the study population 
is thus more likely to be representative of the true test population in a low TB prevalence setting. The majority 
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Figure 1.  Overview of study design. The type of routine PCR test performed varied between the inclusion 
hospitals, and included Cobas Taqman MTB (Roche, Switzerland), Abbott Real Time MTB (Abbot, Des Plaines, 
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of extrapulmonary samples tested for TB in Norway are from patients with other diseases than TB. Hence, it 
may be just as important to avoid false positive test results in the large group of non-TB cases, which can lead to 
overtreatment and potentially severe side effects, as to obtain a more rapid TB diagnosis in the small group of 
TB cases. Our study can provide useful information about test performance in these clinically relevant non-TB 
cases, which we think is of particular importance in our setting. Indeed, the specificity of Ultra in our study was 
Table 1.  Distribution of routine TB diagnostic tests performed and results of routine TB diagnostic tests and 
Xpert MTB/RIF Ultra. HUH Haukeland University Hospital, SUH Stavanger University Hospital. a Two of the 
samples (culture positive biopsy and culture positive fluid sample) are from the same TB case. b Includes three 
samples from clinically diagnosed TB cases (one pus sample, one biopsy and one lymph node aspirate). c The 
two microscopy positive samples were both culture positive for Mycobacterium avium. d Microscopy positive 
sample was culture positive for Mycobacterium avium. e Five culture negative biopsy samples were subjected to 
routine PCR, of which one PCR test result was indeterminate (technical failure). The indeterminate PCR result 
has been excluded from the results and analysis.
Culture and/or PCR positive  samplesa Number of samples
Routine TB diagnostic tests (positive/
total number)
Xpert UltraMicroscopy Routine PCR Culture
Lymph node biopsy 1 0/1 1/1 1/1 1/1
Lymph node aspirate 4 3/4 3/3 4/4 4/4
Pus samples 2 0/2 2/2 1/2 2/2
Other biopsies (pleura) 1 0/1 0/1 1/1 1/1
Fluid samples 1 0/1 0/1 1/1 0/1
Gastrointestinal lavage 1 0/1 1/1 1/1 1/1
Total 10 3/10 7/9 9/10 9/10
Samples per inclusion site
Samples from HUH 8 3/8 5/7 8/8 7/8
Samples from SUH 2 0/2 2/2 1/2 2/2
Culture and PCR negative samplesb
Lymph node biopsy 4 1/4 0/1 0/4 1/4
Lymph node aspirate 11 2/11c 0/3 0/11 0/11
Pus samples 14 1/14d 0/1 0/14 0/14
Other biopsies 13 0/13 0/4e 0/13 0/13
Fluid samples 28 0/17 0/3 0/28 0/28
Gastrointestinal lavage 2 0/1 N/A 0/2 0/2
Total 72 4/60 0/12 0/72 1/72
Samples per inclusion site
Samples from HUH 58 3/53 0/9 0/58 0/58
Samples from SUH 14 1/7 0/3 0/14 1/14
Table 2.  Validation of Xpert MTB/RIF Ultra using culture and/or routine PCR tests as a reference standard. 
95% confidence intervals for sensitivity, specificity and accuracy were calculated using the exact Clopper–
Pearson method. CI confidence interval, TP true positive, FN false negative, TN true negative, FP false positive.
Sample material
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high (99%). This is in concordance with the specificities (97–100%) found in other low TB prevalent settings 
where culture was used as reference  standard15,18. However, in most of the studies that directly compare the 
performance of Xpert and Ultra, the specificity of Ultra is reduced compared to Xpert, both in extrapulmonary 
 specimens14,19,20,22,29 and  sputum9,10,12,13. In low TB prevalent settings, even a small reduction in specificity could 
lead to unacceptable high rates of false positive cases, emphasizing that Ultra should be performed on selected 
samples with a high pre-test probability of TB disease.
Only one culture and routine PCR negative sample in our cohort was Ultra positive (“trace”). The sample came 
from a patient with regional lymphadenitis following BCG vaccination. As the BCG strains are also members 
of the  MTC30,31, the Ultra result may have been true positive for this case. However, Ultra is not able to separate 
non-viable from viable bacilli and cannot provide information as to whether the DNA present in the sample 
represented active mycobacterial disease or remnants of old DNA from the vaccine. This illustrates the challenges 
in interpreting positive Ultra results in certain clinical contexts. The inability of Ultra to separate viable from 
non-viable bacilli also limits its use for detection of relapse and reinfection. Dorman and colleagues reported 
a reduced specificity of Ultra in previously treated TB patients up to seven years after completion of treatment 
compared to patients with no previous history of  TB9. This underlines the importance of culture for TB diagnosis.
Most, but not  all28,29, of the studies that investigate Ultra for the diagnosis of EPTB suggest increased sensi-
tivity of Ultra compared to Xpert in different extrapulmonary  specimens11,14,15,17,19–23,25. When culture is used 
as reference standard, the reported sensitivity of Ultra varies, but is generally high in lymph node specimens 
(90–94%)18,24, FNAs and tissue samples (87–95%)18,22, cerebrospinal fluid (80–100%)17,18,21,25,29 and pus specimens 
(65–95%)18,19, and lower in pleural fluid samples (48–84%)18,20,22,23, which is in line with our findings. Several 
of the studies also show that Ultra can detect MTC in culture negative specimens from clinically diagnosed TB 
 cases17,19–25,28,29, thus, contributing to improved diagnosis of TB in samples with a very low bacillary load.
The ability of Xpert and Ultra to simultaneously detect MTC and RIF-R is considered one of the strengths 
of the assays. In addition to detection of the single-copy rpoB gene for the simultaneous diagnosis of TB and 
rifampicin resistance, Ultra includes two new and more sensitive PCR assays that target the multicopy IS6110 
and IS1081 genes to improve MTC detection in paucibacillary  samples7. However, the increased sensitivity of the 
test comes with an expense, because information about RIF-R is not available in IS6110 or IS1081 positive and 
rpoB negative samples, which are categorised as “trace” by  Ultra7,18. Two of the culture confirmed TB samples in 
our study were Ultra “trace” positive. For these samples, information about drug resistance was only provided by 
culture, and both were drug sensitive. The incidence of multidrug resistant (MDR)-TB is low in our  setting26, but 
in high MDR-TB incidence settings, MDR-TB cases can be missed among the “trace” positive samples. Therefore, 
Ultra should complement, but not replace culture.
This study has some limitations. The small sample number leads to uncertain sensitivity estimates. The study 
was performed in a clinical routine setting, and the combination of routine TB diagnostics used and sample 
processing varied slightly between the inclusion hospitals. The number of cultures performed per sample and the 
use of decontaminated versus not-decontaminated material may affect the sensitivity of culture. At both inclusion 
sites, fluid samples and FNAs with a volume of > 10 mL were concentrated before use. Hence, we cannot evaluate 
the overall effect of sample concentration on Ultra test performance, as some samples were concentrated and 
others were not. The use of frozen sample material for Ultra may also affect the performance of the assay due to 
reduced sample quality. However, studies that have specifically investigated the Xpert/Ultra test performance 
on frozen samples report discordant results, but the effect is small in the studies that find a  difference6,12,18,32. 
Furthermore, DNA remains quite stable under frozen conditions, and our samples were only subjected to one 
freeze–thaw cycle. These findings imply that the impact of frozen samples on Ultra performance is small. Larger 
and more controlled studies with uniform sample processing should be conducted to adjust for these limitations. 
As culture is known to be an imperfect reference standard in paucibacillary cases of EPTB, future studies should 
focus on diagnostic accuracy of TB diagnostic tests both in microbiologically confirmed and clinically diagnosed 
TB subjects to better reflect the true test performance in all clinically relevant groups of the test population.
To conclude, the sensitivity and specificity of Ultra was comparable to culture in most sample materials in this 
study with the advantage of results within hours. These promising findings suggest that Ultra is a useful add-on 
test that can contribute to a rapid diagnosis of EPTB in our setting. However, the inability of Ultra to separate 
viable from non-viable bacilli and the lack of information about drug resistance for “trace” positive samples, 
limits its use in some clinical cases, especially in patients previously treated for TB.
Figure 2.  Euler diagram illustrating overlap of positive results of routine TB diagnostic tests and Xpert MTB/
RIF Ultra in confirmed TB samples (n = 10).
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Data availability
The datasets generated and analysed during the current study are available from the corresponding author on 
reasonable request.
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IP-10 dried blood spots assay 
monitoring treatment efficacy in 
extrapulmonary tuberculosis in a 
low-resource setting
Ida Marie Hoel1,2, Melissa Davidsen Jørstad1,3, Msafiri Marijani4, Morten Ruhwald  5, 
Tehmina Mustafa1,3 & Anne Ma Dyrhol-Riise  2,6,7
Treatment efficacy is difficult to evaluate in extrapulmonary tuberculosis (EPTB) patients. Interferon-γ 
inducible protein (IP-)10 has been suggested as a biomarker for response to treatment. We have 
investigated if IP-10 from dried plasma spots (DPS) or dried blood spots (DBS) can be used in treatment 
monitoring of EPTB patients in a low-resource setting of Zanzibar. IP-10 levels in plasma, DPS and DBS 
samples collected before, during (2 months) and after TB treatment of 36 EPTB patients (6 culture and/
or Xpert MTB/RIF positive and 30 clinically diagnosed) and 8 pulmonary tuberculosis (PTB) patients, 
were quantified by an enzyme-linked immunosorbent assay. There was a high positive correlation 
between IP-10 measured in plasma and DPS and DBS, respectively. We found a significant decline in 
IP-10 levels from baseline to end of treatment in plasma, DPS and DBS, both in EPTB and PTB patients. 
The declines were observed already after 2 months in HIV negative patients. In conclusion, the DPS/
DBS IP-10 assay allows for easy and manageable monitoring in low-resource settings and our findings 
suggest that IP-10 may serve as a biomarker for treatment efficacy in EPTB patients, albeit further 
studies in cohorts of patients with treatment failure and relapse are needed.
Tuberculosis (TB) is a global health problem with an estimated 10.0 million new cases of active TB and 1.6 mil-
lion deaths because of TB in 20171. Rapid and robust tests for TB diagnosis and treatments efficacy are needed 
to achieve global TB control. Although smear microscopy and culture are frequently used to assess treatment 
responses, the sensitivity of these methods is low in paucibacillary disease2, and they also have limited ability to 
predict treatment outcomes3–5. Extrapulmonary TB (EPTB), which accounts for approximately 15–40% of all TB 
cases6–9 with higher numbers in young children and people living with HIV10–14, is typically paucibacillary. As 
smear or culture conversion cannot be used to monitor treatment efficacy in EPTB patients, clinicians must rely on 
clinical evaluation to detect treatment failure, which is often challenging due to the nonspecific symptoms in EPTB 
disease. The emergence of multidrug resistant (MDR-)TB15 further emphasises the importance of early detection 
of ineffective treatment or low treatment adherence. Thus, there is a need for new assays to better predict treatment 
outcomes such as failure, cure and relapse. Biomarkers for early treatment efficacy may also provide surrogate end 
points in clinical trials for development of more effective and shorter personalized treatment regimens16.
Numerous host biomarkers are being investigated as markers for treatment response in TB17–19, including the 
pro-inflammatory chemokine interferon-γ inducible protein (IP-)10, also known as CXCL-10. Several studies 
show that plasma and serum IP-10 levels decline upon efficient treatment of TB20–26. Further, IP-10 is a robust 
marker expressed at higher levels than many other candidate biomarkers20,27, which allows for IP-10 detection 
using simple test platforms.
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Dried plasma spots (DPS) and dried blood spots (DBS) applied on filter paper is a simple and robust method 
for storage and transportation of blood specimens. Several substances, including IP-10, are stable in DPS and 
DBS, even when kept at ambient temperatures27,28, and IP-10 extracted from DPS and DBS can be quantified using 
ELISA-based methods27,29,30. Moreover, a user-friendly quantitative lateral flow assay for detection of IP-10 from 
antigen stimulated blood in TB patients has shown promising results31,32, indicating that IP-10 based assays, even-
tually combined with other biomarkers, have the potential to be developed into simple point-of-care (POC) tests.
We have previously shown that IP-10 levels in DPS decline already after two weeks of therapy both in pulmo-
nary TB (PTB) and EPTB24. Still, most of the studies on IP-10 as a marker for response to treatment are on PTB 
and data on EPTB in resource-constrained settings is scarce. The objective of this study was to compare IP-10 
obtained from DPS and DBS to IP-10 measured directly in plasma in order to evaluate the performance of the 
IP-10 DBS assay as a biomarker for response to treatment in EPTB patients in a clinical low-resource setting.
Results
Study participants and clinical outcome. Eight patients with PTB and 36 patients with EPTB were 
longitudinally followed during TB treatment (Fig. 1). Clinical characteristics are presented in Table 1. All PTB 
patients and six EPTB patients had bacteriologically confirmed TB (positive culture and/or Xpert MTB/RIF) and 
30 EPTB patients had a clinical TB diagnosis, categorised as a probable TB case (n = 23) and possible TB case 
(n = 7), based on a composite reference standard33. All PTB patients were sputum smear positive at baseline. A 
drug susceptible Mycobacterium tuberculosis strain was detected in 5/10 culture positive samples, whereas drug 
susceptibility testing was not performed in the remaining five cases. No genotypical rifampicin resistance was 
detected in the 10 Xpert MTB/RIF positive samples. All PTB patients and 32 EPTB patients received standard TB 
treatment (isoniazid, rifampicin, pyrazinamide and ethambutol) for 6–10 months, whereas four EPTB patients 
received modified treatment because of previous PTB or active hepatitis. After 2 months of treatment, 2/8 PTB 
patients remained sputum smear positive, both of whom demonstrated smear conversion at the follow-up sputum 
Patient presenting with symptoms/findings suggestive of TB
Yes
Lost to follow-up:
• Transfer-out (n = 3)
• Unknown (n = 1)
Lost to follow-up:
• Death (n = 4)
Routine diagnostic investigation:
• Clinical examination
• Acid-fast bacilli smear
• Løwenstein-Jensen culture
• Xpert MTB/RIF
• +/- Histo/cytopathological examination
• +/- diagnostic imaging
Possible TB
• PTB (n = 0)
• EPTB (n = 7)
Composite reference standard
Probable TB
• PTB (n = 0)
• EPTB (n = 23)
Confirmed TB
• PTB (n = 8)
• EPTB (n = 6)
End of treatment control:
• Plasma, DPS and DBS (n = 24)
• No blood sample collected (n = 4)
• Patient refused to give blood
(n = 2) 
• Hemolysis of sample (n = 2))
• Clinical assessment of response to 
treatment (n = 28)
2 months of treatment control:
• Plasma, DPS and DBS (n = 32)
• Clinical assessment of response to 
treatment (n =32)
Baseline control:
• Plasma, DPS and DBS (n = 36)
• Clinical examination (n = 36)
EPTB (n = 36)
Lost to follow-up:
• Unknown (n = 2)
PTB (n = 8)
Baseline control:
• Plasma, DPS and DBS (n = 8)
2 months of treatment control:
• Plasma, DPS and DBS (n = 8)
End of treatment control:
• Plasma, DPS and DBS (n = 6)
Evaluation by local clinician:
Decision to start TB treatment? No
Figure 1. Flow chart of patient inclusion and data collection during the study. Abbreviations: TB, tuberculosis; 
EPTB, extrapulmonary TB; PTB, pulmonary TB; DPS, dried plasma spot; DBS, dried blood spot.
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control one month later. A successful treatment outcome was recorded in the National TB program registers for 
all the PTB patients. All EPTB patients that were evaluated at 2 months showed clinical improvement, except four 
patients, three of them HIV-infected, who presented with a transient enlargement of lymph nodes, possibly due to 
paradoxical immune reactions. At the end of treatment, all EPTB patients that completed therapy demonstrated 
clinical improvement. Blood samples were taken before start of TB treatment, after 2 months and at the end of 
treatment. Altogether, four patients died, six patients were lost to follow-up and a final blood sample was not 
obtained from four patients (Fig. 1). Thus, a complete set of samples at three time points were available for six 
PTB patients and 24 EPTB patients.
IP-10 decline corresponds to sputum conversion in pulmonary TB patients. We first analysed 
IP-10 levels in the eight patients with confirmed active PTB disease (Fig. 2A). There was a significant decline in 
IP-10 from baseline to the end of treatment in plasma samples [1081 pg/mL (886–2321) vs. 203 pg/mL (129–427), 
p = 0.028], DPS samples [25 pg/2 discs (15–63) vs. 4 pg/2 discs (3–7), p = 0.027] and DBS samples [47 pg/2 discs 
(31–98) vs. 15 pg/2 discs (9–19), p = 0.043]. The decline in IP-10 levels was observed in 8/8 PTB patients already 
after 2 months of treatment in plasma (p = 0.012), DPS (p = 0.018) and DBS (p = 0.018), and corresponded with 
sputum conversion for six of the patients.
Plasma IP-10 decline during TB treatment in extrapulmonary TB. We then analysed the plasma lev-
els of IP-10 in the patients with EPTB. There was a significant decline in IP-10 levels from baseline to the end of 
treatment [660 pg/mL (269–1224) vs. 337 pg/mL (210–535), p < 0.001] (Fig. 2B). As for the PTB patients, the IP-10 
decline was observed already after 2 months (p < 0.001). Individual changes in IP-10 levels during TB treatment 
are presented in Fig. 3. In most EPTB patients, plasma IP-10 levels decreased from baseline to each follow-up time 
point and corresponded to a good clinical response to treatment. However, markedly increasing plasma IP-10 
levels towards the end of treatment were seen in four patients despite good clinical response. Two of these patients 
were pregnant during treatment (patient 3–4 in Fig. 3), the third patient was HIV-infected (patient 1 in Fig. 3) and 
the last patient with ascites and pleuritis demonstrated pleural thickening on X-ray at the last visit but was other-
wise in general good clinical state (patient 2 in Fig. 3). No intercurrent infections were registered in any of these 
patients, who all finished treatment successfully. In contrast, only one of four patients that presented with increas-
ing or persistent lymph node swelling at 2 months of therapy showed a corresponding increase in IP-10 levels.
DBS IP-10 and DPS IP-10 decline during TB treatment in extrapulmonary TB. We found a high positive 
correlation between IP-10 measured directly in plasma and IP-10 extracted from DPS (r = 0.809, p < 0.001), and 
DBS (r = 0.767, p < 0.001) in all samples. As in the plasma samples, there was a significant decline in IP-10 levels 
Patient characteristics EPTB (n = 36) PTB (n = 8)
Age in years, median (range) 33 (18–67) 34 (20–52)
Female, n (%) 18 (50) 2 (25)
HIV-infected, n (%) 9 (26)a 2 (25)
TB case category, n (%)
Confirmed TB 6 (17) 8 (100)
Probable TB 23 (64)
Possible TB 7 (19)
Routine diagnostics (positive/total)
Culture (baseline) 3/32 7/7
Xpert (baseline) 5/23 5/5
AFB smear baseline 6/36 8/8
AFB smear 2 months NA 2/8
AFB smear 5 months NA 0/7b
Site of infection, n (%)




Lymph node and PTB 2 (6)
EPTB ≥2 sites/disseminated TB 4 (11)
ART status for HIV-infected patients, n (%)
ART before start of TB treatment 3 (33) NA
ART initiated during TB treatment 4 (44) NA
Patient died before initiating ART 2 (22) NA
Table 1. Characteristics of the study participants. Abbreviations: EPTB, extrapulmonary tuberculosis; PTB, 
pulmonary tuberculosis; AFB, acid fast bacilli; ART, antiretroviral therapy; NA, not available or performed. 
aHIV status was unknown for one EPTB patient. bSputum smear result at 5 months was missing for one PTB 
patient. This patient was registered with a negative sputum smear at 2 months.
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Figure 2. Changes in IP-10 levels in plasma, dried plasma spots (DPS) and dried blood spots (DBS) during 
tuberculosis (TB) treatment. IP-10 concentrations measured using enzyme-linked immunosorbent assay from 
(A) patients with pulmonary TB before treatment (n = 8), at 2 months (n = 6) and at the end of treatment 
(n = 6) and from (B) patients with extrapulmonary TB before treatment (n = 36), at 2 months of treatment 
(n = 32) and at completion of 6–10 months of treatment (n = 24). Boxes represent the median and interquartile 
range, and the whisker show min/max values. Dotted lines indicate statistically significant differences. Statistical 
significance was evaluated by Wilcoxon Signed Ranks test using a significance level of 0.05.


















































































Figure 3. Comparison of IP-10 levels in plasma, dried plasma spots (DPS) and dried blood spots (DBS) for 
individual extrapulmonary tuberculosis (EPTB) patients during TB treatment. IP-10 levels during 6–10 months 
of TB treatment in plasma, DPS and DBS in patients with extrapulmonary TB at baseline (n = 32), at 2 months 
of treatment (n = 32) and at the end of treatment (n = 24). IP-10 levels in baseline samples from the four 
patients who died shortly after start of TB therapy, are not presented in this figure. 1TB pleuritis, 2Combined 
ascites and TB pleuritis, 3–4Pregnant during treatment, 5–7Persistant or increasing lymph node swelling at 2 
months of treatment, 8–9Lymph node TB, 10Abdominal TB. *HIV-infected patient.
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from baseline to the end of treatment in both DPS [12 pg/2 discs (7–24) vs. 7 pg/2 discs (4–11), p = 0.001] and 
DBS [20 pg/2 discs (15–31) vs. 14 pg/2 discs (7–22), p = 0.008] (Fig. 2B). However, a significant decrease in IP-10 
from baseline to 2 months of treatment was only observed in DPS (p = 0.032) and not in DBS (p = 0.217). In 
contrast to the plasma samples, a further decline in IP-10 from 2 months to the end of treatment was seen both in 
DPS (p = 0.009) and DBS (p = 0.031) samples.
Similar patterns of individual changes in IP-10 levels during treatment were observed in the filter paper sam-
ples as in the corresponding plasma samples for the majority of patients. However, an apparent IP-10 increase 
from baseline to 2 months of treatment was seen more often in DPS and DBS filter paper samples compared to 
plasma samples (Fig. 3). Interestingly, this included three of the four patients who did not demonstrate clinical 
improvement after 2 months of therapy (patient 5–7 in Fig. 3), as well as two other patients with lymph node TB 
(patient 8–9 in Fig. 3), one with an intercurrent inflammation, but both with clinical response to TB therapy. 
Further, a transient and high IP-10 increase in DBS only, was seen in one patient with abdominal TB with good 
response to treatment (patient 10 in Fig. 3).
IP-10 levels in various clinical groups of TB patients. In general, there was a tendency to higher IP-10 
levels at baseline in PTB patients compared to EPTB patients both in DPS (p = 0.075) and DBS (p = 0.013), but 
not in plasma (p = 0.114). When EPTB patients with concurrent PTB infection (n = 2) or disseminated TB (n = 4) 
were excluded from the analysis, the difference in IP-10 levels between the PTB and EPTB patients became even 
more apparent both for DPS (p = 0.045) and DBS (p = 0.01).
Since the vast majority of EPTB patients were clinically diagnosed (83%), we also compared IP-10 levels 
between patient groups according to TB diagnostic criteria. At baseline, there was a tendency to higher IP-10 
levels in plasma (p = 0.071) and DPS samples (p = 0.086) from EPTB patients with confirmed TB diagnosis com-
pared to patients with clinical TB diagnosis (Fig. 4). For those groups large enough to analyse we found no signif-
icant differences in baseline IP-10 levels between the various extrapulmonary sites of infection.
The effect of HIV co-infection on IP-10 levels during TB treatment. In the EPTB group, the IP-10 
levels were significantly higher in HIV-infected (n = 9) compared to HIV negative (n = 27) patients at all time 
points and assessed by all three methods (Fig. 4). In contrast to the joint analyses of HIV-infected and HIV 
negative EPTB patients, a significant decline in IP-10 at 2 months of treatment was observed not only in plasma 
(p < 0.001) and DPS (p = 0.011), but also in DBS (p = 0.045) when HIV negative patients were analysed sepa-
rately. For the HIV-infected EPTB patients, the IP-10 decline at 2 months of treatment was only significant in 
plasma (p = 0.043), but only few patients were included in these analysis.
Discussion
In this study, we have evaluated the potential of the DPS/DBS IP-10 assay compared to measuring IP-10 in plasma, 
for assessing treatment responses in EPTB patients in a clinical setting where diagnostic tools and resources are 
limited. To our knowledge, this is the first study evaluating IP-10 from DPS/DBS during the first months of 
TB treatment also in clinically diagnosed EPTB patients. We demonstrate that IP-10 is readily detectable both 
in unstimulated plasma and DPS/DBS filter paper samples. Further, we show that IP-10 levels decrease upon 































































































































Figure 4. IP-10 levels in different clinical groups of extrapulmonary tuberculosis (EPTB) patients during 
treatment in plasma, dried plasma spots (DPS) and dried blood spots (DBS). IP-10 concentrations were 
measured using enzyme-linked immunosorbent assay. EPTB sub-grouped according to (A) HIV status; before 
treatment (n = 35), at 2 months of treatment (n = 32) and at the end of treatment (n = 24), and according to (B) 
TB category; before treatment (n = 36), at 2 months (n = 32) and at the end of treatment (n = 24). HIV status 
was unknown for 1/36 EPTB patients. Boxes represent the median and interquartile range, and the whisker 
show min/max values. Dotted lines indicate statistically significant differences. Statistical significance was 
evaluated by Mann-Whitney U test, using a significance level of 0.05.
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completion of successful treatment in plasma, DPS as well as DBS, and that the decline is significant already after 
2 months of treatment in HIV negative patients.
IP-10 is a pro-inflammatory chemokine expressed by antigen presenting cells, mainly in response to T-cell 
derived interferon-γ34. Increased levels of IP-10 are found in blood, plasma or urine in infections such as HIV35,36, 
hepatitis C37–40, bacteremia41,42 and TB43–50. It has recently been demonstrated that IP-10 secretion during TB 
disease originates from infected macrophages and multinucleated giant cells located in the granulomas, and early 
inactivation of the secreted chemokine by antagonist form of IP-10 which binds to CXCR3 but does not induce 
signalling, may also play a role in the pathogenesis of TB51,52. Several studies show that IP-10 declines during 
efficient treatment of many diseases including TB25,38,42,53,54. Limited data also indicates that IP-10 increases in 
non-cured TB patients from baseline to 2 months of treatment, and in TB patients who relapse or develop active 
TB disease25,55. This makes IP-10 a strong candidate as a biomarker for treatment response although specificity 
is an issue. In our study, we found a significant decline in plasma IP-10 after 2 months and upon completion of 
successful treatment, which is consistent with findings in several other investigations20,22–26. However, as all of the 
TB patients in our cohort responded to treatment, we cannot fully evaluate the potential of IP-10 to detect treat-
ment failure in the present study. Further, a significant decline in plasma IP-10 levels has been reported to occur 
as early as 1–2 weeks after initiation of TB therapy24,26,54. We did not include earlier time points for evaluation due 
to the low-resource setting limiting closer follow-ups, but the DPS/DBS assay may also have potential for earlier 
evaluation of diagnosis and treatment efficacy.
High levels of IP-10 are observed in a variety of inflammatory diseases and conditions56–58. We found mark-
edly increasing IP-10 levels towards the end of treatment despite clinical improvement in four patients. Two of 
the patients were pregnant during therapy, which is known to cause physiological changes in cytokine profiles59, 
and one patient presented with an unspecified inflammatory swelling in a foot. This is in line with our previous 
observation that intercurrent disease could cause IP-10 production24, and emphasises that IP-10 measured in 
unstimulated blood specimens is not a specific marker for TB disease and must be interpreted within a clinical 
context. Likewise, a significantly higher level of plasma IP-10 in HIV-infected patients compared to HIV negative 
TB patients was observed throughout treatment in our study, which may reduce the specificity of IP-10 based 
tests in HIV-infected patients. However, we and others have shown that IP-10 levels can differentiate patients with 
latent TB infection from patients with TB disease irrespective of HIV status23,26. With regard to the impact of HIV 
infection on IP-10 responses during TB treatment, discordant results are reported20,60. We observed a decrease in 
plasma IP-10 during treatment in EPTB patients irrespective of HIV status, which is supported by a recent study 
demonstrating a decline in serum IP-10 levels during the early phases of treatment in HIV-infected patients54. For 
the DPS and DBS samples in our study, the IP-10 decline was only significant in HIV negative patients, but the 
HIV patient group is too small to conclude.
Evaluation of treatment efficacy in EPTB patients is important for timely and proper management, as many 
are started empirically on treatment due to low sensitivity of routine confirmatory tests. Further, smear and cul-
ture conversion cannot be used to assess response, underlining that EPTB patients would greatly benefit from new 
methods for treatment monitoring. We found a tendency to higher levels of pre-treatment plasma IP-10 in bacte-
riologically confirmed EPTB patients compared to clinically diagnosed patients, which supports the assumption 
that clinically diagnosed EPTB patients in general have a lower bacterial burden associated with less advanced 
disease. Still, there was a significant decline in IP-10 both after 2 months and at the end of treatment also for 
patients defined as probable TB cases.
DBS provides a minimally invasive method for blood collection using finger prick blood, and requires no 
centrifugation for sample processing, making DBS particularly user-friendly in low-resource settings. Our data 
indicate that the DBS IP-10 method can be used in settings where storage and transport of plasma is not feasible. 
However, discordant results between the three methods were observed for some patients, mostly HIV-infected. 
We have no clear explanation to this, but due to a limited number of DPS/DBS per patient, all filter paper samples 
were assayed as singlets in the ELISA. The use of triplicates in further studies would provide important informa-
tion about whether variance in the measurements is causing discordant results between methods. Further, appar-
ent stable or weakly fluctuating low levels of plasma IP-10 (<300 pg/mL) throughout treatment were observed in 
a few EPTB patients despite good clinical response. TB patients represent a heterogenous group of patients, both 
in terms of infection sites and variation in systemic inflammation. Thus, low systemic plasma IP-10 levels in some 
patients could reflect low disease activity already at baseline, or compartmentalized production and degradation 
of cytokines at the site of infection, both limiting the use of the assay in this group of TB patients.
There are some limitations to our study. The small sample size gives reduced power to our results. As we did 
not have any TB patients with unsuccessful treatment and only followed patients until completion of treatment, 
the association between IP-10 and treatment failure or relapse cannot be assessed. Further, several factors may 
influence IP-10 levels and lead to variation; firstly, the EPTB group was heterogenous with various TB locali-
sations, secondly, the number of HIV-infected patients was low, CD4 cell counts were not performed and the 
anti-retroviral therapy coverage during TB treatment varied according to decisions made by local clinicians. 
Thirdly, a clinical TB diagnosis is uncertain and elevated IP-10 levels could reflect other diagnoses than TB, 
although we believe that the use of a composite reference standard for TB diagnosis that includes clinical treat-
ment response makes this less likely. Finally, the time points for sample collection during therapy varied some-
what compared to the original study protocol, as many follow-up controls had to be postponed to make it possible 
for the patients to participate in the study. For a couple of patients, the baseline sample was collected a few days 
after start of TB treatment and may not represent the true pre-treatment level of IP-10, as changes in immune 
responses have been reported to occur as early as one week after start of treatment26,54. Accordingly, to measure 
IP-10 levels few weeks after initiation of therapy could also have provided data on the kinetics of IP-10 in a clinical 
setting.
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To conclude, the present study shows that IP-10 declines during successful treatment of a clinically hetero-
geneous EPTB population in a TB endemic area. The simple and robust DPS/DBS IP-10 method allows for easy 
and manageable monitoring in low-resource settings. Our data suggest that IP-10 may serve as a biomarker for 
treatment responses, albeit further studies including larger cohorts of patients with treatment failures and relapses 
are needed to confirm this.
Methods
Study participants. The study was part of a larger study that was conducted at the tertiary care hospital 
Mnazi Mmoja Hospital at Zanzibar, Tanzania, from August 2014 to September 201533. Thirty-six patients ≥18 
years of age with either clinically diagnosed or bacteriologically confirmed EPTB and 8 smear positive and bac-
teriologically confirmed PTB patients, were included in the study and longitudinally followed during TB treat-
ment (Table 1). The TB diagnosis and decision to start TB treatment was made by local clinical/medical officers. 
Exclusion criteria were ongoing or earlier treatment for TB during the last 12 months, or refusal to participate 
in the study. Clinical assessment and collection of blood specimens for the EPTB group were performed before 
treatment [median day 0 (5–95 percentile range −7 −+ 8 days)], after the intensive phase of treatment at 2 
months [median day 71 (5–95 percentile range 54–120)] and at the end of treatment [median day 175 (5–95 
percentile range 149–342)]. Treatment outcome and sputum smear results at baseline, 2 months and 5 months of 
treatment for the PTB patients were collected from the National TB Program registers.
Diagnostic TB groups. Based on a composite reference standard33, the patients were categorized as con-
firmed, probable or possible TB cases. Briefly, a confirmed TB case was defined as a culture and/or Xpert positive 
patient. A culture and Xpert negative patient presenting with one of the following; a positive Ziehl-Neelsen (ZN) 
smear or radiological findings suggestive of TB or histology/cytology consistent with TB or lymphocytosis on 
fluid cytology, was defined as a probable TB case if the patient also demonstrated clinical response to treatment 
or had confirmed concomitant PTB. If clinical response to treatment was unknown (lost to follow-up) and there 
was no concomitant PTB, the same patient was defined as a possible TB case. A patient presenting with symptoms 
suggestive of TB, but for whom all tests (culture, Xpert, ZN smear, histo/cytopathology and diagnostic imaging) 
were negative, was defined as a possible TB case if the patient demonstrated good clinical response to treatment.
Filter paper sample preparation. Whole blood was drawn into EDTA or CPT tubes (Vacutainer, BD). 
2 × 25 μL whole blood was spotted directly onto Whatman 903 filter paper (GE Healthcare) before the remaining 
whole blood was centrifuged within 30–40 minutes after collection to obtain plasma (EDTA tubes at 3000 × g for 
10 min at room temperature (RT), and CPT tubes at 1800 × g for 20 min at RT). Afterwards, 2 × 25 µL plasma was 
spotted onto another Whatman 903 filter paper. The remaining plasma was stored at −80 °C. The filter papers 
were left to dry for 3–4 hours at RT before placed in zip-locked plastic bags with desiccants, and stored at −20 °C. 
The filter paper cards were transported at room temperature and the plasma samples on dry ice to Bergen, 
Norway, for analysis.
Protocol for IP-10 determination in plasma, DPS and DBS samples. Quantification of IP-10 in 
plasma and filter paper samples was performed in triplicates and singlets respectively using ELISA-based assays as 
described elsewhere by Aabye et al. and Drabe et al. respectively27,30. For the DPS and DBS samples, 2 filter paper 
discs of 5.5 mm were punched from the dried plasma or blood spots (1 disc per spot) and stacked horizontally in 
a filter microtiter plate (Luminex, Merck Millipore) and 80 μL dilution buffer was added per well before the plate 
was incubated at RT for 1 hour to allow for diffusion-based extraction of the DPS/DBS sample. After incubation, 
the filter microtiter plate was stacked on top of a capture mAb coated ELISA plate containing 20 μL dilution buffer 
with detection mAb per well. The stacked plates were centrifuged at 700 × g for 10 minutes, to filter the extracted 
sample into the ELISA plate, and incubated at RT for 1 hour. After incubation, plasma, DPS and DBS ELISA plates 
were washed and revealed for 30 min at RT, before stopping the reaction and reading at 450 nm with 630 nm 
reference. Plasma levels were corrected for dilutions, DPS and DBS measurements are presented as pg/2 discs.
Statistical analysis. All values are presented as median and interquartile range (IQR), unless otherwise 
stated. Statistical analyses were performed using SPSS Statistics V25 (IBM). Non-parametric statistical meth-
ods were applied. Wilcoxon Signed Ranks test was used to evaluate change in IP-10 levels between different 
time points during treatment in individual patients. For comparison of difference in IP-10 levels in independent 
groups at baseline, Mann Whitney U test was applied when the groups compared consisted of ≥5 individuals per 
group. Correlation analyses were performed using Spearman’s Rank Correlation Coefficient. A significance level 
of 0.05 was used. Graphical presentations were made using Prism V7.03. (Graphpad).
Ethical considerations. Ethical clearance was obtained from the Regional Committee for Medical and 
Health Research Ethics, Western-Norway (REK Vest) and the Zanzibar Medical Research and Ethics Committee 
(ZAMREC) before conducting the study. All methods were carried out in accordance with the relevant guidelines 
and regulations. Permission to export plasma, DPS and DBS samples out of Tanzania was approved by ZAMREC 
(Ministry of Health, Zanzibar), Mnazi Mmoja Hospital and the study participants. All participants provided 
informed written consent.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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